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Dietary interventions vary in ability to influence immune activity. Separate 
investigations were conducted to determine the immune impact of omega-3 fatty acids, 
dietary fermentable materials (DFM) and high energy (HE) diets. Omega-3 fatty acid 
impact on bovine immunity was examined by comparing effects of fish oil and microalgae 
dietary supplements in the context of different feed management systems (pasture versus 
confinement). Cattle consuming microalgae had higher antibody production and cattle in 
the pasture system had higher anti-keyhole limpet hemocyanin (KLH) and total antibody 
responses on all diets. Overall, effects of omega-3 supplements on bovine immunity were 
influenced by feed management system with heightened impact on antibody production 
observed with a pasture system.  
A double-blind placebo-controlled, randomized crossover clinical trial involving 
30 healthy adults was conducted to examine impacts of β2-1 fructans on immunity. 
Subjects consumed an oligofructose-enriched inulin or maltodextrin supplement for a 28-
day period (5 g, 3× daily with meals). β2-1 fructan supplementation significantly increased 
serum endotoxin and IL-4 concentrations, circulating percentages of CD282+/TLR2+ 
myeloid Dendritic cells (mDC) and ex vivo responsiveness to a Toll-like receptor 2 (TLR2) 
agonist, while serum IL-10 concentrations decreased.  
A rat trial was designed to examine effects of a HE diet supplemented with varied 
DFM (7% wheat bran, oat bran, resistant starch type II, or fructooligosaccharide (FOS)) on 
obesity-associated biomarkers in male Sprague-Dawley rats. After 2 weeks of HE diet 
consumption, rats were segregated into obese-prone and obese-resistant phenotypes and 
shifted to DFM-supplemented HE diets for an additional 11-12 weeks. Obese-prone rats 
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had higher serum insulin and leptin concentrations than obese-resistant rats. FOS-fed rats 
had decreased splenic percentages of B cells, natural killer cells, T lymphocytes, memory 
T cells and cytotoxic T cells compared to rats on the control diet. High-energy diets had 
differential impacts on systemic and mucosal cytokines in both phenotypes; however, DFM 
had relatively less influence on cytokine and adipokine profiles associated with diet-
induced obesity. Taken together, dietary interventions are capable of subtly influencing 
varied immune outcomes in animal models and in human subjects, however the 
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Dietary Polyunsaturated Fatty Acids and the Immune System 
 
Polyunsaturated fatty acids (PUFA) are present in varying amounts in the human 
diet. Common sources of PUFA in the diet are fish oils, which are rich supplies of 
eicosapentaenoic acid (EPA) 20:5(n-3) and docosahexaenoic acid (DHA) 22:6(n-3, 
Appendix A, Figure A1). Unsaturated fatty acids are essential for the maintenance and 
functioning of cell membranes since fatty acids incorporate into the membranes to provide 
structure and fluidity (Calder, 1998). Increasing evidence suggests that dietary intake of 
PUFA can alter cell membrane composition, leading to changes in cell signaling and 
mediator production which would thereby influence immune responses. Elements of the 
immune system that are potentially modified by PUFA intake include suppression of 
lymphocyte, natural killer (NK) cell and macrophage activities (Caroprese et al., 2009; 
Yaqoob and Calder, 1995) as well as decreased production of pro-inflammatory cytokines 
(Mullen et al., 2010). However, the effect of PUFA supplementation on responses to 
immunization and antibody production are not well understood.  
 Dietary fatty acids may be supplied to cattle in an effort to increase energy 
concentration in feeds (Fouladi-Nashta et al., 2009), improve calf weight gain (Garcia et 
al., 2014) improve milk quality (Franklin et al., 1999) and also to modulate immune 
responses (Caroprese et al., 2009; Farran et al., 2008). Feeding cattle sources of omega-3 
fatty acids has been shown to elevate fatty acid profiles within plasma and milk (Fouladi-
Nashta et al., 2009). Evidence suggests the omega-3 PUFA source and the DHA/EPA ratio 
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may modulate the immune response distinctively (Caroprese et al., 2009; Farran et al., 
2008). For example, in a previous study by Caroprese et al. (2009) it was demonstrated 
that cattle fed flaxseed had higher anti-ovalbumin immunoglobulin (Ig) G in response to 
immunization than cattle fed fish oil, which differed in its fatty acid composition. It has 
also been proposed that cattle fed flaxseed may have altered eicosanoid production by 
inflammatory cells in comparison to cattle fed soy or tallow (Farran et al. 2008). Analysis 
of milk from cattle fed fish oil displays EPA concentrations twice that of DHA (Kitessa et 
al., 2004), which is not surprising given that fish oil itself has a higher EPA to DHA ratio. 
Dietary microalgae is an excellent source of omega-3 fatty acids and is a more concentrated 
source of DHA than fish oil, while containing less EPA (Abughazaleh et al., 2009). A 
previous study has shown that dietary marine microalgae feeding altered the fatty acid 
profile of bovine milk by increasing the concentration of DHA (Franklin et al., 1999), 
possibly enhancing the nutritive quality of the milk.  
Few studies have examined the fatty acid profiles of plasma after a dietary algae 
feeding regime, and there have not been any published studies to date which have 
investigated the bovine immunization response after consumption of dietary microalgae. 
There is a need to improve immunization strategies in cattle as they become 
immunosuppressed during transport or after entering new feedlots (Estrada et al., 1999), 
making the cattle more susceptible to infection. Increasing interest into the effects of PUFA 
in immunization strategies prompted this investigation into the immune responses of cattle 
fed dietary omega-3 fatty acids. Research into the enhancement of immune responses in 
cattle will not only benefit the beef and dairy industries, but also further our understanding 
of the potential role of PUFA in immunization strategies. 
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PUFA & Bovine Immunization Responses 
 
KLH is a standard T-cell dependent antigen that is frequently used in investigating 
responses to immunization in cattle (Estrada et al., 1999; Fligger et al., 1997). KLH is 
considered a powerful immunogen and it is isolated from the hemolymph of the Californian 
Pacific coast sea mollusc Megthura crenulata (Harris and Markl, 1999).  It is unlikely that 
dairy cattle will have highly specific natural antibodies for KLH, however they may 
produce a measurable amount of lower affinity natural antibodies capable of recognizing 
the KLH antigen (Harris and Markl, 1999; van Altena et al., 2016; van Knegsel et al., 
2007). Upon immunization with KLH, KLH-specific T cells will recognize the processed 
and presented antigen and facilitate the production of antibodies from KLH-specific B 
cells.  
In order to investigate bovine responsiveness to immunization, antibody production 
profiles must be measured. The main antibody isotypes of interest in this research project 
were IgG, IgM and IgA. IgG is the predominant circulating Ig and cattle have two 
subclasses of this immunoglobulin, IgG1 and IgG2 (Butler et al., 1971). IgM is the antibody 
mainly responsible for the primary immune response and it is also the first antibody 
produced following immunization (Mix et al., 2006). IgG and IgM are quantifiable in 
serum, and are generally measured after systemic immunization. IgA is present in 
measurable but relatively low concentrations in serum since it is a mucosally secreted 
antibody, and it is the predominant isotype capable of neutralizing antigen at mucosal 
surfaces and in secretions (Pabst, 2012). For this reason, IgA is usually quantified in milk 
or colostrum.  
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The characteristic response to primary immunogenic stimulus occurs 5-10 days 
following immunization, with a small peak in antibody production (Liu et al., 1991). The 
primary production of antibody isotypes would follow the order of IgM > IgG > IgA. The 
secondary response occurs more rapidly (after a booster dose of immunogenic stimulus), 
usually within 1-3 days with a much larger peak in antibody production (Liu et al., 1991). 
The production of antibody isotypes would follow the order of IgG > IgA > IgM in the 
secondary response. Antibody production generally returns to protective baseline levels 
after a period of thirty days. 
 Previously, dietary consumption of omega-3 PUFA has been shown to increase 
titres of IgM and IgG in Sprague Dawley rats, and this is more pronounced with DHA 
supplementation than with EPA supplementation (Sugano et al., 2000). The immune 
response to antigens during omega-3 dietary enrichment has been well studied in chickens, 
and the results of these experiments assist in the current understanding of immune 
responses during PUFA supplementation. A previous study investigated the immune 
response of broiler chicks while supplementing the diet with different sources of omega-3 
PUFA, either from tuna oil or sunflower oil (Maroufyan et al., 2012). The main findings 
of the study were that the omega-3 PUFA profiles were significantly increased in the 
plasma of chicks receiving fish oil supplements, and the antibody titres and interleukin-2 
(IL-2) concentrations increased with dietary PUFA enrichment. Increased IL-2 production 
could explain the increased antibody titres, since IL-2 is a key cytokine involved in 
developing adaptive responses. IL-2 is also a key cytokine for T cell activation 
(Popmihajlov et al., 2012), and so it indirectly facilitates immunoglobulin production. In 
another dietary PUFA study involving chickens, it was discovered that birds fed diets 
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enriched in α-linolenic acid, an omega-3 fatty acid, had increased titres of specific 
antibodies after KLH immunization (Sijben et al., 2001). However, when the animals were 
fed both linoleic acid (an omega-6 fatty acid) in combination with α-linolenic acid, lower 
anti-KLH antibody titres were found. These results suggest that α-linolenic acid may have 
involvement in antigen presentation, while linoleic acid may hinder the antigen 
presentation process (Sijben et al., 2001). These studies in chickens illustrate the capability 
of PUFA to modulate the immune system and provide a platform to further study immune 
functions of fatty acids in cattle. 
Flaxseed is also a source of omega-3 fatty acids that may potentially modify bovine 
immune responses. Farran et al. (2008) investigated the immune responses of cattle fed 
diets containing flaxseed (rich source of α-linolenic acid, an omega-3 fatty acid) or soy 
(rich source of linoleic acid, an omega-6 fatty acid). Cattle fed flaxseed had significantly 
higher omega-3 fatty acid concentrations in the plasma (Farran et al., 2008), confirming 
that dietary interventions may alter plasma lipid profiles. In addition, cattle fed flaxseed 
had lower concentrations of tumour necrosis factor-alpha (TNF-α) in response to injection 
of lipopolysaccharide (LPS) and lower body temperatures than cattle receiving the soy 
supplement (Farran et al., 2008). Another study investigated the immune response of cattle 
fed either flaxseed or fish oil as omega-3 supplements (Caroprese et al., 2009). Cattle fed 
flaxseed produced higher titres of IgG antibodies specific for the immunizing antigen, and 
also displayed significantly lower levels of IL-10 than cattle fed fish oil. IL-10 is a 
regulatory cytokine which inhibits TH1 cells as well as macrophage activity (Borish, 1998). 
A lower concentration of this cytokine was interpreted to indicate suppression of TH2 
cytokine production, although it could have also indicated decreased Treg activity. In 
6 
 
another study which solely studied the bovine immunization response after omega-3 fish 
oil supplementation found increased secondary IgG responses to ovalbumin (Ballou and 
DePeters, 2008). The findings from these studies provide evidence that the fatty acid source 
as well as differing amounts of EPA and DHA concentrations in omega-3 supplements 
modulate distinctive aspects of the immune response. Further studies are required to 






















Chapter 1 Study Objectives 
 
 To evaluate effects of dietary supplemented fatty acids on the bovine immune 
system, an experiment was designed to examine impacts of feeding dairy cattle omega-3 
PUFA supplements in two separate feed management systems on responsiveness to 
immunization. This trial was named AIF Trial #7, after the Atlantic Innovation Fund, and 
it was carried out in 2008. In a previous experiment (AIF Trial #6), influences of dietary 
algae on bovine immune responses to KLH immunization were evident, and this provided 
the rationale for continuing with KLH immunization investigation in Trial #7. The omega-
3 fatty acid sources for this trial were dietary microalgae or fish oil. Pasture (grazing cattle 
in open pasture) and confinement (cattle kept in barn tie stalls) were the feed management 
systems utilized in the trial. It was hypothesized that cattle receiving the microalgae 
supplement would have increased responsiveness to KLH immunization compared to cattle 
on the fish oil supplement or control diet, since the microalgae had a distinctively high 
DHA to EPA ratio. Cytokines and immunoglobulins measured while investigating the 
impact of supplementing the diet with fatty acids on response to immunization with KLH 
are shown in Table 1-1.  
 
Objective 1: to directly examine the effects of supplementing fatty acids in the feeding 
regime on the bovine immune system, and specifically on the T-cell dependent antibody 
response to KLH immunization and cytokine production. 
Objective 2: to investigate differences in adaptive immunological responses to KLH 







AIF Trial #7 Experimental Design 
 
 AIF Trial #7 took place in 2008 as a collaborative project with the researchers at 
the Nova Scotia Agricultural College (NSAC). The other researchers involved in the 
project were interested evaluating molecular effects of the dietary fatty acid supplements, 
lipid metabolic pathways, milk quality, health parameters of the calves and placenta 
quality. My primary interests involved measuring the adaptive immune response to 
immunization and potential alterations in immune activity. The trial was constructed as a 
2×3 factorial design involving 48 female Holstein dairy cows over a period of 120 days. 
Cattle were blocked according to parity so that experimental analysis could take place over 
a typical lactation period.  
The dietary supplements used in the trial were a control (no lipid supplement 
provided), a rumen protected fish oil or a rumen protected microalgae. Dietary supplements 
were provided to cattle in a 300 g dose per day. The fish oil supplement was Epax® 5500 
(Pronova Biocare A.S., Lysaker, Norway), a highly refined and enriched fish oil containing 
a minimum DHA and EPA content of 55%. Fatty acid analysis of the fish oil supplement 
conducted by Dr. Payam Vahmani (PhD candidate at NSAC during the time of the trial) 
revealed nearly equal concentrations of DHA and EPA, with the DHA content as 12.33 
g/100 g of total fatty acids and EPA content as 15.85 g/100 g of total fatty acids (Vahmani 
et al., 2013). The microalgae supplement was the same algae species used previously in 
AIF Trial #6 (proprietary), and characteristically has a high DHA content and low EPA 
content. Microalgae DHA content was 24.23 g/100 g of total fatty acids and the EPA 
content was 1.61 g/100 g of total fatty acids (Vahmani et al., 2013). The main difference 
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between supplements were that the fish oil had half of the DHA content of the microalgae 
supplement, while the microalgae had one tenth of the amount of EPA content of the fish 
oil supplement, and the control lacked DHA and EPA. Both omega-3 fatty acid 
supplements were protected against ruminal biohydrogenation using a proprietary process 
by project collaborators at the NSAC. A ruminant nutritionist was involved in the trial and 
balanced the diets to ensure the feeds met cattle nutritional requirements. Details on the 
fatty acid composition as well as the ingredient and nutritive composition of the feeds have 
been published previously (Vahmani et al., 2013; Vahmani et al., 2014). Cattle began 
feeding on the dietary supplements 30 days before calving and continued for 90 days 
following parturition, making the trial a total of 120 days. 
There were two feed management systems utilized in this trial; pasture or 
confinement. In the pasture feed management system, cattle were allowed to graze through 
a rotation of two pastures, and were brought into the barn twice daily to receive 
concentrated dietary supplements. Cattle designated to be in the confinement feed 
management system were fed total mixed rations (TMR) twice daily at ad libitum intake 
while housed in the barn tie stalls, and received the concentrated dietary supplements prior 
to feedings. The cattle in the confinement management system have been referred to as the 
TMR group. All cattle had continuous access to water and were milked twice daily 
following parturition. The pasture management system represented traditional farming 
practices, whereas the confinement/TMR management system represented industrial 
farming practices. Cattle were maintained in the feed management systems for the same 
duration as dietary supplement feeding period. The sample numbers were unbalanced 
between pasture (n = 23) and TMR (n = 25) management systems due to the sudden death 
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of a cow (twisted stomach) in the pasture system and an extra cow in the TMR system. The 
segregation among diets was as follows: on pasture control n = 8, microalgae n = 8, fish 
oil n = 7; and on TMR control n = 9, microalgae n = 8 and fish oil n = 8.  
To measure adaptive immune responses, cattle were immunized with KLH, a 
standard T cell dependent antigen commonly used to determine humoral responses to 
immunization (Estrada et al., 1999). KLH (Sigma Aldrich, St. Louis, MO, USA) was 
reconstituted and diluted in phosphate-buffered saline under aseptic conditions. Each cow 
received a total KLH dosage of 1 mg in 50 mL of solution per immunization, which was 
separated into two 25 mL intramuscular injections. Cattle were injected with a 25 mL 
dosage under the skin of each shoulder, which was gently rubbed following injection for 
distribution and leakage prevention. Cattle received dietary supplements in their feed 
management systems for a total of 39 days before they were administered their primary 
immunization with KLH. Cattle received a booster dose of KLH 14 days after primary 
immunization, which represented 53 days on dietary supplements in the feed management 
systems. Blood was drawn from the tail vein into vacutainer tubes without preservative, 
which was necessary for the measurement of fatty acid composition and hormone assays 
by the other researchers involved on the project. Blood and milk were drawn from cattle at 
baseline (prior to initial KLH injection), 1, 7 and 14 days following primary immunization, 
7 days following secondary immunization, and on the final day of the trial. Serum and milk 
samples were stored at -80°C until analysis. Cattle immunizations, blood draws and 





Measurement of Antibody Production During KLH Immunization 
 
Antibody levels of all 48 cows were measured in order to evaluate whether fatty 
acid supplementation had an effect on the response to immunization, and also to determine 
if there were differences in immune responses of cattle consuming different omega-3 fatty 
acid supplements or on distinct feed management systems. Antibody concentrations were 
measured at four specific days during the trial, which represent the immunization baseline 
(day 0), primary response (7 days after initial KLH immunization), secondary response (21 
days after initial KLH immunization and 7 days following KLH booster) and long-term 
response (51 days after initial KLH immunization and final day of the trial). These KLH 
time points with corresponding days on supplement/feed management system and days 
since calving are shown in Table 1-2. Concentrations of IgM, IgG and its subclasses were 
measured in serum. IgA concentrations were measured in milk since IgA is the 
predominant mucosal isotype, and there was interest in determining if any dietary effects 
were detectable at the mucosal level. Antibody profiles were analyzed using Bovine Ig 
enzyme-linked immunosorbent assay (ELISA) Quantitation Sets (Bethyl Laboratories Inc., 
Montgomery, TX, USA) for IgA, IgM, IgG, IgG1, and IgG2 isotypes. Total Ig 
concentrations were measured as directed by the manufacturer and were carried out using 
96-well high-binding full area microplates (Greiner Bio-One, Frickenhausen, Germany). 
In order to measure KLH-specific antibody concentrations including anti-KLH IgM, anti-
KLH IgG and its subclasses anti-KLH IgG1 and anti-KLH IgG2, and anti-KLH IgA, ELISA 
plates were coated with 10 µg/mL of KLH antigen in 0.05 M carbonate-bicarbonate buffer 
pH 9.6 overnight and blocked with 50 mM Tris, 0.14 M NaCl, 0.05% Tween 20 pH 8.0. In 
separate sequential steps, samples were diluted and incubated on the ELISA plate, and then 
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HRP-conjugated bovine Ig detection antibodies were added to the assay. The chemical 
substrate, 3,3’5,5’ tetramethylbenzidine (TMB; Sigma Aldrich, St. Louis, MO, USA) was 
added and the colorimetric reaction was stopped with the addition of 1.8 N H2SO4. The 
optical density of the reactions in the microplates were read at a wavelength of 450 nm on 
a Synergy HT multi-detection microplate reader using KC4 v3.4 analysis software (BioTek 
Instruments Inc, Winooski VT, USA). The Ig and anti-KLH Ig concentrations were 
calculated in unknown samples from a standard curve. 
 
Measurement of Cytokine Activity During KLH Immunization 
 
Cytokines IL-4, IFN-γ, active and total TGF-β1 were chosen for analysis in order 
to determine possible mechanisms of immunomodulation as well as shifts in the balance 
of TH1 and TH2 cell responses that may have been induced by the omega-3 supplements or 
feed management systems, as these cytokines are involved in Ig class switching. Cytokine 
concentrations were measured in serum using the bovine IL-4 ELISA reagent kit (Thermo 
Fisher Scientific, Waltham, MA, USA), IFN-γ and TGF-β1 DuoSet ELISA Development 
kits (R&D Systems, Minneapolis, MN, USA) according to manufacturer’s procedures. 
Active and total TGF-β1 concentrations were quantified separately due to the requirement 
of a sample activation procedure. “Active” TGF-β1 was measured in serum as any other 
cytokine, since this form of TGF-β1 was already in its immunoreactive form. However, in 
order to measure the “total” amount of TGF-β1, activation of latent TGF-β1 was necessary 
since this cytokine cannot be measured by ELISA with the attachment of its latency-
associated protein (LAP), which inhibits TGF-β1 bioactivity (Annes et al., 2003; Kropf et 
al., 1997). Once the LAP has been cleaved, the total amount of TGF-β1 can be quantified, 
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including both biologically active and previously latent forms, since antibodies used in the 
ELISA bind only to the active form of the cytokine only. The sample activation procedure 
was carried out in microcentrifuge tubes treated with Sigmacote® (Sigma Aldrich, St. 
Louis, MO, USA), which is a solution of chlorinated organopolysiloxane in heptane that 
prevents TGF-β1 protein from binding to the surface of the tubes. In each tube, 20 µL of 
1N HCl was added to 40 µL of serum and incubated for 10 minutes at room temperature. 
Acidification was neutralized with the addition of 20 µL of 1.2 NaOH/0.05M 4-(2-
hydroxyethyl)-1piperazineethanesulfonic acid (HEPES), and samples were subsequently 
diluted in reagent diluent for the analysis of “total” concentrations of TGF-β1. The time 
points chosen for cytokine analysis in serum included KLH d0, d1, d7, d14, d21 and d51. 
Organ tissues were collected from 24 cows involved in the trial, while the 
remaining 24 cows were led to pasture retirement. Spleen and caecum tissues were 
analyzed for 12 cows in the TMR group and 12 cows in the pasture group (n = 4 on fish 
oil, n = 4 on microalgae and n = 4 on control for each feed management system). The spleen 
was chosen to examine immune activity at the systemic level, and the caecum was chosen 
to examine activity at the level of the mucosa-associated lymphoid tissue (MALT). These 
tissues were homogenized in phosphate buffered saline (137 mM NaCl, 2.7 mM KCl, 8.1 
mM Na2HPO4, 1.5 mM KH2PO4, pH 7.4) with the addition of 1% Protease Inhibitor 
Cocktail (Sigma Aldrich, St. Louis, MO, USA). Tissues were suspended in the buffer at a 
ratio of 1:5 (wt/vol) and then homogenized using a VWR®200 homogenizer (VWR 
International, Radnor PA, USA) and centrifuged (17 200 × g for 30 min at 4C). 
Supernatants were collected and stored at -80C until cytokine analysis by the same 
ELISAs used in the analysis of serum samples (IL-4, IFN-γ and active/total TGF-β1). 
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These tissue measures were representative of immune activity from the final day of the 
trial, 51 days after immunization with KLH and 120 days after receiving dietary 
supplements in the feed management systems. All cytokine ELISAs were carried out using 
the same microplates, plate reader and analysis software as the Ig ELISAs. 
Statistical Analyses 
 
For the analyses of the Ig data, assistance was received from a statistician, Sherry 
Fillmore, Statistical Project Manager with Agriculture and Agri-Food Canada (AAFC, 
Kentville, Nova Scotia), since she had history working with previous AIF trials. This 
statistician’s expertise was required due to blinding by dietary supplement identity 
throughout experimentation and to the complexity of the trial design with varying lactation 
cycles. The statistician has access to documents detailing the life history of the cattle; which 
included situations of multiparity and general health information that could have led to the 
exclusion of certain cows from the analysis. Ig data analysis was carried out using Genstat 
v14.0 software (VSN International, Hemel Hepstead, UK). The data was first transformed 
using a log10 transformation, and then analyzed by a restricted maximum likelihood model 
(REML) since the dataset was unbalanced, followed by Fisher’s least significant difference 
(LSD) multiple range test for comparisons within feed management system and supplement 
groups. In the evaluation of Ig changes across days, linear regression was used to collect 
linear and quadratic coefficients across time. The Ig plots demonstrating immunization 
responses to KLH were created using SigmaPlot v13.0 (Systat Software Inc., San Jose, CA, 
USA).  
The statistical analysis program SigmaPlot v13.0 (Systat Software Inc., San Jose, 
CA, USA) was used to analyze cytokine data collected during this trial. Data was analyzed 
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by two-way analysis of variance (ANOVA) to examine differences between omega-3 fatty 
acid supplements and control, pasture and TMR feed management systems as well as feed 
management system and supplement interactions (feed system × suppl.). ANOVA analysis 
was followed by Tukey’s pairwise multiple comparison tests. Data was transformed if it 
did not pass normality (Shapiro-Wilk) or equal variance (Brown-Forsythe) tests, using 
common transformations available in the software program. A P value of < 0.05 was 






















Assessment of Antibody Production in Response to KLH Immunization 
 
 Immunoglobulin concentrations were measured in order to quantify antibody 
production in response to the bovine KLH immunization. Total antibody concentrations 
were measured for each immunoglobulin isotype in addition to antibody concentrations 
specific for the KLH antigen. 
Total IgM and anti-KLH IgM production in response to KLH immunization was 
measured in serum and is displayed in Figure 1-1. There was an overall effect of feed 
management system on total IgM concentrations (P < 0.001), cattle grazing in pasture had 
higher IgM concentrations than those fed TMR while housed in barn tie stalls. On KLH 
d21 (secondary response), cattle in the pasture feed management system displayed higher 
total IgM concentrations than those in the TMR system (P < 0.001). Supplement did not 
have a significant effect on total IgM concentrations, and no interactions of feed system × 
supplement were found. An overall effect of feed management system was also evident on 
anti-KLH IgM concentrations (P < 0.001). Similar to total IgM concentrations, cattle on 
TMR had decreased anti-KLH IgM production in comparison to cattle grazing in pasture. 
On KLH d7 (primary response, P < 0.001) and KLH d21 (secondary response, P = 0.001), 
cattle in the pasture feed management system had higher anti-KLH IgM concentrations 
than those in the TMR system. There was an effect of supplement on anti-KLH IgM 
concentrations (P = 0.043); cattle on microalgae displayed higher concentrations than those 
on control, however cattle on fish oil did not differ from those on control or microalgae. 
There was an overall interaction of feed system × supplement on anti-KLH IgM 
concentrations (P = 0.049). 
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Total IgG and anti-KLH IgG production in response to KLH immunization was 
measured in serum and is displayed in Figure 1-2. There was an overall effect of feed 
management system on total IgG concentrations (P < 0.001), cattle grazing in pasture had 
higher IgG concentrations than those fed TMR while housed in barn tie stalls. On KLH 
d21 (secondary response), there was a significant difference between total IgG 
concentrations based on feed management system (P < 0.001), with cattle in the pasture 
group having higher concentrations than those in the TMR group. Supplement had an effect 
on total IgG concentrations (P = 0.003); cattle on the microalgae supplement had the 
highest total IgG concentrations overall. There was a significant interaction of feed system 
× supplement overall on total IgG concentrations (P = 0.008). An overall effect of feed 
management system was also evident in concentrations of anti-KLH IgG (P < 0.001). 
Similar to total IgG concentrations, cattle on TMR had decreased anti-KLH IgG production 
in comparison to cattle on pasture. On KLH d21 (secondary response), cattle in the pasture 
feed management system displayed higher anti-KLH IgG concentrations than those in the 
TMR system (P < 0.001). There was an effect of supplement on anti-KLH IgG 
concentrations (P = 0.041); cattle on fish oil or algae displayed higher concentrations than 
cattle on control in pasture, while the opposite pattern occurred in cattle on TMR. There 
was an overall interaction of feed management system × supplement on anti-KLH IgG 
concentrations (P = 0.044), and this interaction was also evident at KLH d21 (P = 0.014). 
 Anti-KLH IgG1 and anti-KLH IgG2 production in response to KLH immunization 
was measured in serum and is displayed in Figure 1-3. There was an overall effect of feed 
management system on anti-KLH IgG1 concentrations (P < 0.001); cattle grazing in pasture 
had higher anti-KLH IgG1 concentrations than those fed TMR while housed in barn tie 
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stalls. This difference between anti-KLH IgG1 concentrations due to feed management 
system was apparent on KLH d7 (primary response, P = 0.005), KLH d21 (secondary 
response, P < 0.001) and KLH d51 (long-term response, P = 0.001). Supplement had 
overall trend (P = 0.065) on anti-KLH IgG1 concentrations; cattle on fish oil or microalgae 
supplements tended to have increased concentrations compared to those on control. There 
was a significant interaction of feed management system × supplement overall on anti-
KLH IgG1 concentrations (P = 0.023). An overall effect of feed management system was 
also evident on anti-KLH IgG2 concentrations (P = 0.047); cattle on pasture displayed 
higher concentrations than those on TMR. On KLH d21 (secondary response), cows in the 
pasture feed management system had significantly higher anti-KLH IgG2 concentrations 
than those in the TMR system (P = 0.002). In common with anti-KLH IgG1 concentrations, 
supplement showed a trend toward significance (P = 0.059) on anti-KLH IgG2 
concentrations; cattle on the microalgae supplement tended to have increased anti-KLH 
IgG2 concentrations compared to control, however cattle on fish oil did not differ from 
those on control or microalgae. On KLH d7 (primary response), there was an effect of 
supplement (P = 0.031), and cattle on fish oil and microalgae had higher anti-KLH IgG2 
concentrations than those on control. There was a significant interaction of feed 
management system × supplement overall on anti-KLH IgG2 concentrations (P = 0.013), 
and this was also evident on KLH d7 (primary response, P = 0.026). 
Total IgA and anti-KLH IgA production in response to KLH immunization was 
measured in milk and is displayed in Figure 1-4. There was an overall effect of feed 
management system on total IgA concentrations (P = 0.003); cattle grazing in pasture had 
higher IgA concentrations than those fed TMR while housed in barn tie stalls. Supplement 
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had an effect on total IgA concentrations (P = 0.003); cattle on the fish oil supplement had 
significantly lower concentrations than those on control or microalgae. On KLH d51 (long-
term response), cattle on fish oil had the lowest IgA concentrations (P = 0.038). There was 
a significant interaction of feed system × supplement (P = 0.049) on IgA concentrations at 
KLH d7 (primary response). There was also an overall effect of feed management system 
on anti-KLH IgA concentrations (P < 0.001). Similar to total IgA concentrations, cattle on 
TMR had lower anti-KLH IgA production, while cattle on pasture had higher 
concentrations overall, but the supplement effect was not statistically significant. Anti-
KLH IgA concentrations were significantly different between feed management systems 
on KLH d7 (primary response, P = 0.045), d21 (secondary response, P < 0.001) and d51 
(long-term response, P < 0.001). There was no significant effect of supplement on anti-
KLH IgA production. 
 
Assessment of Cytokine Activity in Response to KLH Immunization 
 
Cytokine concentrations were measured in order to determine the level of immune 
activity in response to bovine KLH immunization. Examination of changes in patterns of 
cytokine concentrations over the course of the immunization schedule allowed for 
determinations of shifts in the balance of TH1 and TH2 cell responses. Analysis of cytokine 
data also provided a means to assess how the omega-3 supplements or feed management 
systems influenced immune activity. 
 IL-4 was chosen for analysis due to its active role in adaptive immunity, in the 
differentiation of naïve CD4+ T cells into helper TH2 cells and in antibody isotype 
switching to IgG1. IL-4 is considered to be a signature TH2 cytokine. Concentrations of IL-
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4 were measured in serum over five different time points throughout the trial (Table 1-3); 
however, concentrations of this cytokine were very low and even below the level of 
quantification (BLQ) in some circumstances. This made statistical analysis difficult since 
there only two cows on control and a single cow on microalgae in the pasture group that 
displayed IL-4 production on KLH d0, a single cow on control and a single cow on fish oil 
in the pasture group that displayed IL-4 production on KLH d1, while no cattle displayed 
measurable serum IL-4 concentrations on KLH d7, and a single cow on microalgae in the 
TMR group had a measurable IL-4 concentration on KLH d21. Increased serum IL-4 
concentrations were observed on KLH d51, however there were no differences in 
concentrations attributable to feed management system or supplement. IL-4 concentrations 
were also quantified in splenic and caecal tissue; however, no differences were found 
between tissue concentrations in cattle from separate feed management systems or 
supplements. 
 IFN-γ was chosen for analysis due to its role in cell-mediated immunity and 
inflammatory responses and is considered to be a TH1 signature cytokine. Concentrations 
of IFN-γ were measured in serum over six different time points throughout the trial (Table 
1-4); however, concentrations of this cytokine were below the level of detection on KLH 
d0, 1, 7, 21 and 51. The only time point with measurable serum IFN-γ concentrations was 
KLH d14 (the day of the KLH booster dose), although no differences in concentrations 
were found due to feed management systems or supplements. In common with the IL-4 
concentrations quantified in splenic and caecal tissue, no differences were found between 




 TGF-β1 was chosen for analysis since is an important regulatory cytokine, which 
influences antibody class switching in B cells to IgA and acts as a Treg cytokine through 
monocyte activation inhibition. Concentrations of active TGF-β1 (Table 1-5) were 
measured in serum over six different time points throughout the trial, as well as splenic and 
caecal measurements at the trial endpoint. On KLH d0, serum active TGF-β1 
concentrations were higher overall in cattle in the pasture feed management system than 
TMR (P = 0.015), and concentrations of active TGF-β1 were different between feed 
management systems in cattle on the fish oil supplement (P = 0.009). No differences in 
active TGF-β1 concentrations between feed management systems or supplements were 
found on KLH days 1, 7 or 14. On KLH d21, there was an overall effect of feed 
management system (P = 0.006) on active TGF-β1 concentrations, with cattle grazing in 
pasture having higher concentrations than those fed TMR in barn tie stalls, and this 
difference was most apparent in cattle on the control diet (P = 0.024). The overall effect of 
feed management system (P < 0.001) on active TGF-β1 concentrations was present again 
on KLH d21, with cattle in pasture having higher concentrations than those fed TMR. 
These feed management system-associated differences in active TGF-β1 concentrations 
were apparent in cattle on the control (P = 0.044) and microalgae supplement (P < 0.001). 
In the spleen, cattle in the TMR feed management system had higher active TGF-β1 
concentrations than cattle in the pasture system. An effect due to feed management system 
on active TGF-β1 concentrations was present within caecal tissue, with cattle in the pasture 
system having higher concentrations than those in the TMR system (P < 0.001). This 
difference between active TGF-β1 concentrations by feed management system was present 
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within each diet; pasture grazing cattle displayed higher concentrations than TMR-fed 
cattle on control (P = 0.020), fish oil (P < 0.001) and microalgae (P = 0.010) supplements.  
 Concentrations of total TGF-β1 (Table 1-6) were also measured in serum over six 
different time points throughout the trial, as well as in splenic and caecal tissue. On KLH 
d0, total TGF-β1 concentrations were higher overall in cattle in the pasture feed 
management system than those in the TMR system (P = 0.046). Within cattle on the fish 
oil supplement, those in the pasture group had higher total TGF-β1 concentrations than 
those in the TMR group (P = 0.039). There was a supplement effect on concentrations of 
total TGF-β1 (P = 0.021), with cattle on fish oil having higher concentrations than those 
on microalgae (P = 0.037), and those on microalgae having lower concentrations than those 
on control (P = 0.047). Within the TMR feed management system, microalgae-fed cattle 
had lower total TGF-β1 concentrations than those on control (P = 0.010). On KLH d1, total 
TGF-β1 concentrations were higher overall in cattle in the pasture feed management 
system than TMR (P = 0.042). No differences in total TGF-β1 concentrations between feed 
management systems or supplements were found on KLH days 7 or 14. On KLH d21, total 
TGF-β1 concentrations were higher overall in cattle in the pasture feed management 
system than those in the TMR system (P = 0.025), and on the microalgae supplement, 
concentrations of total TGF-β1 were higher in cattle in the pasture system than those in the 
TMR system (P = 0.026). A similar pattern was found again on KLH d51, where total 
serum TGF-β1 concentrations were higher overall in cattle in the pasture feed management 
system than in the TMR system (P = 0.009), and on the microalgae supplement, 
concentrations of total TGF-β1 were higher in cattle grazing in pasture that those which 
were TMR-fed (P = 0.029). In the spleen, an overall supplement effect was present in total 
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TGF-β1 concentrations (P = 0.007), with cattle on the microalgae supplement having 
higher concentrations than those on fish oil (P = 0.019) or control (P = 0.012). Within the 
pasture feed management system, splenic total TGF-β1 concentrations were highest in the 
cattle fed the microalgae supplement compared to those on the fish oil supplement (P = 
0.021) or control (P = 0.047). An effect due to feed management system on total TGF-β1 
concentrations was present within caecal tissue, with cattle in the pasture system having 
higher concentrations than those in the TMR system (P < 0.001). This difference between 
total TGF-β1 concentrations by feed management system was present within each diet; 
pasture grazing cattle displayed higher concentrations than TMR-fed cattle on control (P = 
0.070) and microalgae (P = 0.004), and lower concentrations than TMR-fed cattle on the 


















The rationale for continuing experimentation with supplementing the bovine diet 
with omega-3 fatty acids in the form of algae stemmed from previous AIF trials. Results 
obtained by our laboratory during AIF Trial #6 demonstrated that macroalgae 
supplementation with Tasco® (Acadian Seaplants Ltd., Dartmouth, Nova Scotia, Canada), 
an animal feed containing the brown alga Ascophyllum nodosum, increased KLH specific 
antibody production in dairy cattle (unpublished data). Tasco® has been previously shown 
to influence the bovine immune system, as cattle displayed increased macrophage activity 
when they entered new feed lots after feeding on Tasco® (Allen et al., 2001). The division 
of cattle by separate feed management systems (grazing in pasture or confined while fed 
TMR) was introduced in AIF trial #7 to reflect realistic cattle housing methods utilized in 
Canada.  
Cattle in both feed management systems and on all dietary supplements responded 
to KLH immunization, however differences in the magnitude of response were observed. 
IgM are the first class of antibodies produced in the primary response to immunologic 
stimulus (Baumgarth et al., 2005; Liu et al., 1991) and are the first line of defence against 
viral and bacterial antigens (Ehrenstein and Notley, 2010). The IgM antibody class is 
capable of strong complement activation and is highly polyvalent due to its pentameric 
structure, further enabling its ability to neutralize antigen (Ehrenstein and Notley, 2010). 
Total IgM concentrations measured in serum at all timepoints were distinctively higher in 
the cattle which grazed pasture in comparison to those which were confined in barn tie 
stalls and fed TMR, and this difference was most pronounced at the secondary response 
(21 day following immunization). Total IgM concentrations in the pasture group displayed 
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a classic immunization response. However, cattle in the TMR group did not display the 
typical immunization response pattern, and their total IgM response profile resembled that 
of their total IgG response profile which was flattened and did not follow a characteristic 
curve pattern. Cattle fed the microalgae supplement displayed higher total IgM responses 
than cattle on fish oil or control, though there was no significant effect of supplement on 
total IgM concentrations. A similar pattern was observed again in examining anti-KLH 
IgM concentrations, where cattle on pasture responded more robustly than cattle on TMR 
at primary and secondary response measurements, and followed the typical immunization 
response pattern. The anti-KLH IgM response was highest in cattle in the microalgae 
group. Production of IgM and anti-KLH IgM by cattle in the trial were far greater than 
other isotypes measured, and this would have increased the immune capacity in the event 
of viral or bacterial antigen exposure, particularly at the primary response. The cattle in the 
pasture feed management system or cattle receiving microalgae supplements had the 
highest serum total IgM and anti-KLH IgM response to immunization. 
IgG antibodies are found predominantly in blood and have involvement in effective 
viral antigen neutralization (Butler et al., 1971). IgG also facilitate opsonisation and are 
produced more slowly than IgM after a primary response to immunogenic stimulus (Liu et 
al., 1991; Mix et al., 2006). In general, all subclasses of IgG are capable of activating 
complement, although they may do so using classical, alternative or both forms of 
activation (Mix et al., 2006). Cattle which grazed pasture had higher total IgG responses 
to immunization overall in comparison to those which were confined in barn tie stalls and 
fed TMR, and this effect was specifically noted at the secondary response measure. Cattle 
in pasture displayed a classic immunization response with increasing titers at primary and 
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secondary responses, while returning to lower concentrations (maintained above baseline) 
over time. Although cattle in the TMR group did respond to immunization, they did not 
display the expected immunization response pattern for total IgG concentrations, and their 
pattern appeared to be more flattened in comparison. Microalgae-fed cattle produced 
stronger total IgG responses than those fed fish oil supplements or control. Cattle in pasture 
displayed higher anti-KLH IgG responses than those on TMR overall, and this effect was 
most pronounced at the secondary response. The production of anti-KLH IgG antibodies 
appeared to resemble the characteristic immunization response curve more than the total 
IgG antibodies, although this was not surprising given the fact that total IgG concentration 
increased due to anti-KLH IgG production. Cattle receiving both omega-3 supplements had 
higher anti-KLH IgG responses than those on control.  
IgG1 antibodies are produced by B2 cells in response to antigen when TH2 cells 
release IL-4, and this isotype is capable of strong classical and alternative complement 
activation (Butler et al., 1971; Mix et al., 2006). Cattle in the pasture management system 
had significantly higher anti-KLH IgG1 responses overall than those on the TMR system. 
Since cattle on the omega-3 supplements only tended to have higher anti-KLH IgG1 
responses than those on control, this implies that antibody production was more strongly 
influenced by feed management system. The anti-KLH IgG1 response to immunization 
followed a typical pattern. IgG2 antibody production by B2 cells is enhanced by IFN-γ 
production by TH1 cells, a process which actually inhibits IgG1 production (Mix et al., 
2006). IgG2 antibodies are capable of classical and alternative complement activation. 
Cattle in the pasture management system had significantly higher anti-KLH IgG2 responses 
than those in the TMR system, and cattle on the microalgae supplements had higher 
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responses than those on control. Production of anti-KLH IgG2 did not follow the 
characteristic immunization response pattern. The concentrations of anti-KLH IgG2 were 
much lower in quantity than anti-KLH IgG1, which was surprising since IgG2 is usually 
the predominant IgG isotype in bovine serum (Butler et al., 1971).  
A previous study conducted by van Altena et al. (2016) investigated the ability of 
naturally produced antibodies specific for KLH in dairy cattle to recognize common 
microbial structures. These cattle had not been previously immunized with KLH; however, 
they did have non-specific natural antibodies that bound KLH. It was discovered that cattle 
with higher titers of natural anti-KLH IgM displayed higher IgM binding capacity to 
Escherichia coli and Salmonella typhimurium overall (van Altena et al., 2016). Cattle 
which produced high or low titers of natural anti-KLH IgG had equal IgG binding capacity 
to E. coli (van Altena et al., 2016). This study concluded that cattle producing higher 
natural anti-KLH IgM and anti-KLH IgG concentrations had enhanced ability to bind 
pathogen-associated molecular patterns (PAMPs), and also a reduced chance in developing 
mastitis (van Altena et al., 2016). The majority of naturally produced antibodies are of the 
IgM isotype (Baumgarth et al., 2005), and the cattle in AIF Trial #7 displayed almost 63 
fold higher IgM production than IgG. The KLH-specific antibodies were also produced in 
higher quantities belonging to the IgM isotype, which was almost 10 fold higher than the 
IgG isotype at the primary response, and this was typical of a primary response to 
immunization. Since cattle with higher natural anti-KLH IgM titers have been shown to 
have reduced incidence of mastitis (van Altena et al., 2016), cattle in the pasture feed 
management system while consuming the microalgae supplement likely had increased 
antibody binding capacity to PAMPS and decreased risk of developing mastitis.  
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IgA is predominantly a mucosal isotype produced by B1 cells, and contributes to 
mucosal immunity while neutralizing antigen (Liu et al., 1991; Pabst, 2012). Since IgA is 
the major Ig in mucosal secretions (Butler et al., 1971; Guidry et al., 1980), it was 
quantified in bovine milk. Total IgA responses were highest overall in cattle that grazed 
pasture, and microalgae-fed cattle had higher concentrations than fish-oil fed cattle. This 
effect remained at the long-term response measure. Total IgA concentrations did increase 
from the baseline to KLH d7, however total IgA concentrations did not follow the typical 
pattern of an antibody response to immunization with a rapid increase during the secondary 
response followed by a gradual decline in antibody concentrations specific for the 
immunizing antigen. In fact, the responses were completely inconsistent between 
supplements, and the TMR-fed cattle seemed to display diminishing total IgA 
concentrations over the KLH immunization schedule while the cattle in the pasture group 
appeared to increase total IgA concentrations. Anti-KLH IgA responses were higher in the 
pasture group of cattle, and this pattern was consistently observed over primary, secondary 
and long-term responses.  
The presence of anti-KLH IgA production in milk suggests that a mucosal immune 
response occurred during systemic KLH immunization. In order to further explore impact 
of these dietary supplements and feed managements on the mucosal immune response, 
other mucosal samples besides milk should be collected for measurement and analysis of 
Ig concentrations, such as nasal secretions (Corbeil et al. 1984), salivary secretions 
(Sakaquchi et al. 2013), or faecal samples (Tolleson et al. 2013). The total Ig 
concentrations within milk collections may have fluctuated naturally over the weeks 
following parturition, with the possibility of steadily decreasing antibody transfer to the 
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calf influencing the total Ig concentrations in milk more strongly than the KLH 
immunization did. It is also important to consider that the responses over primary, 
secondary and long-term responses may have differed if the KLH was administered 
mucosally instead of the intramuscular (systemic) injection. However, it is possible that 
mucosal KLH immunization may not have induced a stronger Ig production response since 
the delivery of antigen to a mucosal surface may also induce tolerance, and this route of 
antigen tolerization has been shown in cattle (Weiss et al. 2006).  
Specific cytokine concentrations were analyzed an effort to examine mechanisms 
of immunomodulation and shifts in the balance of TH1 and TH2 cell responses. IL-4 was 
chosen as a TH2 marker in the analysis of KLH immunization parameters because its 
signaling regulates the differentiation of naïve CD4+ T cells into helper TH2 cells, (Paul, 
1991), it is involved in B cell isotype class switching to IgG1 (Pinchuk et al., 2003) and is 
considered a TH2 signature cytokine. It was difficult to measure serum IL-4 as it was 
undetectable at the primary and secondary responses. At the long-term response, IL-4 was 
detectable in serum, spleen and caecum, but no differences between feed management 
system or omega-3 supplements were found. IFN-γ was chosen as a TH1 marker in the 
analysis of KLH immunization parameters since it has involvement in cell-mediated 
immunity, and is considered a TH1 signature cytokine (Schroder et al., 2004). Similar to 
IL-4, it was difficult to measure IFN-γ in serum since it was undetectable at most points 
throughout the trial. Splenic and caecal IFN-γ concentrations measured at the end of the 
trial did not differ between feed management systems or dietary PUFA supplements. The 
fact that the IFN-γ tissue concentrations did not differ at the end of the trial may not 
however be representative of tissue IFN-γ concentration fluctuations throughout the trial. 
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Unfortunately, it was not possible to take these tissue measurements during the trial. It was 
interesting that IFN-γ concentrations were highest in serum at KLH d14, which was the 
day cattle received their booster KLH dose, perhaps reflecting a heightened TH memory 
response, as the blood was drawn within hours of the cattle receiving the KLH injections. 
If IL-4 and IFN-γ concentrations had shown change, IL-4/IFN-γ production ratios would 
have been calculated to determine if there was a shift towards either TH1 cell mediated 
activity or TH2 humoral activity (Becker, 2006; Paul, 1991; Roman et al., 1997). However, 
this was not possible because serum concentrations of these TH1 and TH2 cytokines were 
not detectable at several time points during the trial. Serum cytokine quantification is often 
not the optimal measure to monitor the activity of IL-4 and IFN-γ (Albers et al., 2005). 
While tissue measures are preferable, they are not always possible. 
  TGF-β1 was chosen in the analysis of KLH immunization parameters because it is 
an important Treg cytokine (Tran, 2012), it inhibits monocyte activation, influences 
antibody class switching to IgA in B cells and it can be also be considered a TH2 cytokine 
(Li et al., 2006; Rubtsov and Rudensky, 2007). At baseline, secondary and long-term 
response measurement points, cattle in the pasture feed management system produced 
higher serum concentrations of active TGF-β1 than those in the TMR system. In splenic 
tissue (representing a systemic measure), cattle in the TMR system displayed higher active 
TGF-β1 concentrations than those in the pasture system. In caecal tissue (representing a 
mucosal measure), the opposite pattern emerged and cattle in the pasture system on each 
diet produced higher active TGF-β1 concentrations than those in the TMR system. It is 
acknowledged that TGF-β1 may have also been produced not only by immune cells but 
also by the intestinal epithelial cells of the caecal tissue, and this may represent direct 
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effects of the diet in the pasture management system. At baseline, one day following initial 
immunization with KLH, secondary and long-term measurement points, cattle in the 
pasture feed management system produced higher serum concentrations of total TGF-β1 
than those in the TMR system. Higher total TGF-β1 concentrations were also evident in 
the caecal tissue of cattle in the pasture group. At the baseline measure, cattle consuming 
fish oil had the highest serum total TGF-β1 concentrations, while cattle which consumed 
microalgae had the highest splenic total TGF-β1 concentrations suggesting a long-term on 
impact of this supplement on systemic TGF-β1 production. These patterns of serum active 
and total TGF-β1 production do follow the total IgA and anti-KLH IgA responses measured 
in milk, which were most strongly influenced by the pasture feed management system. 
A previous study conducted by Garcia et al. (2014) measured immune responses in 
newborn Holstein calves which received unsaturated fatty acid supplements in the form of 
either high or low linoleic acid (an omega-6 PUFA). The ex-vivo IFN-γ production by 
isolated peripheral blood mononuclear cells (PBMCs) after stimulation with concanavalin 
A was measured, and it was found that PBMCs isolated from calves on high linoleic acid 
had increased production of IFN-γ. The study conclusions were that calves receiving the 
high linoleic acid supplement had earlier development of TH1 activity due to increased 
capacity to produce IFN-γ (Garcia et al., 2014).  
An objective of AIF Trial #7 was to measure whether or not there were shifts in the 
balance of TH1 and TH2 activity based on systemic or mucosal concentrations of IL-4, IFN-
γ, active and total TGF-β1. Since there were no apparent differences due to feed system or 
supplement on concentrations of IL-4 and IFN-γ, it was difficult to determine a direct 
TH1/TH2 shift based on these cytokines. However, active and total TGF-β1 concentrations 
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in serum and tissue were highest in cattle in the pasture feed management system, and 
TGF-β1 is an important regulatory cytokine with an ability to influence TH1 and TH2 
activity. Cattle in the pasture system also produced higher concentrations of total and anti-
KLH specific antibodies, which suggests heighted TH2 activity. Additionally, there was a 
shift in the balance of anti-KLH IgG1 and anti-KLH IgG2 concentrations. IgG2 production 
is associated with TH1 activity and IgG1 production is indicative of TH2 activity (Mix et 
al., 2006). IgG2 antibodies are typically more predominant in bovine serum than IgG1 
(Butler et al., 1971); however, cattle produced higher serum concentrations of anti-KLH 
IgG1 than anti-KLH IgG2 throughout the response to KLH immunization. The total increase 
in Ig production and anti-KLH IgG1/IgG2 antibody prevalence further indicates a shift 
towards TH2 activity. Specifically, cattle in the pasture management system and those 
supplemented with microalgae (higher DHA and lower EPA content than fish oil) 
demonstrated a response indicative of shift towards TH2 activity greater than those in the 
TMR system or on the control.  
Studies have previously investigated differences between pasture and TMR 
management systems in dairy cattle, but their focus has mainly been on milk production 
and overall milk quality (Bargo et al., 2002; Kolver and Muller, 1998). It has been reported 
that cattle in pasture have lower milk production (Kolver and Muller, 1998), and cattle in 
confinement fed TMR produce milk with higher fat and protein content (Bargo et al., 
2002). The differences between these feed systems on cattle immunity and various health 
parameters are under-studied. Diverse variables may contribute to the impact of feed 
system. For example, it is possible that differences in exercise, social interaction or 
isolation and barn-associated stressors may influence immune activity. AIF trial #7 results 
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demonstrate distinct differences between these two feed management systems with respect 
to bovine immunization responses, suggesting that feed management systems do have an 
impact on immune parameters, although the mechanism behind these differences remains 
to be determined. 
Microalgae and fish oil have been previously supplemented in the bovine diet, 
however the extent to which they may influence bovine immunity has not been thoroughly 
investigated. A study which investigated microalgae feeding found that cattle produced 
milk with higher DHA content while on the microalgae supplement, and this milk was 
considered to have higher nutritional quality (Franklin et al., 1999). In a separate study 
investigating the effects of supplementing the bovine diet with fish oil, it was found that 
fish oil consumption did not influence the expression of genes involved in lipid metabolism 
in skeletal muscle or in the liver (Gessner et al., 2016). There have not been any negative 
impacts of omega-3 fatty acid supplementation on bovine health or metabolism parameters 
reported in the literature. After analyzing data collected during AIF Trial #7, cattle on the 
omega-3 supplements produced higher concentrations of total IgA, total IgG, anti-KLH 
IgG, anti-KLH IgG1/IgG2, and anti-KLH IgM than cattle on control, and production was 
most often higher in cattle which consumed microalgae. These findings demonstrate that 
the source of omega-3 and the DHA/EPA ratio may differentially modulate immune 
activity, as suggested by Caroprese et al. (2009) and Franklin et al. (1999). Given that the 
KLH formulations did not contain any adjuvant, supplementing the bovine diet with 
omega-3 fatty acids, specifically microalgae, could be an effective strategy in optimizing 
responses to routine vaccinations. Since polysaccharides from algae have been proposed 
to activate TLR4 (Zhang et al. 2016), this could be a possible adjuvant mechanism involved 
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in the enhancement of the response to immunization induced by dietary microalgae 
supplements. 
It was acknowledged that the group of cattle which grazed in pasture may have had 
more exercise than the cattle fed TMR while housed in barn tie stalls. In a human meta-
analysis study investigating the efficacy of exercise prior to influenza vaccination, it was 
determined that the level of exercise did not influence the efficacy of the vaccination 
(Grande et al., 2016). The influence of exercise on cattle immunization parameters has not 
been well documented, and the amount and frequency of cattle movement or exercise was 
not recorded during the AIF Trial #7, making it difficult to equate the immunological 
findings with exercise. Experimentation on the metabolic properties of these cattle was 
conducted by Dr. Payam Vahmani (PhD candidate at NSAC during the time of the trial), 
and he calculated the net energy balances between feed management systems and 
supplements. There were no significant differences in net energy balance between cattle 
grazing pasture and cattle fed TMR in barn tie stalls, and no significant differences between 
cattle on fish oil or microalgae supplements (Vahmani et al., 2014). However, cattle 
grazing pasture did have lower blood glucose concentrations and lower energy intake 
overall (P ≥ 0.13, Vahmani et al., 2014).  
In future trials investigating immunization responses in cattle on various 
supplements or feed management systems, it will be important to consider the timing of 
sample collections, the types of samples that should be collected, and the immunizing 
agent. In the current trial, serum and milk were collected for Ig concentration 
measurements at baseline, 7, 14, 21 and 51 day following KLH immunization. After Ig 
analysis, the timing of these sample collections did represent strong differences between 
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the two feed management systems, however it did not allow for an investigation of the 
potential impact on kinetics of the anti-KLH response. In order to examine this aspect of 
the response to immunization, blood should be collected every one to two days so that 
potential differences in the time to peak antibody responses may be compared between 
cattle on different dietary supplements and feed management systems. For a full 
investigation of a mucosal response to immunization, other samples in addition to milk 
during a typical lactation cycle should be collected, such as salivary or nasal secretions and 
faecal samples. It would also be interesting in future feed management studies to vaccinate 
cattle with an infectious agent that would be relevant to cattle, such as J-VAC® (Merial 
Canada Inc., Baie d’Urfé, Québec, Canada). This bovine vaccine is protective against E. 
coli mastitis, and also endotoxemia caused by E. coli and S. typhimurium. This vaccination 
strategy may be useful in studying whether pasture grazing cattle have higher 
concentrations of antibodies that will protect against frequently encountered infectious 
agents. 
In conclusion, the pasture feed management system affected the magnitude of the 
bovine response to KLH immunization to a greater extent than the TMR system. The cattle 
which grazed pasture produced higher total and anti-KLH antibody concentrations over 
primary, secondary and long-term responses. Additionally, dietary omega-3 
supplementation improved the bovine response to KLH immunization compared to control, 
and microalgae supplementation (higher DHA/lower EPA ratio than fish oil) was more 
frequently associated with higher total and anti-KLH antibody production than fish oil. The 
pasture feed management system and microalgae supplement supported a shift toward TH2 
activity during KLH immunization, and cattle in these groups displayed higher 
36 
 
concentrations of serum and tissue TGF-β, an important cytokine involved in 
immunoregulation. The pasture management system and supplementation with dietary 
microalgae may lead to improvement of current bovine immunization strategies. This 
information may be useful for the design of feed supplements to optimize immune 
responses to routine immunization programs in dairy cattle and to improve the overall 




















Table 1-1. Cytokines and immunoglobulin isotypes measured for determination of the 
impact of dietary fatty acids on bovine immunity.  
 
Cytokine Cellular Source Cellular Target & Role References 
IFN-γ Interferon-γ is 
produced by activated 
NK cells, CD4+ and 
CD8+ T lymphocytes 
Impact on macrophage 
activation, MHC class I 
and II expression, 




IL-4 Interleukin-4 is 
produced by mast 
cells, T lymphocytes 
and bone marrow 
stromal cells 
Regulates the 
differentiation of naïve 
CD4+ T cells into helper 
TH2 cells 
(Paul, 1991) 
TGF-β1 Transforming growth 
factor-β1 is produced 






Exists in active and 
latent forms. 
(Annes et al., 
2003) 
Immunoglobulin    
IgA Antibody produced by 
plasma cells, 
predominately at 
mucosal surfaces and 
in  milk/colostrum 
Contributes to protective 
immunity and mucosal 
homeostasis, neutralizes 
antigens in epithelial 
endosomes 
(Pabst, 2012) 
IgG Antibody produced by 
plasma cells in blood 
stream and in tissues, 
bovine IgGs are 
divided into two 
subclasses  
Generally involved in 
neutralization of antigen 
and interacts with 
complement 
(Butler et al., 
1971) 
IgG1 Most abundant 
subclass of IgG  
Production induced by 
IL-4 and inhibited by 
IFN-γ, involved in 
neutralization and 
opsonization of antigens 
and interacts with 
complement 
(Butler et al., 
1971; Mix et 
al., 2006) 
IgG2 Second most abundant 
subclass of IgG, 
although most 
prevalent in bovine 
serum 
Production induced by 
IFN-γ and inhibited by 
IL-4, involved in 
neutralization of 
antigens and interacts 
with complement 
(Butler et al., 
1971; Mix et 
al., 2006) 
This table is continued on the next page. 
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Table 1-1 continued. 
Immunoglobulin Cellular Source Cellular Target & Role References 
IgM Plasma cells, 
predominately in the 
blood 
First antibody isotype to 
be produced during an 
immune response, 




opsonization of antigens 









































Table 1-2. AIF Trial #7 days corresponding to the days since calving and days since 
KLH immunization. 
 
Trial Day Day Since Calving Day Since KLH Immunization 
& Activity Completed 
0 - 30 ----- 
30 0  birthing day ----- 
69 39 0  baseline measure, primary 
immunization 
70 40 1  first day following 
immunization 
76 46 7  primary response measured 
83 53 14  booster dose, secondary 
immunization 
90 60 21  secondary response 
measured 
































Table 1-3. Serum IL-4 concentrations at selected time points after KLH immunization, 
and final measurements in systemic and mucosal tissue. 
 
 IL-4*  





Control Fish Oil Microalgae Feed 
System 




Pasture 1.5 ± 1.2 BLQ 1.5 ± 1.5 n/a n/a n/a 
TMR BLQ BLQ BLQ 
Serum 
KLH d1 
Pasture 4.6 ± 4.6 2.6 ± 2.6 BLQ n/a n/a n/a 
TMR BLQ BLQ BLQ 
Serum 
KLH d7 
Pasture BLQ BLQ BLQ n/a n/a n/a 
TMR BLQ BLQ BLQ 
Serum 
KLH d21 
Pasture BLQ BLQ BLQ n/a n/a n/a 
TMR BLQ BLQ 2.0 ± 2.0 
Serum 
KLH d51 




7.2 ± 3.0 0.392 0.485 0.988 
TMR 9.4 ± 5.1 7.0 ± 4.5 2.3 ± 1.3 
Spleen 
KLH d51 




52.4 ± 26.2 0.661 0.702 0.621 




53.9 ± 26.9 
Caecum 
KLH d51 




0.0 ± 0.0 0.107 0.144 0.702 






* IL-4 concentrations (pg/mL in serum and pg/g in tissue) are presented as mean ± SEM. Significance (P < 
0.05) for phenotype, diet, and interaction between phenotype × diet was determined by two-way ANOVA.  
** n = 4 per supplement/feed management system, with the exception of KLH d1 which measured all cows 
in the trial; n = 8 on control, n = 7 on fish oil and n = 8 on microalgae in the pasture feed management 


















Table 1-4. IFN-γ concentrations in serum at selected time points after KLH 
immunization, and final measurements in systemic and mucosal tissue. 
 
 IFN-γ*  





Control Fish Oil Microalgae Feed 
System 




Pasture BLQ BLQ  BLQ n/a n/a n/a 
TMR BLQ BLQ BLQ 
Serum 
KLH d1 
Pasture BLQ BLQ  BLQ n/a n/a n/a 
TMR BLQ BLQ BLQ 
Serum 
KLH d7 
Pasture BLQ BLQ  BLQ n/a n/a n/a 
TMR BLQ BLQ BLQ 
Serum 
KLH d14 






0.953 0.263 0.578 




429.5 ± 43.2 
Serum 
KLH d21 
Pasture BLQ BLQ  BLQ n/a n/a n/a 
TMR BLQ BLQ BLQ 
Serum 
KLH d51 
Pasture BLQ BLQ  BLQ n/a n/a n/a 
TMR BLQ BLQ BLQ 
Spleen 
KLH d51 






0.338 0.281 0.112 




167.5 ± 69.4 
Caecum 
KLH d51 
Pasture BLQ 293.2 ± 
220.7 
BLQ 0.338 0.281 0.112 






* IFN-γ concentrations (pg/mL in serum and pg/g in tissue) are presented as mean ± SEM. Significance (P 
< 0.05) for phenotype, diet, and interaction between phenotype × diet was determined by two-way 
ANOVA.  
** n = 8 on control, n = 7 on fish oil and n = 8 on microalgae in the pasture feed management system. n = 9 
on control, n = 8 on fish oil and n = 8 on microalgae in the TMR feed management system. n = 4 per 















Table 1-5. Active TGF-β1 concentrations in serum at selected time points after KLH 
immunization, and final measurements in systemic and mucosal tissue. 
 
 Active TGF-β1*  





Control Fish Oil Microalgae Feed 
System 




Pastureα 9.9 ± 4.0 13.9 ± 
5.3α 
7.5 ± 2.7 0.015 0.644 0.197 
TMRβ 2.3 ± 2.0 0.8 ± 0.6β 4.1 ± 3.1 
Serum 
KLH d1 




5.5 ± 2.6 0.731 0.302 0.973 




7.9 ± 3.8 
Serum 
KLH d7 




18.8 ± 4.6 0.319 0.955 0.629 




17.4 ± 3.0 
Serum 
KLH d14 
Pasture 10.3 ± 
5.7 
4.2 ± 4.2 6.2 ± 4.3 0.666 0.296 0.934 
TMR 8.5 ± 6.0 1.2 ± 1.2 3.6 ± 2.8 
Serum 
KLH d21 




33.9 ± 6.1 0.006 0.269 0.701 




19.3 ± 8.8 
Serum 
KLH d51 




58.6 ± 10.4α < 0.001 0.613 0.136 




15.1 ± 5.2β 
Spleen 
KLH d51 
Pastureα BLQ 23.6 ± 
8.9  
 29.2 ± 10.7 0.017 0.335 0.881 




87.0 ± 37.7 
Caecum 
KLH d51 






< 0.001 0.551 0.159 
TMRβ 27.5 ± 
21.0β 
5.4 ± 5.4β 22.5 ± 22.5β 
* Active TGF-β1 concentrations (pg/mL in serum and pg/g in tissue) are presented as mean ± SEM. 
Significance (P < 0.05) for phenotype, diet, and interaction between phenotype × diet was determined by 
two-way ANOVA. Different symbols denote significant differences between feed system overall or within 
a particular diet group as determined by Tukey’s multiple comparison test. 
** n = 8 on control, n = 7 on fish oil and n = 8 on microalgae in the pasture feed management system. n = 9 
on control, n = 8 on fish oil and n = 8 on microalgae in the TMR feed management system. n = 4 per 





Table 1-6. Total TGF-β1 concentrations in serum at selected time points after KLH 
immunization, and final measurements in systemic and mucosal tissue. 
 
 Total TGF-β1*  





Control Fish Oil Microalgae Feed 
System 










0.046 0.021 0.096 














0.042 0.110 0.688 














0.230 0.210 0.170 















0.100 0.659 0.975 















0.025 0.545 0.421 















0.009 0.165 0.543 














25 260.9 ± 
4471.4b 
0.749 0.007 0.498 














25 260.9 ± 
4471.4α 
< 0.001 0.925 0.841 
TMRβ 10 339.8 
± 2324.3β 
13 837.9 
± 965.6 β 
20 446.5 ± 
5048.2 β 
* Total TGF-β1 concentrations (pg/mL in serum and pg/g in tissue) are presented as mean ± SEM. 
Significance (P < 0.05) for phenotype, diet, and interaction between phenotype × diet was determined by 
two-way ANOVA. Superscripted letters denote significant differences between supplements, and symbols 
denote significant differences between supplement overall or feed system overall as determined by Tukey’s 
multiple comparison test.  








Figure 1-1. IgM concentrations quantified in serum following KLH immunization over 
primary, secondary and long-term time points in cattle on omega-3 dietary supplements 
and separate feed management systems. Significance (P < 0.05) for feed management 
system, supplement and interactions were determined using REML analysis, with Fisher’s 
LSD multiple range test to determine differences between groups. a. Total IgM 
concentrations; the effect of feed system (P < 0.001) was significant. b. Anti-KLH IgM 
concentrations; the effect of feed system (P < 0.001), supplement (P = 0.043) and feed 










Figure 1-2. IgG concentrations quantified in serum following KLH immunization over 
primary, secondary and long-term time points in cattle on omega-3 dietary supplements 
and separate feed management systems. Significance (P < 0.05) for feed management 
system, supplement and interactions were determined using REML analysis, with Fisher’s 
LSD multiple range test to determine differences between groups. a. Total IgG 
concentrations; differences between feed systems (P < 0.001), supplements (P = 0.003) 
and feed system × supplement interaction (P = 0.008) were significant. b. Anti-KLH IgG 
concentrations; the effect of feed system (P < 0.001), supplement (P = 0.041) and feed 









Figure 1-3. Anti-KLH IgG subclass concentrations quantified in serum following KLH 
immunization over primary, secondary and long-term time points in cattle on omega-3 
dietary supplements and separate feed management systems. Significance (P < 0.05) for 
feed management system, supplement and interactions were determined using REML 
analysis, with Fisher’s LSD multiple range test to determine differences between groups. 
a. Anti-KLH IgG1 concentrations; the effect of feed system (P < 0.001) and feed system × 
supplement interaction (P = 0.023) were significant. b. Anti-KLH IgG2 concentrations; the 









Figure 1-4. IgA concentrations quantified in milk following KLH immunization over 
primary, secondary and long-term time points in cattle on omega-3 dietary supplements 
and separate feed management systems. Significance (P < 0.05) for feed management 
system, supplement and interactions were determined using REML analysis, with Fisher’s 
LSD multiple range test to determine differences between groups. a. Total IgA 
concentrations; the effect of feed system (P = 0.003) and supplement (P = 0.003) were 











The Intestinal Barrier and Mucosal Immunity 
 
Mucosal surfaces of the body are in direct contact with the external environment 
and are protected by the mucosal immune system. The gastrointestinal (GI) tract is the 
largest mucosal surface in the body. Human intestines are colonized by commensal bacteria 
shortly after birth and the GI tract provides bacteria with nutrients from digested food 
(Honda and Takeda, 2009). Commensal bacteria of the intestinal tract are beneficial for the 
host since they aid in food digestion to supply essential nutrients and also prevent the 
invasion of pathogenic microbes (Honda and Takeda, 2009). Intestinal epithelial cells 
(IEC) form a physical barrier dividing the intestinal tissues from direct contact with the gut 
microbiota. Several mechanisms operate at the IEC level for separating the host from the 
microbiota, and these include tight junctions to prevent bacteria from moving between the 
epithelial cells, microvilli-covered surfaces to prevent bacterial attachment, and secretions 
from goblet cells which create mucous to prevent bacteria from penetrating the cells (Artis, 
2008). Antimicrobial proteins such as defensins are also considered an immune mechanism 
in protecting the IEC as they aid in eliminating bacteria that penetrate the mucus layer 
(Hooper and Macpherson, 2010). The single monolayer of IEC has many important duties, 
including not only nutrient uptake, but also transmitting signals from luminal bacteria to 
immune cells such as macrophages and natural killer cells to respond to microbial threats 
(Vizoso Pinto et al., 2009). Due to these roles, IEC are often considered to be participants 
in the innate immune response.  
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The mucous membranes of the GI tract comprise the MALT and are essential in 
protecting the host from pathogenic bacteria. The synthesis of secretory immunoglobulin-
A (sIgA) by B cells is a very important component in mucosal immunity. Mucosal IgA is 
involved in regulating the balance and composition of bacteria within the intestines and it 
has the ability to affect bacterial glycosylation (Peterson et al., 2007). sIgA produced by B 
cells is transcytosed across IEC into the lumen via the polymeric immunoglobulin receptor 
(pIgR), where it can bind to bacteria. sIgA thus creates an effective immunological barrier 
which may prevent infection by neutralization of pathogens (Leblanc et al., 2004), and 
therefore offers protection for the host since it maintains mucosal homeostasis (Johansen 
et al., 1999). The presence of sIgA often prevents enteropathogens from adhering to the 
intestinal epithelium walls and subsequent colonization or invasion (Leblanc et al., 2004). 
In addition, sIgA has been shown to play an essential role in creating a “firewall” 
environment in the mesenteric lymph nodes, preventing the gut microbiota from 
penetrating further into the MALT and the lymphatic system (Macpherson and Uhr, 2004).  
 
Dietary Fibre, Prebiotics and Bifidobacteria 
 
Prebiotics are nondigestible oligosaccharides which selectively stimulate the 
growth of certain bacteria within the colon, and are believed to improve host health (Gibson 
and Roberfroid, 1995). The definition of a prebiotic demonstrates the fulfilment of three 
specific criteria for the classification of prebiotic fibre (Gibson et al., 2004). These criteria 
are that the fibre must be resistant to enzymatic digestion and gastrointestinal absorption, 
the fibre must be fermentable by the colonic microbiota, and the fibre must promote growth 
of intestinal bacteria which initiates a change towards a healthier microbiota balance 
(Gibson et al., 2004). Prebiotics have been widely claimed to be beneficial for the host, as 
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these fermentable materials have been reported to promote the activity of Bifidobacteria 
and Lactobacilli species (Brownawell et al., 2012; Kau et al., 2011). Associations of these 
bacteria with potentially health-promoting qualities such as mucin production by IEC have 
been described in the literature (Gibson and Roberfroid, 1995). Bifidobacteria have been 
associated with accelerated colonic transit time (Marteau et al., 2002), synthesis of vitamins 
in the GI tract (Crittenden et al., 2003), and protection of the IEC barrier (Lievin et al., 
2000). However, the effects of increased Bifidobacteria content in the gut may vary 
between individuals (Macfarlane et al., 2006), and while there are numerous reports of 
effects of Bifidobacteria on the immune system, there are also many questions surrounding 
the extent of their effects in healthy adults. 
Much remains to be determined about the full extent of the effects of prebiotic 
fibres on the gut microbiota community structure. The degree to which the dietary fibre is 
fermented is characterized by the structure of the fibre as well as by the composition of the 
gut microbiota (Abnous et al., 2009). An area of key interest is determining if shifts in gut 
microbiota composition induced by the fermentation of these dietary fibres impose a health 
benefit for the host (Abnous et al., 2009). Until recently, most gut microbiota studies have 
relied on cultivation-based techniques to enumerate and identify the gut bacteria – an 
ineffective approach as many of these microbes are strict anaerobes and are not readily 
cultured. Current molecular approaches should reveal the true extent of prebiotic effects 






Effects of β2-1 Fructans on the Immune System 
 
β2-1 Fructans include fructooligosaccharides (FOS) and inulin; they are among the 
most well-known fermentable materials which have been claimed to have effects on the 
gut microbiota. These substrates have been reported to stimulate the growth of 
Bifidobacteria in vivo (Bouhnik et al., 2006) and in vitro (Langlands et al., 2004), however 
the use of Bifidobacterium levels has been debated as a biomarker of gut health (Ouwehand 
et al., 2005). FOS is composed of short-length chains of 2-8 fructose units with a terminal 
glucose linked by β2-1 glycosidic bonds, whereas inulin is composed of 9-60 repeating 
fructose units (Roberfroid, 2005; Singh and Singh, 2010). β2-1 Fructans are rapidly and 
completely fermented in the proximal colon (Singh and Singh, 2010). Fermentation of β2-
1 fructans leads to the production of lactate and short chain fatty acids (SCFA) (Looijer-
van Langen and Dieleman, 2009).  
The presence of SCFA in the gut has been reported to stimulate the attachment of 
Lactobacilli species to the intestinal mucosa and to deter pathogen adhesion (Bomba et al., 
2002). The terminal sugars of oligosaccharides inhibit the adherence of pathogenic bacteria 
and prevent colonization of the intestinal epithelium (Fukuda et al., 2011; Zopf and Roth, 
1996). There is evidence to suggest that SCFA are important mediators in the interactions 
between gut microbiota on the immune system, as the SCFA butyrate has been shown to 
modulate the ubiquitination and degradation of Nuclear Factor-κB (NF-κB) inhibitor IκB-
α (Kumar et al., 2009). The SCFA liberated from dietary fibre fermentation have also been 
associated with increased intestinal IgA concentrations in rats (Kudoh et al., 1998; Lim et 
al., 1997). It has been hypothesized that the production of SCFA in the intestine may be 
involved in regulating a mucosal immune response (Looijer-van Langen and Dieleman, 
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2009), and it has been reported that these SCFA have involvement in immunomodulatory 
activities in the event of colonic inflammation (Kumar et al., 2009). In murine models, 
dietary supplementation with SCFA has been shown to attenuate colitis in wild type mice 
through the enhancement of FOXP3+ Treg cell activity, however the same effect was not 
observed in Gpr43-/- mice, which lacked an important signaling receptor for SCFA (Smith 
et al., 2013). 
β2-1 Fructans have been shown to prevent attachment of pathogenic strain 
Clostridium difficile using in vitro experiments (Hopkins and Macfarlane, 2003), and to 
stimulate the growth of protective bacteria including Bifidobacterium spp. and 
Lactobacillus spp. (Looijer-van Langen and Dieleman, 2009) suggesting an association 
with IEC defense mechanisms. Lactic acid produced by β2-1 fructan fermentation lowers 
the pH of the colon, and this has been suggested as a mechanism to exclude pathogens from 
the gut (Lomax and Calder, 2009). However, several contradictions regarding the 
protective nature of β2-1 fructan fermentation in the gut exist in the literature. For example, 
FOS has been shown to impair resistance to Salmonella enteritidis infection and increase 
intestinal permeability in rats (Ten Bruggencate et al., 2004; Ten Bruggencate et al., 2005), 
and also to decrease intestinal barrier function in healthy men (Ten Bruggencate et al., 
2006).  
Rodent models have been used to collect the majority of data on the physiological 
and immunological effects of β2-1 fructans (Bovee-Oudenhoven et al., 2003; Ryz et al., 
2009; Ten Bruggencate et al., 2005), and only a few studies to date have investigated the 
impact of β2-1 fructans on immune parameters in healthy human subjects in homeostatic 
conditions. A study investigating impacts on the immune system in healthy middle-aged 
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subjects who consumed β2-1 fructans for 4 weeks did not find alterations in immune cell 
populations of neutrophils or monocytes, NK cell activity, or circulating Ig concentrations 
(Lomax et al., 2012). A separate study investigating non-smoking men found decreased 
percentages of NK cells and immune cells expressing intercellular adhesion molecule-1 
(ICAM-1) (Seidel et al., 2007). In another study involving women with type 2 diabetes, 
circulating concentrations of LPS and TNF-α decreased after 8 weeks of β2-1 fructan 
consumption (Dehghan et al., 2014), suggesting an anti-inflammatory effect. The most 
consistent finding reported regarding β2-1 fructan supplementation in human subjects is 
that it increases faecal Bifidobacteria content (Bouhnik et al., 2006; Lomax et al., 2012), 
although it is not clear whether this generates an immunological or physiological benefit 
for the majority of healthy adults who have consumed it. 
Functional parameters of systemic immunity should be analyzed in order to 
determine if gut microbiota shifts are beneficial for the host. TLRs are pattern-recognition 
receptors (PRR) which are expressed on innate immune cells such as macrophages and 
dendritic cells (DC). When TLRs bind microbial motifs, referred to as PAMPs, a signal 
transduction pathway is activated. TLR2 is activated by peptidoglycan or lipoteichoic acid 
while TLR4 is activated in the presence of LPS.  Stimulated TLR2 and TLR4 receptors 
induce a signalling cascade through adaptor molecules including myeloid differentiation 
factor 88 (MyD88), and TLR4 can also induce signalling via the MyD88-indepent pathway 
involving TIR domain-containing adapter-inducing interferon-β (TRIF) and TRIF-related 
adaptor molecule (TRAM) (Abreu, 2010). These signalling cascades ultimately facilitate 
the activation of the NF-κB transcription factor and lead to production of proinflammatory 
cytokines (Abreu, 2010).  
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There have been suggestions in the literature that the gut microbiota influence TLR 
expression (Furrie et al., 2005; Vizoso Pinto et al., 2009), and this is an aspect of prebiotic 
fibre delivery that has not been analyzed in detail. Changes in TLR expression or in 
responses to TLR agonists may provide a sensitive indicator of alterations in the innate 
immune response. The measurement of TLR expression on immune cell populations can 
be carried out through immunofluorescence with anti-TLR antibodies, and assessed 
functionally by stimulation of monocytes and DCs with TLR2 and TLR4 agonists (Schaaf 
et al., 2009; Versteeg et al., 2009). Since systemic immunity has been shown to be 
influenced by the gut microbiota (Balmer et al., 2014; Clarke et al., 2010), measuring 
responses to TLR agonists provides a novel method to determine effects of dietary FOS on 




Chapter 2 Study Objectives 
 
A randomized, double blind, cross-over clinical trial was conducted to examine 
whether ingestion of β2-1 fructans could influence the immune system in healthy adults. 
Direct comparison of fermentable and non-fermentable dietary supplements was used to 
determine if consumption of β2-1 fructans influenced the gut microbiota community 
structure and whether such changes created detectable changes in immune activity. This 
investigation was a collaborative project with researchers at Health Canada (Ottawa, ON) 
and Agriculture and Agri-Food Canada (Guelph, ON and Kentville, NS), who performed 
analyses on the gut microbiota, and with researchers at McMaster University (Hamilton, 
ON), who performed analyses on gastrointestinal distress and parameters of well-being. 
My role in the trial was to determine the impact of β2-1 fructan supplementation on 
immune parameters in healthy subjects through examining its effects on the immune 
system using a range of immunological measures. It was hypothesized that dietary β2-1 
fructan supplementation would have a pronounced impact on the immune system, and 
subjects would have higher levels systemic pro-inflammatory activity on the β2-1 fructan 
phase of the trial in comparison to placebo. The cytokines measured in determining the 
impact of β2-1 fructan supplementation on immune parameters are shown in Table 2-1.  
 
Objective: to examine impacts of β2-1 fructans on immune activity in healthy subjects 







Human Clinical Trial Subjects 
 
Subjects were recruited for this investigation from Guelph, Ontario and its 
surrounding area by a newspaper advertisement. The trial involved 30 healthy adults (13 
men and 17 women) who were not taking medication or other dietary supplements, and did 
not have a history of GI diseases or food allergies. The average age of the subjects was 28 
years, and the ages ranged between 20-42 years. All subjects provided informed consent 
for their participation. Clinical visits took place at Nutrasource Diagnostics Inc. (Guelph, 
Ontario, Canada). 
 
Human β2-1 Fructan Trial Design 
 
The clinical β2-1 fructan trial began in January 2011 was designed as a double-
blind, placebo-controlled, randomized crossover experiment. Since each participant 
consumed both dietary supplements, individuals served as their own control for each 
dietary supplement. The test supplement contained an oligofructose-enriched inulin, while 
the control diet was maltodextrin (did not contain β2-1 fructans). The trial subjects were 
randomized into groups based on the order in which they were to receive placebo or the 
β2-1 fructan supplement using an online randomization program (Seed no. 26285, Tufts 
University, Medford, MA, USA: www.tufts.edu/~ gdallal/random_block_size.htm). 
Subjects were instructed to consume the individually packaged 5 g supplement three times 
daily mixed in a beverage and taken with meals, for a total of 15 g of supplement each day. 
The trial participants consumed either the test or control dietary supplements for 28 days, 
followed by a 14 day wash out period, and continued with consuming the alternate 
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supplement for another 28 days. Fasting blood (12 hours) and faecal samples were 
collected at the beginning and end of each dietary supplement period for a total of four 
sample collection points. Subjects maintained daily diaries to record bowel movements, 
self-reported adverse events, or changes in their normal routine. 
The test diet was Orafti®Synergy1 (Beneo-Orafti, Tienen, Belgium); a dietary 
supplement containing oligofructose-enriched inulin derived from chicory root. This 
supplement is currently available in European countries and is marketed as a prebiotic 
nutritional supplement with bone health properties (Holloway et al., 2007). The control 
supplement (placebo) was food grade maltodextrin (Beneo-Orafti, Tienen, Belgium); a 
soluble fibre which is digested rather than fermented in the GI tract. Maltodextrin is a 
common food additive used as a thickening or bulking agent (Oliveira et al., 2009). Subject 
compliance was calculated from the amount of returned (unconsumed) supplement 
packets. β2-1 fructans present in the background diet were estimated for each subject using 
a semi-quantitative food frequency questionnaire and data on the average portion sizes 
from the Canadian Community Health Survey (http://www.hc-sc.gc.ca/fn-
an/surveill/nutrition/commun/cchs_focus-volet_escc-eng.php). The midpoint of the ranges 
reported was used in calculating the consumption of β2-1 fructan-containing foods 
(Moshfegh et al., 1999) to obtain a value representative of the average grams/day 
consumption of β2-1 fructans in the base diet. 
 Approval was received from the UOIT Research Ethics Board (REB) to commence 
the investigation in fall 2011. To have full involvement in the human clinical trial, I 
attended two Tri-Council Policy Statement (TCPS) training seminars to become informed 
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of the appropriate ethical conduct, procedures and limitations for research involving human 
subjects.  
 
Measurement of Blood Parameters 
 
Serum blood urea nitrogen (BUN) concentrations were measured at Health Canada 
using an ABX Pentra 400 automated clinical chemistry analyser and ABX Pentra Urea CP 
(urease-glutamate dehydrogenase) test kits (Horiba Canada Inc., Burlington ON, Canada). 
All other biochemical and haematological biomarkers were analyzed by LifeLabs Medical 
Services (Toronto, Ontario, Canada). These measures included standard haematological 
profiles, serum biochemistry (fasting glucose, creatinine, aspartate, γ-glutamyl-transferase, 
C-reactive protein (CRP), globulin, albumin and total blood protein) and lipid profiles 
(low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, 
total cholesterol and triglycerides. 
 
Peripheral Immune Cell Population Analysis by Flow Cytometry 
 
The flow cytometry laboratory technologist at Health Canada, Emily Chomyshyn, 
performed whole blood cell population analysis using flow cytometry with monoclonal 
antibodies to estimate population percentages of specific circulating immune cells. The list 
of antibodies used in the analysis are shown in Table 2-3. Peripheral populations analyzed 
included T cells and T cell subsets (CD4+ and CD8+), B cells, NK cells, plasmacytoid 
Dendritic cells (pDC) and myeloid DC (mDC), macrophages and granulocytes. Flow 
cytometry analysis was completed at the time of blood collection for the final day (d28) of 
each dietary supplement period. Blood samples were initially treated with Immunoprep™ 
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Reagent system (Beckman Coulter, Indianapolis, IN, USA) to remove erythrocytes that 
could interfere with cell staining. Flow cytometry analysis was performed using a BD 
FACSCaliburr™ flow cytometer (BD Biosciences, San Jose, CA, USA), equipped with a 
blue laser (488 nm) and a red diode laser (488 nM). Forward scatter and side scatter gating 
techniques used during acquisition of 10 000 viable cells/lymphocytes were standard and 
similar to those outlined by Shingadia et al. (2001). Analysis of immune cell populations 
was conducted using BD FACSDIVA™ software (BD Biosciences, San Jose, CA, USA). 
In addition to cell population analysis, a subset of the whole blood samples was 
stimulated with the TLR-4 agonist LPS (1 µg/mL; Sigma Aldrich, St. Louis, MO, USA) 
diluted in Roswell Park Memorial Institute (RPMI) 1640 medium (Sigma Aldrich, St. 
Louis, MO, USA) in order to investigate effects of β2-1 fructan supplementation on 
monocyte and mDC TLR-signaling activity. After a 1-hour incubation with the TLR4 
agonist at 37°C and 5% CO2, samples were treated with Brefeldin A (BFA; 10 µg/mL; 
Sigma Aldrich, St. Louis, MO, USA) in order to allow accumulation of intracellular 
cytokines. BFA is a known inhibitor of protein transport that prevents cytokine secretion 
(Della Bella et al., 2008), and BFA treatment is a standard technique to optimize 
intracellular cytokine detection. Samples were further incubated at 37°C and 5% CO2 for 
an additional 2 hours. Following the incubation, immune cells were collected by 
centrifugation and were permeabilized for intracellular staining with anti-TNF-α and anti-
IL-12p70. Once treated, the cells were analyzed by flow cytometry and intracellular 





Measurement of Circulating Cytokine Profiles 
 
Initially, a BD™ Cytometric Bead Array (CBA) Human Flex set (BD Biosciences, 
San Jose, CA, USA) was used to quantify circulating cytokine concentrations. This assay 
system was customizable and utilized flow cytometry to detect soluble analytes, such as 
cytokines. The assay system was analogous to an ELISA, however the CBA was less time 
consuming than conventional ELISAs and offered high throughput capabilities since 
multiple cytokines could be measured in a single assay. The assay beads had a capture 
surface for specific proteins, and the cytokines were detected by the flow cytometer 
through the attachment of fluorescent antibodies. A collection of cytokines representing 
anti-inflammatory, pro-inflammatory, regulatory, TH1 and TH2 responses were measured 
to obtain a complex profile and include IFN-γ, TNF-α, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10 
and IL-12p70. 
Serum samples from all subjects at baseline and end point for each supplement were 
analyzed using the BD CBA Flex Set system on a BD LSRFortessa™ Flow Cytometer 
(BD Biosciences, San Jose, CA, USA). However, there were no serum samples containing 
measurable amounts of cytokines IFN-γ, IL-2, IL-4, IL-6 or IL-12p70. Out of all the tested 
samples, there were only two samples with detectable TNF-α, a single sample with IL-1β, 
and a single sample with IL-10. The only cytokine that was consistently detected in all 
serum samples was IL-8. Circulating cytokine concentrations are usually low in serum 
from healthy individuals, and the lack of detection of most cytokines may reflect the 
relative sensitivity of the multiplexed CBA approach compared to that of optimized 
ELISAs (Dossus et al., 2009; Young et al., 2008). For this reason, serum cytokines were 
quantified again using ELISA, and cytokine concentrations in keeping with those 
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anticipated in healthy adults were obtained with this format. The cytokine profile was 
expanded to include granulocyte-colony stimulating factor (G-CSF), granulocyte-
macrophage colony stimulating factor (GM-CSF), IFN-γ, IL-1 receptor antagonist (IL-
1Ra), IL-1β, IL-4, IL-6, IFN-γ-induced protein 10 (IP-10/CXCL10), soluble CD40 ligand 
(sCD40L/TNFSF5), all measured using DuoSet ELISA Development kits (R&D Systems, 
Minneapolis, MN, USA); IL-10, IL-12p70 and TNF-α using ELISA Max™ Sets 
(BioLegend, San Diego, CA, USA); and IL-8 was measured using a human IL-8 ELISA 
kit (Invitrogen, Carlsbad, CA, USA). Both active and total TGF-β1 concentrations were 
measured in plasma using the same methods as outlined in Chapter 1. In addition to the 
cytokines, LPS binding protein (LBP) was measured in serum using the HK315 Human 
LBP ELISA Kit (Hycult Biotech, Uden, The Netherlands).   
ELISAs were carried out using 96-well high-binding half area microplates (Greiner 
Bio-One, Frickenhausen, Germany), using antibody concentrations recommended by the 
manufacturers protocols. Serum and plasma samples were pre-tested for appropriate assay 
dilutions. ELISA plates were coated with capture antibody diluted in phosphate buffered 
saline, and incubated overnight at 4°C. Following sample incubation, biotinylated 
detection antibody and horseradish peroxidase-conjugated streptavidin were added at 
separate steps, and its substrate TMB (Sigma Aldrich, St. Louis, MO, USA) was added. 
The colorimetric reaction was stopped with the addition of 1.8 N H2SO4, and the optical 
density of the reactions in the microplates were read at a wavelength of 450 nm on a 
Synergy HT multi-detection microplate reader using KC4 v3.4 analysis software (BioTek 




Endotoxin Detection in Serum Samples 
 
Initially, a HEK-Blue™ hTLR4 cell based assay (SEAP Reporter HEK293 cells 
expressing the human TLR4 gene; InvivoGen, San Diego, CA, USA) was tested to quantify 
the presence of LPS in plasma and serum samples. However, this assay system was difficult 
to use and results were inconsistent. The success of the assay depends on completely 
consistent cell culture growth rate and density, and is easily influenced by any biological 
contaminants (for example, selected cytokines and free fatty acids). The HEK293 cells 
used in this assay system retain expression of TLR3, TLR5 and NOD1 receptors in addition 
to increased expression of TLR4. Additionally, low concentrations of TNF-α are capable 
of activating NF-κB and lead to a colorimetric change in this assay, influencing the 
interpretation of LPS concentration that may be calculated. Many trial subjects had 
measurable concentrations of circulating TNF-α, so it was highly possible that this factor 
would have influenced LPS measurements in this assay system. After preliminary testing, 
it was decided to shift to a more established protocol to measure endotoxin concentrations, 
the Limulus Amebocyte Lysate (LAL) Assay. 
Serum endotoxin concentrations were quantified using the LAL QCL-100 Assay 
(Lonza, Basel, Switzerland). All reagents and samples were brought to room temperature 
prior to reconstitution and use. Great care was used in minimizing potential sources of LPS 
contamination during this assay, and the entire experiment was carried under aseptic 
conditions. Only sterile, endotoxin-free consumables were used in this assay, such as 
endotoxin-free reagent reservoirs, sterile 96-well microplates suitable for cell culture, filter 
pipette tips and serological pipettes. The water used for preparing reagents and sample 
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dilutions was HyPure Cell Culture Grade Water, endotoxin-free < 0.005 EU/mL (Hyclone 
Laboratories, Logan, UT, USA). 
 To prepare for the assay, LAL was reconstituted immediately before use with 
endotoxin free water (3.0 mL/vial lysate) and vials were pooled to create one master LAL 
reagent. The LAL was gently swirled to avoid foaming and was protected from direct light. 
E. coli O111:B4 endotoxin was reconstituted by the addition of 1.0 mL endotoxin-free 
water, to obtain a stock concentration of 26 EU/mL. The endotoxin vial was shaken 
vigorously for 15 minutes on a vortex mixer to ensure even distribution. Endotoxin 
standards were then prepared in glass vials: 1.0, 0.5. 0.25, 0.1 EU/mL in endotoxin-free 
water. Each standard was mixed vigorously for 1 minute before use. The chromogenic 
substrate was reconstituted by the addition of 6.5 mL of endotoxin-free water to the vial, 
gently swirled and protected from light exposure. The LAL assay instructions suggested 
adjusting the pH of all samples to be within a biological range of 6.0 – 8.0 using 1N sodium 
hydroxide or 0.1N hydrochloric acid. In a subset of serum samples, the pH ranged from 7.6 
– 7.78. Since these measurements were within a biological range, pH adjustments were not 
necessary. 
 To carry out the assay, a lidded 96-well sterile tissue culture grade plate was pre-
warmed to 37°C using a dry heat block (VWR, Randor, PA, USA). To begin the assay, 50 
µL of undiluted serum samples (run in duplicate), standards and blanks were dispensed in 
appropriate wells. All reagent additions and incubations were absolutely identical. At T = 
0, 50 µL LAL was added to each well, and the plate was gently tapped to ensure thorough 
mixing before it was returned to the heating block. The samples were then incubated for 
10 minutes at 37°C. At T = 10 minutes, 100 µL of pre-warmed chromogenic substrate 
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solution was added to each well, and the plate was gently tapped to ensure thorough mixing 
before it was returned to the heating block and incubated for an additional 6 minutes at 
37°C. At T = 16 minutes, 100 µL of stop reagent (25% glacial acetic acid in endotoxin-
free water v/v) was added to each well, and the plate was gently mixed by tapping. The 
absorbance of the microplate was then immediately read at 405 nm using a Synergy HT 
microplate reader (Bio-Tek, Winooski, VT, USA).  
Since the serum samples had varying shades of colour ranging from pale wheat to 
amber, possibly due to red blood cell (RBC) lysis, the creation of serum sample blanks was 
necessary to ensure that background colour did not interfere with endotoxin quantification. 
Individual sample background blanks were created by mixing 50 µL sample, 150 µL 
endotoxin-free water and 100 µL stop reagent without incubation. Once the microplate was 
read at 405 nm and the assay background was subtracted from all samples, individual 
sample backgrounds were separately subtracted from each sample value before endotoxin 
concentrations were calculated. If sample endotoxin concentrations were above the 
standard curve, serum samples were diluted 1/5 and assayed again. A simplified procedure 
for endotoxin detection is shown in Table 2.4. 
 
Measurement of Serum and Faecal Antibody Profiles 
 
Resting-state serum antibody isotype profiles were measured using the Human 
Immunoglobulin Isotyping Magnetic Bead Panel (MILLIPLEX Map Kit; EMD Millipore 
Corp. Billerica, MA, USA) using a Luminex 200 analyzer (Austin, TX, USA). The 
immunoglobulin isotype profile quantified consisted of IgG1, IgG2, IgG3, IgG4, IgA and 
IgM. The Luminex assay format utilizes magnetic beads and detection antibodies 
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conjugated to phycoerythrin (PE), which is a fluorescent reporter signal used to quantify 
the proteins of interest. Advantages to this immunoassay format include customizable 
assays, an automated 96 well plate system that enables high throughput screening, and 
reduction of measuring inaccuracies since many samples can be measured all at once. Total 
IgG concentrations were not quantified by Luminex since the IgG subclasses cannot be 
measured at the same time (multiplexed) as total IgG, and this was a rather expensive assay 
to run with only one parameter. A random group of serum from 6 subjects over all four 
time points was retested by ELISA to confirm the results obtained by Luminex.  
In order to quantify the resting-state faecal Ig concentrations, thawed faeces were 
prepared in a 1:5 (w/v) PBS solution containing 10 mg/mL bovine serum albumin (BSA) 
and 1% Protease Inhibitor Cocktail (Sigma Aldrich, St. Louis, MO, USA) and incubated 
for 10 minutes at room temperature. Samples were then completely homogenized using a 
Brinkman Polytron PT3000 homogenizer (Kinematica, Luuzern Schweiz, Switzerland), 
centrifuged (4000 × g for 30 minutes at 20°C), and supernatants were collected and stored 
at -80°C until analysis. The faecal antibody isotype profiles were measured using the 
Human Ig ELISA Quantitation Set for IgA, IgG and IgM (Bethyl Laboratories Inc., 
Montgomery, TX, USA), and ELISA plates were read at a wavelength of 450 nm on a 
microplate reader (Infinite® 200 Pro Series; Tecan, Männedorf, Switzerland).  
 
Measurement of ex vivo TLR-Induced Responses in Whole Blood Culture 
 
 Whole blood cultures from the end points of the β2-1 fructan and placebo phases 
of the trial were treated with TLR ligands to investigate responsiveness to TLR stimulation. 
Whole blood cultures which had been collected in sodium heparin blood collection tubes 
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were stimulated separately with TLR2 agonist Pam3Cys (P3C; 10 µg/mL; Novabiochem 
(EMD Millipore Corp.) and TLR4 agonist LPS (1 µg/mL; Sigma Aldrich, St. Louis, MO, 
USA) diluted in RPMI-1640 medium, in addition to an unstimulated control. Whole blood 
cultures were incubated at 37°C and 5% CO2 in a humidified incubator. After 20 hours of 
incubation, blood assay tubes were centrifuged at 1300 × g for 5 minutes, and the 
supernatants were stored at -80°C until analysis.  
Cytokine production profiles within the supernatants collected from the whole 
blood culture assay were measured using the BD CBA Human Flex set BD and acquired 
on a BD LSRFortessa™ flow cytometer (BD Biosciences, San Jose, CA, USA), equipped 
with blue (488 nm), red (640 nm) and violet (405 nm) lasers. Cytokine concentrations 
measured in the supernatants included anti-inflammatory, pro-inflammatory and regulatory 
cytokines – specifically IFN-α, TNF-α, IL-1β, IL-6, IL-8, IL-10 and IL-12p70. These 
stimulated samples from the whole blood culture assay had higher cytokine concentrations 
and were above the concentration of the lowest assay standard, making it possible to use 
the CBA multiplex approach at this stage.  
After the majority of the physiological, immunological, psychological, and 
microbiological data were collected and analyzed, the identities of the supplements as 
either placebo or β2-1 fructan test diet were revealed. Immediately following the 




The statistical program Statistica v12 (StatSoft Inc., Tulsa, OK USA) was used to 
analyze data collected during this trial. Repeated-measures ANOVA (rANOVA) was 
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utilized with time point (d0 and d28) and supplement (placebo and β2-1 fructan) as the 
repeated variables. In cases where there was only a single time point, as in the immune cell 
phenotype data, rANOVA were used with supplement as the repeated measure. A P value 
of < 0.05 was considered statistically significant. When significant values were obtained, 
rANOVA analysis was followed by Tukey’s honest significant difference (HSD) test to 
determine differences within groups. For some measures, there were several values that 
were below the limit of quantification (LoQ). In these instances, the values were set to 
LoQ/2 (Armbruster et al., 1994) for analysis with Friedman’s test (non-parametric) 
followed by a Wilcoxon’s matched-pairs signed-rank test. Data was normalized using Box-









Characteristics of the Trial Subjects 
 
The baseline demographic data of the individual subjects at the study baseline is 
shown in Appendix B, Table A1. All subjects were found to have a healthy status before 
the trial began. The average participant age was 27 and the average BMI was 24.2 kg/m2. 
Daily intakes of β2-1 fructans in the base diet were estimated (Table 2-5), and no 
significant difference (P = 0.150) was found between the placebo (1.09 g/day) and β2-1 
fructan (0.96 g/day) supplement phases in the regular diets of the subjects. Supplement 
receiving order was analyzed for every measured immune parameter in the study as a 
factor in a rANOVA, however no differences were attributable to the order in which 
subjects entered the supplement phases. Subject compliance was calculated by the 
number of supplements consumed/total amount provided for each phase of the trial; the 
placebo phase compliance was 97.6 ± 0.5 %, and the β2-1 fructan phase compliance was 
99.9 ± 6.9 %. 
 
Assessment of Blood Parameters 
 
 Supplementation with either β2-1 fructan or placebo had no impact on BMI, 
BUN, standard blood biochemistry including lipid profiles, or haematological profiles 
(Table 2-6).  
 
Analysis of Peripheral Immune Cell Populations and mDC/Monocyte Cytokine Activity 
 
Immune cell populations were examined to determine if the consumption of β2-1 
fructans had an impact on circulating population profiles. Percentages of CD282+/TLR2+ 
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mDC significantly increased after β2-1 fructan supplementation (P = 0.008; Table 2-7). 
A tendency of higher CD284+/TLR4+ mDC (P = 0.060) and CD284+/TLR4+ granulocyte 
(P = 0.050) percentages was also found after β2-1 fructan supplementation. No other 
differences were found between placebo and β2-1 fructan supplementation for 
percentages of mDC, pDC, monocytes, granulocytes, neutrophils, NK cells, B cells, T 
cells or T cell subsets.  
Following LPS stimulation of whole blood samples, intracellular cytokine 
production was measured in mDC and monocytes using flow cytometry to further 
investigate responses to TLR4 activation at a cell-specific level. In a subgroup of six 
subjects, accumulation of TNF-α and IL-12 in mDC and monocytes was measured at the 
supplement phase end points (Table 2-8). The percentages of mDC and monocytes 
expressing TNF-α and IL-12 did not differ between supplement phases in unstimulated 
controls or after LPS stimulation. Percentages of mDC and monocytes expressing TNF-α 
did increase after LPS stimulation, however this was not linked with supplementation. 
Percentages of mDC and monocytes expressing IL-12 did not change after LPS 
stimulation, suggesting that the 1 µg/mL stimulation may not have been strong enough to 
induce a response. 
  
Assessment of Circulating Cytokine Profiles, Serum Endotoxin and LBP  
 
 Circulating cytokine profiles, LPS and LBP concentrations were measured to 
determine if β2-1 fructan supplementation influenced systemic immune activity. The 
mean serum concentrations are presented in Table 2-9a, and the median values with the 
25th-75th percentiles are presented in Table 2-9b to show the natural variation in these 
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measures in healthy adult subjects. By the end of the β2-1 fructan phase, subjects had 
lower concentrations of regulatory cytokine IL-10 (P < 0.001), and increased 
concentrations of TH2 cytokine IL-4 (P < 0.001) and proinflammatory cytokine GM-CSF 
(P = 0.002). Concentrations of TNF-α were higher on day 28 of the placebo phase than 
day 0 (P < 0.001), however the day 28 placebo value was not different from either time 
point measured during the β2-1 fructan phase. IP-10 (CXCL10) concentrations were 
lower on day 28 of the β2-1 fructan phase than day 0 (P = 0.010), however this value was 
not different from the values obtained during the placebo phase. No effects due to 
supplement or phase day were found for serum concentrations of sCD40L, G-CSF, IFN-
γ, IL-1β, IL-1Ra, IL-6, IL-8 and IL-12p70, or for plasma concentrations of active and 
total TGF-β1.  
Serum LPS concentrations were significantly higher after 28 days of β2-1 fructan 
supplementation than any other time point measured in the trial (P < 0.03). Serum LBP 
concentrations did not differ significantly within or between supplement phases. 
 
Assessment of Circulating and Faecal Ig Profiles 
 
 Resting-state antibody profiles were measured to determine if supplement had an 
impact on adaptive immunity in the absence of a defined challenge. Although there were 
several differences between serum Ig concentrations over the time points measured, these 
differences did not correlate with treatment phase (Table 2-10). Concentrations of IgA, 
IgM and all subclasses of IgG (IgG1, IgG2, IgG3, IgG4) were significantly different 
between day 0 and day 28 of the placebo phase, however the d-28 values did not differ 
from the values measured in the β2-1 fructan phase. Serum IgA was lower on day 28 of 
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the β2-1 fructan phase, and it was not different from the values measured in the placebo 
phase. Serum IgG1 and IgG2 were lower on day 28 of the β2-1 fructan phase than day 0 
and day28 of the placebo phase. 
β2-1 Fructan supplementation did not appear to impact faecal Ig profiles either; 
the only difference was found for IgM concentrations between day 0 and day 28 during 
the placebo phase (P < 0.005), and the values on placebo at day 28 were not different 
from either time point measured in the β2-1 fructan phase. 
 
Assessment of Responses to ex vivo TLR2 and TLR4 Stimulation in Whole Blood Cultures 
 
 The ex vivo whole blood TLR stimulation assay was utilized to examine 
differences in TLR responsiveness to microbial-derived agonist stimulation between 
supplement phases and was analyzed by measuring cytokine production. There were no 
significant differences in cytokine production in the unstimulated or LPS stimulated 
blood cultures (Table 2-11). P3C-induced IL-10 concentrations significantly increased at 
the end of the β2-1 fructan phase (P = 0.016). TNF-α concentrations were higher after 
stimulation with LPS than P3C, however these differences were not associated with a 
supplement phase. IFN-α was below the level of detection at all time points measured, 
and only one individual displayed IL-12p70 production after P3C stimulation on day 28 









After four weeks of supplementing the diet of healthy adults with β2-1 fructans, 
several impacts on host immune activity were identified. However, supplementation with 
either β2-1 fructan or placebo had no impact on BMI, BUN, routine blood biochemistry 
including lipid profiles, or haematological profiles. The subjects who participated had a 
healthy status entering the trial, so the unchanged blood chemistry and haematological 
profiles according to phase provided assurance that supplements did not change these 
clinical biomarkers. Several studies have suggested β2-1 fructan consumption may be 
associated with lowering blood lipid profiles and total cholesterol concentrations. Serum 
triglyceride concentrations decreased after 20 g per day of β2-1 fructan consumption over 
three weeks in hypercholesterolemic men (Causey et al. 2000), and HDL-cholesterol 
concentrations increased after 10 g per day of β2-1 fructan and soy supplementation in 
hyperlipidemic adults (Wong et al., 2010). No alterations in blood lipids were found during 
this trial, which is similar to a study in healthy women who consumed 14 g of β2-1 fructans 
over a four-week period, where no differences were found in plasma concentrations of total 
cholesterol, HDL-cholesterol, LDL-cholesterol or triacylglycerol after supplementation 
(Pedersen et al., 1997). The differences in findings from these studies suggest β2-1 fructans 
may impact blood lipids differentially in healthy adults versus those with conditions of 
high blood lipids. 
An interesting topic regarding β2-1 fructans in the literature is their potential use in 
promoting satiation. In a study of healthy females consuming 6 g of inulin daily with their 
breakfast meal for a period of eight days, it was found that inulin consumption lowered the 
desire to eat and prospective food consumption, but did not influence hunger or overall 
energy intake (Heap et al., 2016). Another study involving both males and females who 
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had consumed 22.4 g of inulin per day for a seven-day period found no changes in 
qualitative or quantitative appetite measures (Darzi et al., 2016). These indices of appetite 
were not evaluated in the current trial, although it is unlikely that this β2-1 fructans 
supplement had long-term influences on appetite since the BMI or total weight did not 
fluctuate between phases. 
Serum and faecal antibody concentrations were measured since Ig concentrations 
and isotype profiles can serve as a biomarker for changes in host adaptive immune activity 
(Albers et al., 2005; Cassidy et al., 1974). After 4 weeks of consuming β2-1 fructans at a 
dose of 15 g per day, there were no associations found between β2-1 fructan 
supplementation and Ig concentrations or isotype profiles, which was in common with 
another study of healthy middle-aged adults in which subjects consumed 8 g of β2-1 
fructans daily for 4 weeks (Lomax et al., 2012). A considerable degree of variation was 
observed in both serum and faecal Ig concentrations over the course of the trial, which 
occurred independently of placebo or β2-1 fructan supplementation. Circulating Ig 
concentrations are subject to short-term periodic fluctuations; serum IgA and IgG 
concentrations may change by 20% on a bi-weekly basis in healthy individuals (Veys et 
al., 1977). Ig concentrations can change in response to seasonality, with greatest variation 
observed during fall and winter months, markedly between mid-August to mid-February 
(Nordby and Cassidy, 1983). Since this trial took place from January to April, it is possible 
that some of the Ig fluctuations could be attributed to seasonality, as treatment order 
analysis did not reveal any differences in Ig concentrations. Natural variations in 
concentrations of serum Ig exist between healthy individuals due to effects of gender, 
ethnicity and age (Cassidy et al., 1974; Maddison et al., 1975), menstrual cycles (Vellutini 
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et al., 1997), alcohol consumption and cigarette smoking (Gonzalez-Quintela et al., 2008), 
adding complexity to the interpretation of changes in total serum Ig in this type of study.  
In a trial involving infants, faecal sIgA concentrations significantly increased after 
16 weeks of consumption of a β2-1 fructan-supplemented formula in comparison to 
standard formula-fed infants (Bakker-Zierikzee et al., 2006). A separate study following 
infants for the first 26 weeks after birth found that a β2-1 fructan-supplemented formula-
fed infants had higher faecal sIgA than infants on a control formula (Scholtens et al., 2008). 
It is not clear in the literature how β2-1 fructans influence faecal Ig concentrations in 
healthy adults. Positive correlations have been found between dietary fibre consumption 
and intestinal IgA concentrations in rat models (Kudoh et al., 1998; Lim et al., 1997), 
which has led to suggestions that dietary fibre or the products of its fermentation may 
support B cell responses in the gut and thus influence IgA production (Kim et al., 2016). 
While β2-1 fructans had no clear impact on serum or faecal Ig concentrations or isotype 
profiles in this study, these determinations were carried out under resting conditions and it 
remains a possibility that differences might be apparent following an immune challenge 
such as an infection or immunization.  
β2-1 fructans have been shown to modulate adaptive immunity in response to 
immunization. Infants between 7-9 months of age who had consumed a β2-1 fructan-
supplemented cereal (0.2 g β2-1 fructan per kg body weight per day) for 10 weeks had 
higher serum antibody concentrations of anti-measles IgG after vaccination to protect 
against measles (Firmansyah et al., 2001; Saavedra and Tschernia, 2002). In a recent study 
involving healthy middle-aged adults consuming β2-1 fructans (8 g per day) subjects were 
immunized with a trivalent seasonal influenza vaccine after 4 weeks of supplementation. 
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Concentrations of serum vaccine-specific IgG1 antibodies and serum antibody titers against 
influenza H3N2 were higher in those consuming β2-1 fructan two weeks post-vaccination 
(Lomax et al., 2015). These studies suggest that β2-1 fructan supplementation may enhance 
responses to immunization, however these small sample sizes of infants and middle-aged 
adults may not be representative of effects on larger cohorts of adults. 
There were several results of this study which suggest that immune cells had 
increased exposure to microbial components during the β2-1 fructan phase of the trial. 
Peripheral percentages of CD282+/TLR2+ mDC significantly increased and 
CD284+/TLR4+ mDC and CD284+/TLR4+ granulocyte percentages tended to be higher 
following β2-1 fructan supplementation. Increased exposure to TLR ligands has been 
shown to increase TLR2 and TLR4 expression (Juarez et al., 2010; Visintin et al., 2001), 
suggesting the increase in TLR2+ and TLR4+ mDC populations reflect increased contact 
with microbial components. DC in the gut may interact with bacteria through epithelial 
tight junctions, as they are capable to extending dendrites to sample the gut lumen, they 
may encounter bacterial components within the lamina propria, or they may indirectly 
interact with bacterial components through M cells (Bekiaris et al., 2014; Farache et al., 
2013). In a study investigating rectal biopsies of Crohn’s disease patients, increased 
percentages of intestinal DC expressing TLR2 and TLR4 were found after β2-1 fructan 
supplementation, in addition to increased percentages of IL-10 producing DC (Lindsay et 
al., 2006). This study demonstrated impacts of β2-1 fructan supplementation on immune 
cells in local gut tissue, however peripheral immune cells percentages were not examined 
to determine if the supplement had a systemic impact. In the current investigation, it was 
76 
 
not possible to biopsy gut tissue, although it is speculated that there may have been impacts 
at the local gut level since effects on immune cells had manifested systemically.  
There were no alterations in lymphocyte populations observed in this trial, in 
keeping with another β2-1 fructan study investigating impacts on immune parameters in 
middle-aged healthy adults (Lomax et al., 2012). However, a study utilizing elderly 
subjects found that β2-1 fructan supplementation increased percentages of total T 
lymphocytes and subsets CD4+ and CD8+ T cells (Guigoz et al., 2002). Taken together, 
these findings suggest that β2-1 fructan supplementation may differentially modulate 
immune parameters in separate age categories. 
β2-1 fructans had an impact on circulating cytokines, as concentrations of TH2 
cytokine IL-4 and proinflammatory cytokine GM-CSF increased, and regulatory cytokine 
IL-10 concentrations decreased. Higher concentrations of IL-4 would lead to increased B 
and T cell proliferation, higher GM-CSF concentrations would lead to increased 
macrophage, neutrophil and DC activity, and lower IL-10 concentrations implies decreased 
ability to maintain immune homeostasis, however interpreting the outcome of cytokine 
concentration is context dependent. Circulating concentrations of LPS were significantly 
higher after the β2-1 fructan phase. Measuring circulating LPS is an indirect measure of 
assessing gut permeability (Albers et al., 2005; Bala et al., 2014; Bischoff et al., 2014), 
and increased LPS concentrations insinuate that microbial contents were translocated 
across the IEC barrier. A study of healthy men consuming β2-1 fructans for 2 weeks 
suggested that β2-1 fructans irritate the gut mucosa since increased faecal mucin excretion 
and intestinal discomfort were observed (Ten Bruggencate et al., 2006), effects likely 
stemming from rapid β2-1 fructan fermentation and liberation of SCFA which decrease 
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lumen pH. This study of healthy men had a similar β2-1 fructan dosage to the current trial 
(20 g per day versus 15 g day), and it was only half of the duration (two weeks versus four 
weeks), so it is probable that β2-1 fructan may have had a greater impact on gut mucosa 
irritation with the increased length of supplementation. In rat models, β2-1 fructan 
consumption has been associated with increased intestinal permeability and also increased 
translocation of S. enteritidis (Ten Bruggencate et al., 2004; Ten Bruggencate et al., 2005). 
Heightened potential for microbial components to cross the IEC barrier could explain the 
alterations observed in circulating cytokine profiles, and also the increase in TLR2 and 
TLR4-expressing peripheral immune cells. However, LBP concentrations did not differ 
between phases, and neither did CRP, a measure of inflammation (Pagana and Pagana, 
2002), suggesting that changes to IEC barrier integrity were non-acute. 
The ex vivo whole blood culture assay allowed for determination of effects of β2-1 
fructan supplementation on responses to TLR agonist stimulation, as TLR-expressing cells 
in blood samples respond by producing and releasing cytokines. This assay provided a 
means to determine the effects of β2-1 fructan fermentation on this aspect of the immune 
response at the systemic level. The profile and cytokine production amount provided a 
measure of the strength of the TLR-induced response, and some insight into the responding 
cell types, as certain cytokines are produced by distinct cell types. The cytokines analyzed 
in plasma included IFN-α, the pro-inflammatory cytokines TNF-α, IL-1β, IL-6, IL-8 and 
IL-12p70, and the regulatory cytokine IL-10. IFN-α is produced by pDCs in response to 
TLR stimulation; monocytes and macrophages produce IL-6, IL-8 IL-10, IL-12p70 and 
TNF-α; T lymphocytes produce IL-6 and IL-10 and TH1 cells produce TNF-α; B cells 
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produce IL-10, IL-12p70 and TNF-α; and mDC produce IL-1β, TNF-α and IL-12p70 
(Della Bella et al., 2008).  
β2-1 Fructans may also directly influence immune activity through interaction with 
TLRs. Previous in vitro studies have shown TLR2 activation by FOS in human T84 IECs 
(Vogt et al., 2014), predominant TLR2 activation and mild TLR4, 5, 7, 8 and nucleotide-
binding oligomerisation domain-containing protein (NOD) 2 activation in reporter cell 
lines, and stimulation of cytokine production by human PBMCs (Vogt et al., 2013). Cross 
talk between immune cells and gut microbiota through PPRs including TLRs may 
influence MyD88 signaling, which is necessary for NF-κB activation and subsequent 
proinflammatory cytokine production. Although the impact of the gut microbiota on TLR 
expression may vary with specific type of TLR (Brandao et al., 2015). Microbiota 
depletion via antibiotics has been shown to influence TLR expression in the ileum and in 
the colon in a murine model; however, increases or decreases in TLR expression depended 
on which TLR was examined (Grasa et al., 2015).  
Analysis of the cytokine profiles produced in the ex vivo whole blood culture assay 
revealed that IL-10 concentrations increased after stimulation with TLR2 agonist P3C in 
whole blood collected from the endpoint of the β2-1 fructan phase. This finding suggests 
increased sensitivity to a TLR2 agonist, which may influence the host’s ability to respond 
to infection since TLRs and the innate immune system are the primary line of defence 
(Barreiro et al., 2009; Turvey and Hawn, 2006). The increased sensitivity to a TLR2 
agonist is also consistent with the increased peripheral mDC CD282+/TLR2+ populations, 
and could be indicative of increased microbial component exposure during the β2-1 fructan 
phase. Stimulation with TLR4 agonist LPS did not change the cytokine profiles between 
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supplement phases. Since circulating LPS concentrations increased during the β2-1 fructan 
phase, peripheral immune cells had contact with this bacterial motif. The diminished TLR 
response to LPS stimulation could be interpreted in two ways, either TLR synergy or the 
phenomenon of LPS tolerance. TLR synergy implies that costimulation with both TLR2 
and TLR4 agonists will amplify cytokine production (Cao, 2016; Sato et al., 2000), and 
the increased LPS concentrations in the blood combined with P3C stimulation may have 
synergized to increase the production of IL-10. LPS tolerance may have also occurred, 
which is decreased surface expression of TLR4 due to continuous exposure to LPS (Cao, 
2016; Sato et al., 2000; Ziegler-Heitbrock, 1995). The latter reason may be less probable, 
since mDC CD284+/TLR4+ tended to increase at the end of the β2-1 fructan phase, however 
TLR4 expression was not measured on all immune cell populations. Cigarette smoking 
may influence TLR responsiveness in whole blood assay cytokine production after 
stimulation with LPS and P3C, and also TLR2 and TLR4 expression on monocytes 
(Versteeg et al., 2009), however it was not known if any of the subjects in the trial were 
active smokers as it was not a factor in trial exclusion criteria or in the initial health 
assessment.   
Immune responses can vary between sexes, and males have been shown to have 
higher macrophage TLR4 expression and macrophage proinflammatory cytokine 
production than females (Klein and Flanagan, 2016). Additionally, IL-10 production 
stimulated by TLR9 and TNF-α production by LPS is greater in PBMCs isolated from 
males than females (Asai et al., 2001; Klein and Flanagan, 2016). A study in a rat model 
has shown differences in concentrations of colonic and liver IL-10 and caecal and liver IL-
6 between males and females after β2-1 fructan feeding (Shastri et al., 2015b). It is highly 
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probable that sex differences in immune responses may have been apparent in the 
peripheral immune cell population analysis and in the cytokine production of the TLR 
agonist ex vivo whole blood culture assay. Since this current trial was not designed to 
investigate differences between males and females, the sample numbers for sex were not 
evenly matched, as there were 13 males and 17 females. In separating the data according 
to sex, there were several pronounced differences found in mDC CD282+ and CD284+ 
subpopulations, circulating cytokine and LPS concentrations, serum and faecal Ig 
concentrations, and ex vivo TLR-induced cytokine production (Appendix B, Figure B1, 
Table B2, Table B3, and Table B4), suggesting that sex differences would be an 
interesting consideration in future dietary supplement clinical trial design. 
In this human clinical trial, the amount of blood volume per subject was limited to 
20 mL for each sampling time point; higher volumes were considered to be above the safe 
blood draw limit for healthy volunteers. This blood volume limited the number of TLR 
agonists that could be used in the ex vivo whole blood culture assay, and also limited the 
number of samples available for the mDC and monocyte TLR-signaling activity assay 
involving intracellular cytokine production measurements. Vaccination with a seasonal 
influenza preparation would be interesting in determining impacts at a systemic level and 
to further understand the role of β2-1 fructans in adaptive immunity. It was not possible to 
directly explore mucosal responses to β2-1 fructan supplementation since tissue samples 
could not be taken from these healthy volunteers. Measurement of the mucin content in 
faeces using newly available ELISA formats may provide information in determining if 
alterations in mucin excretion exist after continuous β2-1 fructan consumption, as 
increased mucin sloughing has been suggested as a result of mucosal irritation induced by 
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β2-1 fructans (Ten Bruggencate et al., 2006), although this effect has varied between 
studies of healthy human (Scholtens et al., 2006). Lastly, measuring the urinary excretion 
of chromium-labeled EDTA (Ten Bruggencate et al., 2006) could provide a way to confirm 
the suggestions made in this study regarding β2-1 fructan consumption compromising the 
integrity of the IEC barrier.   
Several non-immunological impacts of β2-1 fructans on host well-being and gut 
microbiota structure were discovered by other researchers involved in the trial, and these 
findings have been published in Clarke et. al (2016). Dr. Premsyl Bercik and Dr. Christian 
Avila (McMaster University, Hamilton, ON) investigated measures of well-being and gut 
symptomology. It was found that β2-1 fructan consumption significantly increased 
indigestion and these subjects and had a tendency of increased abdominal pain. β2-1 
fructan supplementation was also associated with increased headaches, gas, bloating and 
cramping. Dr. Martin Kalmokoff (AAFC, Kentville, NS) and Dr. Stephen Brooks (Health 
Canada, Ottawa, ON) investigated the impacts of β2-1 fructans on faecal Bifidobacteria 
populations from subjects in this study. It was determined that β2-1 fructan 
supplementation increased the content of faecal Bifidobacteria 16S rRNA genes, in 
keeping with findings from other human clinical trials (Lindsay et al., 2006; Lomax et al., 
2012). However, there was no effect on the frequency of daily bowel movements, a claim 
that has been frequently contradicted in previous human trials (Dahl et al., 2005; Marteau 
et al., 2011; Slavin and Feirtag, 2011). 
 In conclusion, supplementation with β2-1 fructans had some impact on immune 
activity in healthy subjects under steady-state conditions. β2-1 fructan supplementation 
significantly increased serum GM-CSF and IL-4 concentrations, while IL-10 
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concentrations decreased. Circulating population percentages of CD282+/TLR2+ mDC 
increased, and there was a tendency toward higher CD284+/TLR4+ mDC and 
CD284+/TLR4+ granulocyte population percentages. β2-1 fructan supplementation was 
associated with higher serum LPS concentrations, suggesting heightened microbial contact 
during this phase. Increased IL-10 production was observed in response to TLR2 
stimulation with P3C in an ex vivo whole blood culture assay, implying increased 
sensitivity to TLR2 agonists. While TLR cross talk patterns can be complex, heightened 
sensitivity to one TLR ligand can occur as a result of prior exposure to another TLR ligand 
(Cao, 2016). Whether this sensitivity extended to other TLR agonists would require further 
testing of a range of TLR agonists, which could not be performed in this study due to 
sample volume limitations. Collectively, the findings of this study suggest that the innate 
immune system had increased contact with microbial-derived stimuli during the β2-1 
fructan phase of the trial, possibly due to alterations in gut barrier integrity, and 
demonstrate that dietary supplementation with β2-1 fructans can, to an extent, influence 








Table 2-1. Cytokines measured in subjects receiving β2-1 fructan supplementation or 




Cellular Source Cellular Target & Role References 
sCD40L Cell surface protein released 
from B cells, monocytes, 
dendritic cells and T 
lymphocytes 
Involved in proliferation and 
differentiation of B cells, and 
Ig class switching 
(Huang et al., 
2012) 
G-CSF Macrophages, fibroblasts, 
endothelial cells and bone 
marrow stroma 
Stimulates the development of 
progenitor cells to neutrophils 
(Demetri and 
Griffin, 1991) 
GM-CSF Monocytes, T-lymphocytes, 
fibroblasts and endothelial 
cells 
Stimulates development of 
neutrophils, dendritic cells and 
macrophages, promotes 
eosinophil proliferation and 
development 
(Caux et al., 
1992) 
IFN-α Peripheral blood leukocytes 
and lymphoblastoid cells 
Influences cell proliferation, 
modulates immune responses, 
promotes resistance against 
viral infections and inhibits 




IFN-γ Activated NK cells, CD4+ 
and CD8+ T lymphocytes 
Promotes macrophage 
activation, MHC class I and II 
expression, antigen processing 




IL-1β Monocytes, tissue 
macrophages and dendritic 
cells 
Proinflammatory cytokine, 
promotes IL-2 release, B-cell 
maturation and proliferation 
(Dinarello, 
1989) 
IL-1Ra Monocytes and 
macrophages 
Competitively inhibits the 
activity of IL-1β 
(Arend and 
Gabay, 2000) 
IL-2 T lymphocytes Promotes signaling required 
for T-cell proliferation 
(Popmihajlov 
et al., 2012) 
IL-4 Mast cells, T lymphocytes 
and bone marrow stromal 
cells 
Regulates the differentiation of 
naïve CD4+ T cells into helper 
TH2 cells; TH2 signature 
cytokine 
(Paul, 1991) 
















Cellular Source Cellular Target & 
Role 
References 
IL-6 T lymphocytes, 
monocytes, macrophages, 
fibroblasts and endothelial 
cells 
Proinflammatory 
cytokine and also 
considered an 
adipokine, regulates 
immune responses and 
stimulates antibody 
production 





and endothelial cells, and 
is considered a chemokine 
Proinflammatory, 
chemoattractant of 
neutrophils and T cells 
(Hersh et al., 1998) 
IL-10 Monocytes, macrophages 
(M2), T lymphocytes, B 
cells and keratinocytes 
Regulatory, inhibits 
TH1 cell activity, 
prevents macrophage 
cytokine release; Treg 
signature cytokine. 
(Borish, 1998) 
IL-12p70 Activated monocytes, 
macrophages and B cells 
Induces IFN-γ 
production by NK and 
T cells, promotes 






Interferon and LPS 
stimulated cells in the 
thymus, spleen and lymph 
nodes 
Chemoattracts 
monocytes and TH1 
lymphocytes, 
stimulates adhesion of 
activated T cells and 
NK cells to endothelial 
cells 
(Dufour et al., 
2002) 






involved in class 
switching to IgA 
(Annes et al., 
2003) 
TNF-α TH1 cells, adipocytes, B 

















Table 2-2. Description of standard biochemistry and haematological markers analyzed in 
subjects receiving β2-1 fructan supplementation or placebo. 
 
Clinical Indicator Clinical Marker 
Diabetic/pre-diabetic/insulin resistant fasting glucose 
 
Renal function creatine, glomerular filtration rate, globulin, 
albumin, total protein, blood urea nitrogen 
 
Liver function aspartate aminotransferase, gamma- 
glutamyltransferase 
 




Complete Blood Cell Counts Haematocrit, white blood cell count, red 
blood cell count, mean corpuscular volume, 
mean corpuscular haemoglobin, mean 
corpuscular haemoglobin  
 
Differential Blood Cell Counts Neutrophil, lymphocyte, monocyte, 
eosinophil and basophil counts 
 
Serum lipids Total cholesterol; LDL-C – Low density 
lipoprotein cholesterol; HDL-C - High 
density lipoprotein cholesterol; T/HC – 





















Table 2-3. Flow cytometry antibodies used in peripheral cell population analysis. 
 
Marker Description Clone Conjugate1 Manufacturer2 
Control Isotype – IgG1 T1B9 PE Invitrogen 
Control Isotype – IgG1 T1B9 FITC Invitrogen 
CD33 T lymphocytes SK7 FITC BD Biosciences 
CD43 TH1 and TH2 T 
cells, monocytes, 
macrophages 
SK3 APC BD Biosciences 
CD83 cytotoxic T cells SK1 PE BD Biosciences 
CD11c myeloid DC S-HCL-3 APC BD Biosciences 
CD14 monocytes  M5E2 APC BD Biosciences 
CD16 NK cells and 
granulocytes 
3G8 AF647 BD Biosciences 
CD163 NK cells and 
granulocytes 
B73.1 PE BD Biosciences 
CD193 B cells SJ25C1 APC BD Biosciences 
CD45 leukocytes  2D1 (HLe-1) FITC BD Biosciences 
CD453 leukocytes 2D1 (HLe-1) PerCP BD Biosciences 
CD563 NK cells NCAM 16.2 PE BD Biosciences 
CD86 monocytes, 
activated B cells, 
DC 
2331 (FUN-1) PE BD Biosciences 
CD123 plasmacytoid DC 9F5 PE BD Biosciences 
CD282 TLR-2 TLR2.1 PE BioLegend 
CD284 TLR-4 HTA125 PE BioLegend 
HLA-DR MHC II, B cells, 
monocytes, 
activated T cells 
L243 PerCP BD Biosciences 
IL-12 intracellular IL-12 C8.6 FITC Invitrogen 












FITC BD Biosciences 
TNF-α intracellular TNF-α 6401.1111 PE BD Biosciences 
1 AF647, Alexa Fluor 647; APC, allophycocyanin; FITC, fluorescein isothiocyanate; PE, phycoerythrin; 
PerCP, peridinin–chlorophyll–protein complex. 
2 Location of manufacturers: BD Biosciences, San Jose CA; BioLegend, San Diego CA, USA; Invitrogen, 
Carlsbad CA, USA. 




Table 2-4. Simplified LAL assay procedure. 
 
Procedure Sample Blank 
Test sample or standard 50 µL ------ 
LAL reagent water ------ 50 µL 
LAL 50 µL 50 µL 
Mix and incubate at 37°C 10 minutes 10 minutes 
Substrate solution at 37°C 100 µL 100 µL 
Mix and incubate at 37°C 6 minutes 6 minutes 
Stop Reagent 100 µL 100 µL 
Mix immediately   




































Table 2-5. Estimated daily background dietary β2-1 fructan intakes in subjects during 
placebo and β2-1 fructan phases.  
 
ID1 Placebo Phase  
(g β2-1 fructan)2 
β2-1 Fructan Phase  
(g β2-1 fructan) 
001 1.29 0.52 
002 0.83 1.14 
003 1.86 2.40 
004 0.58 0.94 
005 1.45 0.92 
006 1.10 0.50 
007 0.69 0.77 
008 1.31 1.39 
009 1.17 0.35 
010 0.80 0.68 
011 1.06 1.13 
012 1.82 2.13 
013 0.49 0.42 
015 2.36 0.74 
016 1.18 1.48 
018 0.22 0.52 
022 2.04 1.53 
023 0.47 0.30 
024 0.74 0.65 
025 1.40 0.98 
026 1.28 0.92 
027 0.32 0.22 
028 1.13 0.70 
029 2.29 2.05 
030 1.74 2.12 
031 0.13 0.42 
032 0.95 0.95 
033 1.24 0.69 
034 0.17 0.13 





1 n = 30. 











Table 2-6. BMI, BUN and routine biochemical and haematological biomarkers at 










BMI 24.1 ± 0.5 24.2 ± 0.5 24.1 ± 0.5 24.2 ± 0.5 
BUN 5.0 ± 0.2 4.7 ± 0.3 4.9 ± 0.3 4.8 ± 0.3 
fast Glu 4.9 ± 0.1 4.9 ± 0.1 4.9 ± 0.1 4.9 ± 0.1 
Creat 77.1 ± 2.7 76.7 ± 0.1 75.8 ± 2.4 75.4 ± 2.3 
eGFR 91.0 ± 2.5 90.8 ± 2.2 91.4 ± 2.4 92.5 ± 2.2 
AST 24.1 ± 1.6 23.4 ± 1.2 23.8 ± 0.9 24.1 ± 1.0 
GGT 18.9 ± 1.7 20.2 ± 1.8 19.8 ± 2.2 20.4 ± 1.8 
Glob 26.6 ± 0.5 27.2 ± 0.5 26.5 ± 0.5 27.2 ± 0.6 
T-Pr 71.9 ± 0.5 72.9 ± 0.5 71.9 ± 0.5 72.7 ± 0.6 
Alb 45.3 ± 0.5 45.7 ± 0.5 45.7 ± 0.5 45.5 ± 0.4 
hs CRP 2.7 ± 0.8 3.4 ± 1.3 3.0 ± 1.0 2.5 ± 0.9 
TC 4.6 ± 0.1 4.5 ± 0.1 4.5 ± 0.1 4.7 ± 0.1 
LDL 2.6 ± 0.1 2.5 ± 0.1 2.4 ± 0.1 2.6 ± 0.1 
HDL 1.5 ± 0.1 1.5 ± 0.1 1.5 ± 0.1 1.5 ± 0.1 
TC/HDL 3.3 ± 0.2 3.1 ± 0.1 4.0 ± 0.9 3.2 ± 0.2 
TG 1.0 ± 0.1 1.3 ± 0.3 1.1 ± 0.1 1.2 ± 0.1 
Hgb 138.0 ± 2.2 137.9 ± 2.4 137.1 ± 2.0 138.7 ± 0.6 
HCT 0.4 ± 0.0 0.4 ± 0.0 0.4 ± 0.0 0.4 ± 0.0 
WBC 6.4 ± 0.4 6.4 ± 0.4 6.5 ± 0.3 6.3 ± 0.3 
RBC 4.7 ± 0.1 4.7 ± 0.1 4.6 ± 0.1 4.7 ± 0.1 
MCV 89.0 ± 0.6 89.1 ± 0.7 88.9 ± 0.7 88.9 ± 0.7 
MCH 29.6 ± 0.3 29.6 ± 0.3 29.5 ± 0.3 29.8 ± 0.3 
MCHC 333.3 ± 1.9 332.6 ± 1.7 332.5 ± 1.7 334.7 ± 1.8 
RDW 13.0 ± 0.1 13.0 ± 0.1 13.0 ± 0.1 13.1 ± 0.1 
Pl.Ct. 257.9 ± 14.3 264.0 ± 13.6 270.4 ± 13.6 264.2 ± 13.5 
1 Values expressed as mean ± SEM (n = 30). rANOVA analysis did not find differences between time 
points or phases for any marker. 
2 Alb, albumin; AST, aspartate aminotransferase; BMI, body mass index; BUN, blood urea nitrogen; Creat, 
creatinine; eGFR, calculated glomerular filtration rate; fast GLU, fasting glucose; GGT, gamma 
glutamyltransferase; Glob, globulin protein; HCT, haematocrit; Hgb, haemoglobin; HDL, high-density 
lipoprotein; hs CRP, high sensitivity C-reactive protein; LDL, low-density lipoprotein; MCH, mean 
corpuscular haemoglobin; MCHC, mean corpuscular haemoglobin concentration; MCV, mean corpuscular 
volume; Pl.Ct., platelet count; RBC, red blood cell count; RDW, red cell distribution width; T-Pr, total 
protein; TC, total cholesterol; TC/HDL, total cholesterol/high-density lipoprotein ration; TG, triglycerides; 












Table 2-7. Peripheral immune cell populations on day 28 of placebo and β2-1 fructan 
phases. 
 






lymphocytes2 34.2 ± 1.7 34.9 ± 1.1 NS 
CD3+ T cells3 74.2 ± 1.2 73.9 ± 1.2 NS 
CD3+CD4+ TH cells3 45.5 ± 1.5 45.6 ± 1.4 NS 
CD3+CD8+ cytotoxic T cells3 27.5 ± 1.2 27.0 ± 1.2 NS 
CD3-CD19+ B cells3 12.6 ± 0.7 13.0 ± 0.7 NS 
CD3+CD16+CD56+ NK cells3 12.4 ± 1.1 12.2 ± 1.1 NS 
CD3+CD4-CD8- γδ T cells3 3.0 ± 0.3 2.9 ± 0.3 NS 
CD3-14+ monocytes4 7.2 ± 0.4 7.0 ± 0.3 NS 
CD3-16+ neutrophils and 
granulocytes4 
47.3 ± 1.6 45.3 ± 1.7 NS 
lin1-HLA-DR+CD123+ pDCs5 10.4 ± 1.3 10.8 ± 1.1 NS 
lin1-HLA-DR+CD11c+ mDCs5 23.2 ± 1.3 22.2 ± 1.9 NS 
CD86+ mDCs5 13.5 ± 1.0 13.3 ± 1.2 NS 
CD282+/TLR2+ mDCs5 8.8 ± 0.8 11.2 ± 1.2 0.008 
CD284+/TLR4+ mDCs5 9.7 ± 1.0 11.4 ± 1.3 0.060 
HLA-DR+CD14+ monocytes4 5.5 ± 0.3 5.3 ± 0.3 NS 
CD282+/TLR2+ monocytes4 6.5 ± 0.8 7.8 ± 0.9 NS 
CD284+/TLR4+ monocytes4 7.3 ± 0.9 8.8 ± 1.1 NS 
HLA-DR-CD16+ granulocytes4 28.1 ± 1.8 30.2 ± 1.6 NS 
CD282+/TLR2+ granulocytes4 0.6 ± 0.2 1.6 ± 0.5 NS 
CD284+/TLR4+ granulocytes4 1.0 ± 0.2 2.7 ± 0.8 0.050 
1 Data is shown as the percentage of immune cells expressing the surface markers indicating the cell type ± 
SEM (n = 30). 
2 Determined by white blood cell differential count on a Beckman Coulter instrument. 
3 Expressed as % of lymphocytes. 
4 Expressed as % of leukocytes. 



















Table 2-8. Peripheral mDC and monocyte intracellular cytokine production after placebo 
and β2-1 fructan supplementation. 
 
Unstimulated (control) or LPS 
Stimulation1 Cell Population % 
Placebo 
day 28 






Mean %  
mDC 
Control 25.13 ± 1.38 22.10 ± 1.76 0.086 0.270 
LPS 23.92 ± 0.77 20.67 ± 2.67 
% Actual  
TNF-α+ mDC 
Control 1.68 ± 1.39 3.36 ± 2.70 0.938 0.012 
LPS 17.68 ± 6.85 15.10 ± 4.22 
% Actual 
IL-12+ mDC 
Control 6.40 ± 2.08 7.92 ± 3.25 0.375 0.953 
LPS 5.55 ± 1.68 10.76 ± 5.27 
Mean %  
monocytes 
Control 5.78 ± 0.63 4.86 ± 0.72 0.179 0.351 
LPS 6.18 ± 0.82 4.96 ± 0.52 
% Actual 
TNF-α+ monocytes 
Control 0.00 ± 0.00 7.47 ± 4.52 0.590 0.034 
LPS 30.49 ± 6.66 25.78 ± 6.02 
% Actual 
IL-12+ monocytes 
Control 3.99 ± 1.94 8.36 ± 3.18 0.780 0.571 
LPS 7.95 ± 2.34 7.90 ± 1.91 
1 Data is shown as the percentage of immune cells expressing the surface markers indicating the cell type 
and the actual percentage of the specific cell type producing cytokines ± SEM (n = 6). 
2 rANOVA P value according to phase. 






























Table 2-9a. Mean values for serum LPS, LBP and cytokine/chemokine concentrations 
from participants receiving placebo or β2-1 fructan supplements. 
 
Marker1 Placebo β2-1 Fructan 
day 0 day 28 day 0 day 28 
LPS  
(EU/mL) 
0.52 ± 0.09 0.53 ± 0.09 0.53 ± 0.07 0.62 ± 0.102 
LBP 
(µg/mL) 
12.8 ± 1.3 15.2 ± 1.7 13.8 ± 1.5 14.2 ± 1.4 
sCD40L  
(ng/mL) 
6.6 ± 4.7 6.7 ± 4.9 6.2 ± 4.8 5.5 ± 4.0 
G-CSF  
(pg/mL) 
11.7 ± 4.20 14.4 ± 3.63 2.9 ± 1.6 5.4 ± 2.5 
GM-CSF 
(pg/mL) 




BLQ 2.7 ± 2.1 15.2 ± 7.9 66.5 ± 22.9 
IL-1β  
(pg/mL) 
164.4 ± 104.7 162.3 ± 104.9 165.1 ± 105.1 169.5 ± 114.2 
IL-1Ra  
(pg/mL) 
81.2 ± 40.4 107.1 ± 51.4 71.0 ± 41.6 573.5 ± 413.2 
IL-4  
(pg/mL) 
13.0 ± 6.45 11.6 ± 6.35 10.4 ± 5.5 14.0 ± 7.234 
IL-6  
(pg/mL) 
93.3 ± 57.7 78.6 ± 48.7 46.6 ± 31.1 82.9 ± 51.1 
IL-8  
(pg/mL) 
18.4 ± 5.00 23.1 ± 8.39 26.8 ± 8.3 30.3 ± 9.5 
IL-10  
(pg/mL) 
71.5 ± 36.2 79.8 ± 42.15 51.9 ± 28.0 41.2 ± 29.04 
IL-12p70 
(pg/mL) 
215.7 ± 153.1 199.8 ± 139.0 153.9 ± 118.4 206.7 ± 161.8 
IP-10  
(pg/mL) 




61.4 ± 39.3 123.0 ± 85.56 106.7 ± 83.1 123.5 ± 100.9 
Active TGF-β1 
(pg/mL) 











1 Concentrations are shown as mean ± SEM (n = 30). 
2 Value was significantly different from all other time points (rANOVA with LSD test P < 0.03).  
3 Value was significantly different from all other time points (rANOVA with LSD test, P = 0.002). 
4 Values were significantly different from all other time points (rANOVA with LSD test, P < 0.001). 
5 Value was significantly different from fructan d0 (rANOVA with LSD test, P = 0.01). 
6 Value was significantly different from placebo d0 (rANOVA with LSD test, P < 0.001). 
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Table 2-9b. Median values for serum LPS, LBP and cytokine/chemokine concentrations from participants receiving placebo or β2-1 
fructan supplements. 
 
Marker1 Placebo β2-1 Fructan 









LPS EU/mL 0.27 0.17-0.89 0.28 0.16-1.08 0.37 0.12-0.90 0.36 0.27-0.83 
LBP µg/mL 10.7 9.7-32.0 11.9 9.1-19.3 11.7 9.9-15.1 12.5 9.3-15.1 




 449.1 209.6-646.7 
G-CSF pg/mL 0.6 0.6-11.8 0.6 0.6-31.0 0.6 0.6-0.6 0.6 0.6-0.6 
GM-CSF pg/mL 3.7 0.2-39.0 6.2 0.2-28.0 5.1 0.2-23.2 0.2 0.2-27.8 
IFN-γ pg/mL 4.1 4.1-4.1 4.1 4.1-4.1 4.1 4.1-4.1 4.1 4.1-101.5 
IL-1β pg/mL 1.3 0.3-32.9 5.4 0.3-24.6 0.3 0.3-21.2 0.3 0.3-11.1 
IL-1Ra pg/mL 5.0 5.0-32.3 5.0 5.0-127.9 5.0 5.0-61.5 5.0 5.0-47.0 
IL-4 pg/mL 0.1 0.1-5.8 0.1 0.1-4.7 0.1 0.1-2.9 1.5 0.6-7.5 
IL-6 pg/mL 2.9 0.1-18.9 0.4 0.1-13.6 1.3 0.1-12.7 0.1 0.1-14.4 
IL-8 pg/mL 8.6 7.8-28.2 6.7 5.6-11.8 8.4 6.8-17.0 8.1 4.4-23.7 
IL-10 pg/mL 4.1 1.6-33.3 8.3 3.9-57.0 7.4 3.9-20.8 2.5 0.5-29.1 
IL-12p70 pg/mL 2.9 2.9-24.3 2.9 2.9-19.9 2.9 2.9-19.2 2.9 2.9-31.3 
IP-10 pg/mL 54.8 38.7-114.7 71.1 41.2-104.2 71.1 43.6-178.6 60.3  37.5-116.5 
TNF-α pg/mL 0.2 0.2-8.4 1.5 0.2-17.1 0.2 0.2-16.0 0.2 0.2-9.1 
Active  
TGF-β1 pg/mL 














Table 2-10. Concentrations of serum and faecal Ig at baseline and endpoint of placebo and β2-1 fructan phases. 
 
Sample1 Class Placebo β2-1 Fructan 
day 0 day 28 day 0 day 28 
Serum 
(ng/mL) 
IgA     698.4 ± 75.6   1490.8 ± 236.72   1389.9 ± 234.2     911.7 ± 138.23 
IgM     403.8 ± 33.3     821.3 ± 138.32     776.6 ± 124.8     485.8 ± 66.5 
IgG1   2746.9 ± 217.6   7196.4 ± 1257.22   5148.6 ± 797.7   2878.6 ± 214.53,4 
IgG2   1655.0 ± 130.9 20 759.1 ± 6911.72   9659.1 ± 2348.5   1595.6 ± 181.43,4 
IgG3 10 452.2 ± 1237.7 28 181.8 ± 3644.52 28 647.1 ± 2913.6 30 560.7 ± 3355.6 
IgG4     677.1 ± 122.6   2203.7 ± 472.52   1767.1 ± 364.5   2148.0 ± 440.2 
Faecal 
(ng/g) 
IgA 95 076.4 ± 17 617.1 92 189.3 ± 15 075.2 84 686.0 ± 15 752.7 87 428.8 ± 12 137.8 
IgM   6009.3 ± 2581.5 13 399.3 ± 2955.42 22 513.8 ± 7029.3 14 108.7 ± 4834.1 
IgG   2704.2 ± 1538.6     918.5 ± 261.0     697.2 ± 154.1   2406.9 ± 983.6 
1 n = 30 for serum Ig, n = 30 for faecal Ig at time points except for placebo d0, n = 29, values expressed as mean ± SEM. 
2 Value was significantly different between placebo d-0 and d-28 (rANOVA with LSD test, P < 0.005). 
3 Value was significantly different between placebo d-28 and β2-1 fructan d-28 (rANOVA with LSD test, P < 0.005). 












Table 2-11. Ex vivo cytokine production in unstimulated and TLR agonist-stimulated whole blood cultures from subjects at the 






















BLQ BLQ BLQ BLQ BLQ BLQ 
IL-1β 
(ng/mL) 
BLQ 0.03 ± 0.0 8.2 ± 1.1 9.2 ± 1.6 0.3 ± 0.1 0.5 ± 0.1 
IL-6 
(ng/mL) 
0.1 ± 0.0 0.4 ± 0.3 34.4 ± 1.4 36.6 ± 1.7 8.5 ± 0.9 11.5 ± 1.9 
IL-8 
(ng/mL) 
5.3 ± 1.3 17.8 ± 8.1 64.8 ± 1.9 72.7 ± 2.3 57.0 ± 3.2 60.7 ± 4.9 
IL-10 
(pg/mL) 
BLQ 21.14 ± 21.1 2044.0 ± 147.0 2001.0 ± 188.0 16.0 ± 7.2 52.0 ± 18.53 
IL-12p702 
(pg/mL) 
BLQ BLQ BLQ BLQ BLQ 3.3 ± 3.3 
TNF-α 
(ng/mL) 
BLQ 0.1 ± 0.1 2.6 ± 0.3 3.0 ± 0.3 0.2 ± 0.0 0.2 ± 0.0 
1 n = 30 for unstimulated samples and LPS stimulation; n = 24 for P3C stimulation; concentrations expressed as mean ± SEM. 
2 IL-12p70 was detected in only 1 subject after P3C stimulation in whole blood culture collected at the end of the β2-1 fructan phase. 








Chapter 3: Effects of Dietary Fermentable Material and a High-Energy Diet on 




Obesity, High Energy Diets and Inflammation 
 
Interactions between metabolic parameters and the immune system are evident in 
obesity and metabolic syndrome disorders (Iyer et al., 2015; Matarese and La Cava, 2004). 
Obesity has been associated with continuous low grade systemic inflammation (Barbarroja 
et al., 2010). In metabolic syndrome, gut level inflammation increases with high energy 
(HE) diets (Hotamisligil et al., 1995), which further perpetuate systemic inflammation. 
Obese individuals have been shown to have higher expression of proinflammatory 
cytokines TNF-α, IL-1β, IL-6, and also have greater macrophage infiltration in visceral 
adipose tissue when compared to lean subjects (Barbarroja et al., 2010). Greater expression 
of TNF-α has been positively correlated to adipose mass in obese subjects (Hotamisligil et 
al., 1995). The increase in expression of proinflammatory cytokines has also been observed 
in HE feeding trials involving obese animal models, including Wistar (Stemmer et al., 
2012; Zhu et al., 2014) and Sprague Dawley rats (Boonloh et al., 2015; Barbier de La Serre 
et al., 2010). Continuous and dysregulated expression of proinflammatory cytokines 
contribute to the metabolic dysfunction observed in obese subjects (Weisberg et al., 2003).  
Peroxisome proliferator-activated receptors (PPAR) are a family of transcription 
factors (PPARα, PPARβ/δ & PPARγ) which regulate inflammation and also have 
involvement in energy homeostasis (Stienstra et al., 2007). Activation of PPARα prevents 
hepatic fat storage through stimulating hepatic fatty acid oxidation (Kersten et al., 1999), 
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and also inhibits inflammatory gene expression through blocking NF-κB activation of IL-
6 transcription (Delerive et al., 1999). PPARβ/δ activation has also been associated with 
decreased fat storage in the liver and reduced production of IL-6 and TNF-α (Nagasawa et 
al., 2006). Activation of PPARγ reduces macrophage accumulation and inflammatory gene 
expression, thereby reducing production of nitric oxide, TNF-α, IL-1β and IL-6 (Weisberg 
et al., 2003). Both obese humans and animal models typically have decreased activation of 
PPAR transcription factors, which may in part account for obesity-induced inflammation 
(Stienstra et al., 2007).  
Proinflammatory cytokines TNF-α, IL-1β and IL-6 are of special interest in obesity 
studies since these cytokines are continuously produced by macrophages and adipocytes 
residing in adipose tissue, and continuous and dysregulated production of these 
proinflammatory cytokines may lead to insulin resistance (Aroor et al., 2013) and 
contribute to metabolic dysfunction (Weisberg et al., 2003). Within adipose tissue, 
macrophages and adipocytes are involved in local cross-talk which propagates continuous 
proinflammatory cytokine release (Schaffler et al., 2007). Macrophages produce TNF-α, 
which activates the TNF-α receptor on adipocytes and induces NF-κB activation. 
Activation of TLR4 by LPS on both macrophages and adipocytes will also induce NF-κB 
activation, leading to the production of proinflammatory cytokines (Suganami et al., 2007). 
Additionally, NF-κB activation induced by TNF-α leads to lipolysis in adipocytes 
(Suganami et al., 2005), which releases free fatty acids that are capable of activating TLR4 
on macrophages (Schaeffler et al., 2009; Suganami et al., 2005; Suganami et al., 2007). 
The continuous cytokine and free fatty acid release by macrophages and adipocytes leads 
to a steady state of inflammation in the adipose tissue. To further propagate inflammation, 
98 
 
consumption of a high fat diet increases LPS absorption across the intestinal barrier and 
leads to increased serum LPS concentrations; this effect has been observed in rodents (Cani 
et al., 2007; Barbier de La Serre et al., 2010) and in humans (Erridge et al., 2007).  
Macrophages may be activated into distinct states, including the classically 
activated M1 macrophage phenotype or the alternatively activated M2 macrophage 
phenotype (Gordon and Taylor, 2005; Mantovani et al., 2002). M1 macrophages may be 
polarized by TH1 cytokine activity involving IFN-γ or TNF-α, and also through TLR4 
activation by LPS (Martinez and Gordon, 2014). The classically activated macrophage 
phenotype will promote TH1 responses, has involvement in antigen presentation, and 
contributes to high levels of proinflammatory activity leading to tissue damage (Mantovani 
et al., 2002). The M1 macrophage cytokine profile has been identified as having high IL-
12 and IL-23 expression and low IL-10 expression (Mantovani et al., 2004). M2 
macrophages are polarized by IL-4, a signature TH2 cytokine, and this macrophage 
phenotype is typically involved in tissue remodelling and anti-inflammatory activity 
(Biswas and Mantovani, 2010; O'Neill and Pearce, 2016). The M2 macrophage cytokine 
profile has been identified as having high expression of IL-10 and IL-1Ra, and low 
expression of IL-12 (Mantovani et al., 2002), although the alternatively activated 
macrophages have been further classified into a spectrum of M2 macrophages, including 
M2a, M2b and M2c (Mantovani et al., 2004). These subsets are defined by differences in 
cytokine production and cell surface molecule expression, although these differences are 
not as clear-cut in their identification and overlap one another. A mouse model of diet-
induced obesity has shown macrophage polarization to the M1 phenotype in adipose tissue, 
which contributed to greater inflammation and insulin resistance (Lumeng et al., 2007). 
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However, there remains debate regarding the appropriate cellular markers and cytokine 
measurements to categorize macrophage phenotypes, as well as differences between 
humans and rodents. 
Key adipokines of interest in studying the onset of obesity and metabolic disease 
include leptin, adiponectin and resistin, and these are produced by adipocytes in adipose 
tissue deposits. Leptin in particular has been shown to be a mediator involved in innate and 
adaptive immune responses (Mackey-Lawrence and Petri, 2012), and increases in leptin 
concentrations have been associated with autoimmune disorders (Fernandez-Riejos et al., 
2010; Matarese and La Cava, 2004). Since the primary production source of leptin is 
adipocytes, obese subjects are more prone to leptin-resistance and dysregulation of appetite 
and energy expenditure (Villanueva and Myers, 2008), and to interruptions in lymphocyte 
homeostasis, such as an altered balance between TH1-TH2 activity (Matarese et al., 2002). 
Leptin also functions as a hormone in that it decreases appetite while increase energy 
expenditure (Friedman, 2010). Adiponectin has a role in energy metabolism as it regulates 
blood glucose and fatty acids, and also plays a role in inflammation (Cheng et al., 2012). 
Adiponectin has been shown to suppress TNF-α and IL-6 production while increasing IL-
10 production by macrophages stimulated with LPS (Wulster-Radcliffe et al., 2004). 
Resistin has been shown to promote TNF-α, IL-6 and IL-8 production (Dong et al., 2013), 
and also has a role in energy metabolism. Dysregulation of resistin production impairs 
glucose tolerance (Flier, 2001) and may lead to insulin resistance (Aroor et al., 2013).  
Peptide hormones of interest in studying metabolic disease include insulin and 
glucagon, and these are produced in the pancreas and function to regulate blood glucose 
levels. Insulin is an important peptide hormone that functions to regulate and reduce blood 
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glucose levels through facilitating glucose absorption by muscle, liver or fat cells. Insulin’s 
activity may be impacted by adipokines and dysregulated inflammation, such as the 
continuous release of TNF-α and IL-6 in adipose tissue, which could mediate the onset of 
insulin resistance (Aroor et al., 2013). Glucagon functions in a manner opposite to insulin, 
raising glucose levels in instances when blood glucose is low, and has a role in appetite 
control and energy intake (Flint et al., 1998). Glucagon production increases in the 
presence of inflammatory cytokine IL-6 (Barnes et al., 2014), and also after LPS injection 
in rodents (Nguyen et al., 2014). Circulating concentrations of sICAM-1/sCD54 are 
elevated in obese animal models (Matarese et al., 2002) and increased concentrations of 
this marker correlate with increased risk of cardiovascular disease (Albers et al., 2005). 
Dysregulation of sICAM-1 release has been shown to impair neutrophil emigration (Sligh 
et al., 1993) and wound healing, to influence disease progression (van de Stolpe and van 
der Saag, 1996; Witkowska, 2005), and has been associated with insulin and leptin 
resistance (Kent et al., 2004). Adipokines and peptide hormones are intricately connected 
with the immune system and dysregulated in obesity; leptin and resistin concentrations 
increase in obesity while adiponectin and glucagon concentrations are lower, and insulin-
resistance is common. 
 
Gut Microbiota and Inflammation 
 
 It has been previously suggested that alterations in the gut microbiota structure 
affect energy homeostasis since certain bacterial communities may extract or store energy 
more efficiently (Ley et al., 2005), and changes with the gut bacterial community have 
been linked with obesity (Ley, 2010). These statements have insinuated that shifts in the 
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presence and abundance of communities within the microbiota could therefore alter the 
energy balance so that more energy could be potentially obtained from food. Gut 
microbiota shifts have been shown in obese mice, and these shifts created a reduction in 
Bacteroidetes and increased the abundance of Firmicutes when compared to lean 
counterparts (Ley et al., 2005). However, the gut microbiota shifts that have occurred in 
mouse models are not always indicative of shifts that may occur in other animal models or 
in humans. A meta-analysis investigation has shown that signature microbiome structures 
of lean and obese individuals are inconsistent between studies, even when similar methods 
of analysis are employed (Walters et al., 2014). A separate meta-analysis investigation has 
also determined that variability between studies is greater than the differences found in 
lean and obese individuals of the same study (Finucane et al., 2014). Investigators involved 
in these meta-analyses have concluded that the low Bacteroidetes/Firmicutes is not an 
accurate representation of every obese individual, the ratio is frequently inconsistent, and 
that cohort selection, methodology, and statistical analysis strategies will need to mirror 
each other for appropriate comparisons (Finucane et al., 2014; Walters et al., 2014).  
 Although the exact alterations of gut microbiome structure of obese models have 
been debated, HE diets have been shown to shift microbiota profiles and increase systemic 
inflammation. Studies in mice have shown that diets high in saturated fats altered the gut 
microbiota profile and increased gut permeability compared to control diets (Lam et al., 
2012), which suggests that HE diets may further increase systemic inflammation in an 
obese-prone model. Studies in obese rat models have also shown shifts in gut microbiota 
composition after consumption of HE diets, and that the fluctuation may have been 
associated in the development of systemic inflammation (Barbier de La Serre et al., 2010). 
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Specifically, obese rats had higher plasma LPS concentrations, and this was likely due to 
intestinal inflammation diminishing the epithelial barrier integrity (Barbier de La Serre et 
al., 2010). Further studies are required in obese models to determine if gut microbiota shifts 
introduced through dietary fermentable material (DFM) consumption alter the 
inflammation that is typically observed in obesity. 
 
Dietary Fibre and Inflammation 
 
Acetic acid, propionic acid and butyric acid are SCFA liberated after fermentation 
of dietary fibre by the gut microbiota. SCFA can significantly decrease the pH of the 
intestinal tract and cause mucosal injury in otherwise healthy humans (Ten Bruggencate et 
al., 2006) and in rats (Lin et al., 2002). High concentrations of butyrate can inhibit 
proliferation and induce apoptosis of the human IEC line Caco-2 (Peng et al., 2007), 
suggesting one route through which butyrate could influence epithelial integrity. In 
addition, increased permeability in the colon after acute exposure to butyrate has been 
reported in normal rat colonic mucosa (Mariadason et al., 1999). Butyrate has also been 
reported to cause cell necrosis and reduction of functional tight junctions between IEC 
(Mariadason et al., 1999), which would result in increased permeability in intestinal 
mucosa. Intestinal trefoil factor (ITF) is expressed in goblet cells within the intestinal tract 
and has involvement in mucosal defense (Lin et al., 2005). An investigation of mucosal 
injury in newborn rats has shown that ITF gene expression is down-regulated in the 
presence of SCFA (Lin et al., 2005). This down-regulation may indicate that the goblet 
cells are among the first to perish during mucosal injury. With decreases in goblet cell 
populations, there would also be decreases in mucin secretion, which combined with IEC 
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death and the accompanying decrease in IgA translocation, would further diminish mucosal 
defense, suggesting a negative role for SCFA production by the gut microbiota. However, 
the role of SCFA is not easily classified as completely detrimental or beneficial. 
Interestingly, acetate production by Bifidobacterium has been reported to inhibit IEC 
uptake of Shiga-like toxin during infection by Escherichia coli O157:H7, suggesting some 
beneficial effects of SCFA in the context of host defence (Fukuda et al., 2011). These 
contradictory roles of SCFA highlight the need for further study on its effects on the 
immune system. 
The effects of fructooligosaccharides (FOS, 2-8 repeating fructose units) and inulin 
(9-60 repeating fructose units) during intestinal infections have been studied in rats (Ten 
Bruggencate et al., 2004; Ten Bruggencate et al., 2005). It has been determined that dietary 
FOS and inulin impair resistance to Salmonella enteritidis due to increases in intestinal 
permeability (Ten Bruggencate et al., 2004; Ten Bruggencate et al., 2005). The altered 
permeability would subsequently increase translocation of Salmonella to sites beyond the 
intestinal tract enhancing opportunities for systemic infection. Feeding upon FOS and 
inulin also increased mucin production in rat colonic contents (Ten Bruggencate et al., 
2005). Increases in mucin secretion may actually be a protective action for IEC to prevent 
damage from the SCFA produced as a result of FOS and inulin fermentation. Since 
increased mucin production is also considered to be a basic mechanism of host defence, it 
appears that the effects of FOS in the context of infection are not clear cut. However, the 
observations during intestinal infection with Salmonella do reveal how dietary FOS and 
inulin could potentially increase systemic inflammation.  
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The SCFA profile differs during the fermentation of specific fibres, as does the 
context in which DFM may influence bacterial community structure and immune activity. 
A study analyzing the faecal community composition of BioBreeding rats found increased 
bacterial community richness in animals which received either wheat bran or oat bran 
compared to the control diet (Abnous et al., 2009). BioBreeding rats on diets supplemented 
with wheat bran have been previously shown by Shastri et al. (2016) to have decreased T 
cell and CD4+TH cell percentages in the mesenteric lymph nodes (MLN), while having 
increased B cell percentages in the spleen in comparison to rats on a control diet. In this 
same study, rats on oat bran and resistant starch (RS)-supplemented diets displayed 
increased concentrations of TGF-β in the liver (Shastri et al. 2016), indicating impact at 
the systemic level. A study which investigated effects of dietary supplementation with 
wheat bran, oat bran, RS and FOS on colon tumor formation in male Fischer 344 rats found 
that tumor burden was significantly reduced in rats on the wheat bran diet (Raju et al., 
2016). RS-supplemented diets have led to increased faecal SCFA concentrations in 
BioBreeding rats (Kalmokoff et al., 2013); however, RS diets have also been shown to 
decrease faecal and caecal bacterial community diversity compared to control diets in this 
same rat strain (Kalmokoff et al., 2015). FOS has been previously shown to interact directly 
with TLRs (Vogt et al., 2013; Vogt et al., 2014); RS may also directly influence immune 
activity through TLR activation. A study by Bermudez-Brito et al. (2015) has shown that 
RS binds to TLR2 on human DC and modulates immune activity through increased 
chemokine production. With the results of the above trials taken together, it seems that 
different DFM distinctly influence immune activity and may have compartmental effects 
on either systemic or mucosal immunity. 
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An Obesity Model to Study Inflammation and Fibre Supplementation 
 
Sprague Dawley rats are an outbred multipurpose albino rat breed which are 
frequently used in medical and metabolic studies. When Sprague Dawley rats are fed HE 
diets, they can be readily separated into diet-induced obesity prone or obesity resistant 
phenotypes based on weight gain after 2 weeks of feeding diets higher in fat and energy 
density than regular rodent diets (Aziz et al., 2009; Barbier de La Serre et al., 2010). Under 
these conditions, some of the rats will gain significantly more weight than others, an 
outcome that parallels the human situation. While roles for the gut microbiota in the 
development of obesity and systemic low-grade inflammation have been proposed (Bleau 
et al., 2015), much remains to be determined about the nature of gut microbiota interactions 
with the immune system, outcomes with respect to immunometabolism and the extent to 














Chapter 3 Study Objectives 
 
A trial was designed to evaluate the effects of DFM on inflammation and obesity 
in the context of a high fat diet using a rat model. The purpose of the experiment was to 
investigate interactions of DFM and a HE diet on obesity-associated immune biomarkers 
in Sprague Dawley rats. The trial took place from July to November 2014. DFM were 
selected to include a range of structural properties and degree of fermentability, and 
included wheat bran, oat bran, high amylose corn starch (resistant starch type II: RS) and 
FOS. These DFM have been previously shown to differ in their effects on gut microbiota 
diversity, short and branched chain fatty acid production, gut mucosal cytokine profiles, 
and in the ability to influence cytokine profiles at the mucosal and systemic level in rat 
models (Kalmokoff et al. 2015; Shastri et al. 2015b, 2016). A preliminary phase of the trial 
was utilized for the development of obese and non-obese phenotypes while rats consumed 
a HE diet. Immediately following the segregation of phenotypes, rats consumed HE diets 
supplemented with DFM for 11 to 12 weeks. It was hypothesized that the obese rats would 
have higher levels of inflammation than the non-obese rats, and that rats on the HE FOS 
diet would have increased concentrations of proinflammatory cytokines than rats on the 
other diets. The fermentation properties of the DFM utilized in this study are shown in 
Table 3-1, and the cytokines and chemokines measured while investigating immune 
activity are shown in Table 3-2.  
 
Objective 1: to evaluate associations between diet-induced obesity, inflammation and 
associated immune parameters after consumption of a HE diet for a 2-week period (the 
preliminary phase of the trial).  
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Objective 2: to evaluate inflammation and immune parameters associated with obesity after 
an 11 to 12-week period on selected HE DFM diets, while monitoring differences between 








Sprague Dawley rats display a continuum of weight gain when exposed to a 
moderately high-fat/HE diet. This diet was based on the standard rat chow, the American 
Institute of Nutrition 93G growth purified diet (AIN-93G; ingredients and nutritional 
profile is provided in Appendix C, Table C1), with increased fat content. Feeding 
Sprague-Dawley rats high fat diets is a common method for promoting the exhibition of 
obesity-prone or obesity resistant phenotypes (Barbier de La Serre et al., 2010; Levin et 
al., 1997). In this model, obese rats (Diet-Induced Obesity, DIO) are identified as 
belonging to the upper 40% of weight gainers and resistant rats (Diet-Induced Obesity 
Resistant, DR) are identified as the lower 40% of weight gainers.  
Initially, 176 weanling male Sprague Dawley rats were obtained from Charles 
River (Saint Constant, QC) in July 2014. The animals were 28-32 days old upon arrival at 
the Animal Research Division at the Banting Research Centre, Health Canada (Ottawa, 
ON). Animals were numbered (the odd-numbered rats received a black marking on their 
upper tail) and paired-housed in Sealsafe® PLUS Rat IVC Green Line cages with wire 
mesh bottoms separating the rats from the corn cob bedding (Bed-o’Cobs, The Andersons 
Lab Bedding Products, Maumee, OH, USA). This separation was necessary to prevent 
coprophagia and ingestion of bedding material, which could influence the study outcome 
(Le Leu et al., 2015). The environmental enrichment provided included sanitized nylon 
gnawing sticks, a flat stainless steel sheet for resting, a covered tunnel, and continuous 
music from a radio (French-Canadian Radio). Water and AIN-93G rat chow were provided 
ad libitum in self-feeding hoppers. The animal room was programmed with a 12-hour 
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light/dark cycle, and temperature was held constant at 22°C. Animals were assessed daily 
by the Animal Research Division staff for signs of distress (reduced feed consumption, 
sensitivity to handling, sensitivity to noise or light, and listlessness). The protocol for 
animal care procedures was approved by the Health Canada Animal Care Committee and 
the University of Ontario Institute of Technology’s Animal Care Committee. In order to 
participate in the trial sample collections and necropsies, I completed the Canadian Council 
on Animal Care in Science’s Institutional Animal User Training Program and received 
additional training in animal handling and sample collection procedures.   
After animals experienced an acclimatization period of seven days, a HE diet 
consisting of 16% dietary fat (HE AIN-93G) was introduced for two weeks to identify DIO 
and DR phenotypes. The DIO rats were the 40% highest weight gainers and the DR rats 
were the 40% lowest weight gainers, with 70 animals per group, and the remaining 36 rats 
were designated as intermediate responders (MID). At this time, the 10 highest weighing 
DIO and 10 lowest weighing DR rats were autopsied (August 2014) to determine effects 
of the HE diet alone on physiological measures in both groups. After the initial two-week 
feeding trial, a tail vein blood sample was obtained from the remaining 60 DIO and 60 DR 
rats for immune and metabolic measures. At this same time, faecal samples were collected 
to establish baseline structures of the bacterial community before fibre diets were 
introduced. Animals were then re-paired if necessary to match DIO, DR and MID rats 
together in cages, and the odd-numbered rats received ear notches to reinforce their 
markings. Rat pairs were randomly assigned to receive one of six diet groups (ten rats per 
diet group for DIO and DR) for a further 11-12 weeks. These diets were formulated from 
modifications of the standard AIN-93G rat chow, and include control (AIN-93G), HE 
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control (AIN-93G modified with high fat content) and HE DFM-supplemented diets (AIN-
93G modified with high fat content and DFM) including HE wheat bran, HE oat bran, HE 
high amylose corn starch resistant starch type II (RS), and HE FOS. The diet formulations 
were created by Dr. Stephen PJ Brooks (Bureau of Nutritional Sciences, Health Canada) 
and are shown in Table 3-3. Each rat in the trial had their weight recorded on a weekly 
basis. 
Upon trial completion, necropsies were performed on all animals. Euthanasia by 
exsanguination was carried out under isoflurane anesthesia. Pathologist Dr. Don Caldwell 
(Scientific Services Division, Bureau of Chemical Safety Food Directorate, Health 
Products and Food Branch, Health Canada) inspected all rats for abnormalities and 
performed tissue sectioning. Tissues were collected, rinsed in ice-cold PBS, weighed and 
immediately cryopreserved in liquid nitrogen to examine effects on cytokine/adipokine 
production, and included systemic (serum, liver, spleen), mucosal (ileum, ileal Peyer’s 
patches (PP), caecum, proximal colon, distal colon, MLN), and adipose tissue (epididymal 
fat and mesenteric fat). Tissues were then transferred to -80°C storage pending 
homogenization. Caecal and faecal contents were also collected cryopreserved to 
determine bacterial community structures and SCFA analysis.   
In order to conduct histological scoring of the gut tissue and examination of 
immune cells present in the gut wall, additional intestinal tissues were preserved in 1.0 cm 
cylindrical sections in 10% neutral buffered formalin in 20 mL glass scintillation vials. 
These tissues included duodenum, mid jejunum, ileum, proximal colon and mid colon.  
Blood samples were divided into lavender cap BD Vacutainer K2EDTA blood collection 
tubes (#367861, BD, Franklin Lakes, NJ, USA) for whole blood TLR assay (4.0 mL), 
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lavender cap BD microtainer K2EDTA tubes (#365974, BD, Franklin Lakes, NJ, USA) for 
hematology (0.2 mL), orange cap BD Vacutainer serum separation tubes (SST; #367983, 
BD, Franklin Lakes, NJ, USA) for serum immunological analysis (3.5 mL), and yellow 
cap BD microtainer SST (#365967, BD, Franklin Lakes, NJ, USA) for BUN and glucose 
measurements. Anti-coagulated whole blood samples collected in lavender cap BD 
Vacutainer K2EDTA was used immediately following necropsies for hematological 
measures and the TLR agonist assay. Once blood collected in the orange and yellow cap 




Dr. Don Caldwell (Scientific Services Division, Bureau of Chemical Safety Food 
Directorate, Health Products and Food Branch, Health Canada) performed histological 
scoring of gut tissue collected during the preliminary and final necropsies. Samples fixed 
in neutral buffered formalin were trimmed, processed and embedded into 4 µM thick H 
and E stained slides. Pathological examination was carried by light microscopy on 
duodenum, jejunum, ileum, proximal and mid colon samples from three rats of each diet 
group, using an assessment protocol adapted from Dickson et al. (2006). Attention was 
focused on the following: mucosal inflammation, villous architecture and ratio, crypts, 
lamina propria, muscularis mucosae, enterocytes, the composition of and numbers of 
inflammatory cells in the lamina propria and lining enterocytes, the brush border and the 
lumen border. Intraepithelial lymphocytes (IELs) were counted per 100 villous enterocytes 




Immune Cell Population Analysis by Flow Cytometry 
 
Hematology measures were used to investigate circulating cell populations from 
blood collected immediately following both preliminary and final necropsies. 
Hematological measures were performed by Dominique Patry (Hematology & 
Biochemistry lab, Animal Research Division, Health Canada) using the AcT™ 5diff Cap 
Pierce hematology analyzer (Beckman Coulter, Brea, CA, USA). This same cell counter 
was used to determine cell concentrations for flow cytometry analysis.  
Analysis of cell population patterns allows determination of DFM effects on total 
leukocytes, B and T lymphocytes (including T helper (TH) cells, cytotoxic T cells, γδ-T 
cells, and Foxp3+ regulatory T cells which will be referred to as Treg cells), T cell homing 
receptor expression (referred to as memory T cells (Obhrai et al., 2006)), Dendritic cells 
(DC), Natural Killer (NK) cells and macrophages (total macrophages and M1/M2 subsets). 
At the final necropsy, immunofluorescence and flow cytometry were utilized to examine 
immune cell populations (n = 5 per diet/phenotype/tissue) in systemic tissue (spleen) and 
mucosal tissues (MLN and ileal PP). To prepare cells for staining, tissues were placed on 
a 70 µm cell strainer in a 50 mL Falcon tube. Cells were strained through using a syringe 
plunger and 5 mL of ice-cold RPMI-1640 medium supplemented with 10% fetal bovine 
serum (Sigma Aldrich, St. Louis, MO, USA). Cell suspensions were centrifuged at 340 × 
g for 6 minutes, and re-suspended in phosphate buffered saline to determine concentration.  
The immune cell markers were divided into three separate panels and details on all 
antibodies and conjugated fluorochromes may be found in Table 3-4. The same panels 
were used to enumerate immune cell population percentages in the spleen, MLN and ileal 
PP. To determine concentrations for optimal detection, fluorescent antibodies against 
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standard cell markers were titrated and tested. A viability stain was used to irreversibly 
label dead cells prior to permeablization and staining procedures to ensure that viable cells 
were gated separately, and an isotype control was used to assess non-specific binding in 
Foxp3+ T cells. Cells were diluted to 1 × 107 cells/mL for viability staining, and a minimum 
of 1 × 106 cells/mL was required for antibody staining. 
Flow cytometry was performed using a BD LSRFortessa™ flow cytometer (BD 
Biosciences, San Jose, CA, USA), equipped with blue (488 nm), red (640 nm) and violet 
(405 nm) lasers. The forward scatter and side scatter gating techniques used during 
acquisition of 10 000 viable cells/lymphocytes were standard and similar to those outlined 
by Shingadia et al. (2001). Initial analysis of immune cell populations was conducted using 
BD FACSDIVA™ software (BD Biosciences, San Jose, CA, USA), and additional analysis 
was conduced on cell populations with improved gating using FlowJO 10.0.8 software 
(Ashland, OR, USA) with assistance from Jason Fine, flow cytometry technician with 
Animal Research Division at Health Canada.  
 
An ex vivo Whole Blood TLR Stimulation Assay 
 
Direct measurement of TLR expression on rat immune cell populations using 
immunofluorescence with anti-TLR antibodies was not possible due to the unavailability 
of anti-rat CD282 and CD284 antibodies suitable for flow cytometry. However, TLR 
activity may be measured functionally by stimulating monocytes and DCs with TLR 
ligands, such as peptidoglycan (TLR2), LPS (TLR4), Flagellin (TLR5) and CpG DNA 
(TLR9). This whole blood stimulation method allows for determination of effects on 
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responses to TLR agonist stimulation, as TLR-expressing cells in blood samples will 
respond by releasing cytokines.  
Blood collected from 20 animals at the preliminary necropsy was stimulated with 
the following TLR agonists; P3C (TLR2, Calbiochem, EMD Millipore, Etobicoke, ON, 
Canada), LPS (TLR4, Sigma Aldrich, St. Louis, MO, USA), Flagellin (TLR5, Alexis 
Biochemicals, Enzo Life Sciences, Farmingdale, NY, USA), Escherichia coli ssDNA 
(TLR9, InvivoGen, San Diego, CA, USA), CpG ODN 2006 DNA (TLR9, Imgenex, Novus 
Biologicals, Littleton, CO, USA), and RPMI-1640 medium (unstimulated control, Sigma 
Aldrich, St. Louis, MO, USA). The TLR agonist stimulation concentrations tested in the 
preliminary trial are listed in Table 3-5, are were selected based on other studies using this 
approach (Gillaux et al., 2011; Li et al., 2012; Liu et al., 2012). All TLR agonists were 
diluted in RMPI-1640 medium, and stock concentrations were prepared in volumes which 
made it possible to add 12 µL of agonist to 1.2 mL of whole blood to achieve the desired 
concentration. 
To begin the assay, lavender cap BD Vacutainer K2EDTA (#367861, BD, Franklin 
Lakes, NJ, USA) blood collection tubes were gently inverted five times to ensure mixing, 
and three 1.2 mL aliquots were prepared from each rat in 5 mL polypropylene round-
bottom tubes (#352063, BD, Franklin Lakes, NJ, USA). In an effort to maintain aliquot 
reproducibility and reduce sample retention, Axygen Maxymum Recovery Universal Fit 
filter pipette tips (Union City, CA, USA) were used. From each rat, two aliquots were used 
for stimulation with two different TLR agonists, and the third aliquot was used as an 
unstimulated control. Once 12 µL of the appropriate TLR agonist was added to whole 
blood, the tube was lightly vortexed to ensure the agonist was evenly distributed in the 
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sample. Blood tubes were subsequently placed in a 5% CO2 humidified incubator set at 
37°C on a 5° slant with loose caps to prevent evaporation but allow for gas exchange. 
After 20 hours of incubation, blood assay tubes were centrifuged at 1300 × g for 5 minutes. 
The supernatants were carefully transferred into microtubes (approximately 2 × 200 µL) 
and frozen at -80°C until analysis. Cytokines analyzed in these samples included pro-
inflammatory cytokines CINC-1/CXCL1, CINC-2αβ/CXCL3, IFN-γ, IL-1β, IL-6 and 
TNF-α, and the regulatory cytokine IL-10. All cytokines were measured using rat DuoSet 
ELISA Development kits according to manufacturer’s procedures (R&D Systems, 
Minneapolis, MN, USA). After the preliminary trial samples were analyzed, it became 
clear that whole blood stimulation with a TLR-9 agonist would not be possible at the end 
of the trial due to cost. The optimal stimulating concentrations determined for each agonist 
at the final necropsy were 10 µg/mL for P3C, 5 µg/mL for LPS, and 100 ng/mL for 
Flagellin. 
Whole blood collected from DIO and DR animals at the final necropsy (n = 60) 
was stimulated with TLR2, TLR4 and TLR5 agonists using the same protocol as outlined 
for the preliminary trial. At the end of the trial, the concentrations of cytokines measured 
included CINC-1, IL-1β, IL-6, IL-10 and TNF-α. 
 
Detection of Serum Endotoxin 
 
Serum endotoxin was quantified in order to determine whether circulating 
concentrations of this gut microbial component differed between HE DFM-supplemented 
diets. Serum endotoxin levels were analyzed from blood drawn at the preliminary necropsy 
(n = 20) and at the end of the trial for DR (n = 60) and DIO rats (n = 60), using the LAL 
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Assay QCL-100 (Lonza, Basel, Switzerland) following the procedure as described in 
Chapter 2. In a subset of serum samples, the pH ranged from 7.63 – 7.69. Since these 
measurements were within a biological range, pH adjustments were not necessary. There 
were several amendments made to the LAL assay during pre-testing with rat serum. This 
time, serum samples were diluted 1/5 in endotoxin-free water, heat-inactivated for 10 
minutes at 70°C in a water bath (Cani et al., 2008), and Pyrosperse Dispersing Reagent 
F188 (Lonza, Basel, Switzerland) was added to samples at a 1/200 final dilution prior to 
beginning the LAL assay (Dehghan et al., 2014). Pyrosperse is a metallo-modified 
polyanionic dispersant, and it is used to reduce interference during the endotoxin assay. 
The heating and Pyrosperse steps were added to reduce and disperse lipid micelles which 
may have been introduced by the high fat diet in an effort to maintain LAL assay 
sensitivity. An alternate stop reagent, sodium dodecyl sulfate (10% w/v) was necessary for 
use with the Pyrosperse Dispersing Reagent. 
 
Assessment of Blood Glucose and Blood Urea Nitrogen 
 
Non-fasting blood glucose and blood urea nitrogen (BUN) were measured from 
serum collected at the preliminary necropsy and from all animals (DR, DIO and middle 
gainers) at the end of the trial to determine if HE and selected fibre diets altered glucose or 
nitrogen metabolism. Fasting measurements were not possible since this would have 
diminished the available fresh caecal and feceal sample collections, which were needed for 
bacterial community analysis and to measure SFCA content. Serum BUN and glucose 
concentrations were measured at Health Canada using a VITROS® 5,1 FS automated 
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clinical chemistry analyser with VITROS® urea/BUN and glucose test kits (Ortho-Clinical 




Tissue homogenates were prepared in an immunoprecipitation buffer adapted from 
Burgos-Ramos et al. (2012; 50 mM NaH2PO4, 100 mM Na2PO4, 0.1% sodium dodecyl 
sulfate, 0.5% NaCl, 1% Triton X-100, 5 mg/mL sodium deoxycholate) with the addition 
of 1% Protease Inhibitor Cocktail (Sigma Aldrich, St. Louis, MO, USA). The tissues were 
suspended in immunoprecipitation buffer at a ratio of 1:5 (wt/vol) and then homogenized 
using a VWR®200 homogenizer (VWR International, Radnor PA, USA) and centrifuged 
(17 200 × g for 30 min at 4C). Supernatants were collected and stored at -80C until 
cytokine analysis. Only MLN tissue homogenates required a second round of centrifuging 
due to high lipid levels. A small section from the left lateral lobe of the liver was 
homogenized in place of the entire organ. 
Before tissue homogenates were analyzed for cytokine, chemokine and adipokine 
profiles, Bradford assays were carried out to ensure consistent protein concentrations 
among tissue homogenates. Coomassie Plus Protein Assay Reagent and albumin standards 
(Thermo Fisher Scientific, Waltham, MA, USA) were used in this assay. Samples were 
diluted 1/15 in water, and standards were diluted in a 1/15 solution of homogenization 
buffer to account for background. Microplates were read at a wavelength of 595 nm to 





Assessment of Cytokine Profiles 
 
Cytokine quantifications allow insight into the effects of each diet on gut-associated 
lymphoid tissue, and more specifically the T cell subsets. Cytokines profiles analyzed in 
serum and tissue homogenates collected from both preliminary (n = 10 per diet) and final 
necropsies (n = 10 per diet/phenotype) included both regulatory and proinflammatory 
cytokines/chemokines. Regulatory cytokines included in the analysis were active and total 
TGF-β1, IL-10 and IL-22; proinflammatory cytokines and chemokines included CINC-1, 
CINC-2αβ, CINC-3, GM-CSF, soluble ICAM-1/CD54, IFN-γ, IL-1β, IL-4, IL-6, IL-17 
and TNF-α. Cytokine/chemokine profiles were examined in serum and both mucosal and 
systemic immune tissue homogenates (spleen, liver, epididymal fat, mesenteric fat, MLN, 
ileum, ileal PP, caecum, distal colon and proximal colon). All cytokines in serum and 
tissues were quantified using rat DuoSet ELISA Development kits according to 
manufacturer’s procedures (R&D Systems, Minneapolis, MN, USA). ELISAs were carried 
out using 96-well high-binding half area microplates (Greiner Bio-One, Frickenhausen, 
Germany). The optical density of the reactions in the ELISA plates were read at wavelength 
of 450 nm on a Synergy HT multi-detection microplate reader (BioTek Instruments Inc, 
Winooski, VT, USA) using KC4 v3.4 analysis software (BioTek Instruments Inc., 
Winooski, VT, USA). In addition to the cytokine analysis, CRP was quantified in serum 
and liver homogenates via ELISA (R&D Systems, Minneapolis MN, USA).  
For quantification of IL-22 in ileum, caecum, distal colon and MLN homogenates 
collected from the preliminary trial (n = 3 per diet/phenotype), a Mouse/Rat IL-22 
Quantikine® ELISA kit was used (R&D Systems, Minneapolis MN, USA). This same IL-
22 ELISA format was utilized again for distal colon and caecal homogenates collected 
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from the end of the trial (n = 10 per diet/phenotype). Due to the expensive cost of this 
assay, it was not possible to expand the IL-22 measurements to other tissues. 
MLN and ileal PP of DIO and DR animals (n = 5 per diet group/phenotype/tissue) 
at the final necropsy were analyzed separately for CINC-2αβ, CINC-3, GM-CSF, sICAM-
1/sCD54, IFN-γ, IL-1β, IL-2, IL-4, IL-6, IL-10 and TNF-α using the Rat Magnetic 
Luminex® Screening Assay (R&D Systems, Minneapolis, MN, USA) on a Luminex 200 
analyzer (Austin, TX, USA).  
 
Assessment of Peptide Hormone and Adipokine Profiles 
 
Peptide hormone and adipokine concentrations (non-fasting) were measured to 
determine if the selected diets created alterations in insulin signaling and metabolism. 
Leptin was quantified in mesenteric fat, epididymal fat, distal colon homogenates and 
serum collected during the preliminary trial (n = 3 per phenotype/tissue) using the 
Mouse/Rat Leptin ELISA kit (B-Bridge International Inc., Santa Clara, CA, USA). Leptin, 
insulin and glucagon were measured in final necropsy serum samples (n = 5 per 
diet/phenotype) using the MILLIPLEX Map Kit Rat Metabolic Magnetic Bead Panel 
(EMD Millipore Corp. Billerica, MA, USA) on a Luminex 200 analyzer (Austin, TX, 
USA). Adiponectin was measured in serum and epididymal fat tissue homogenates (n = 10 
per diet/phenotype) via Rat Adiponectin/ARP30 ELISA (R&D Systems, Minneapolis MN, 
USA), since this is the most prevalent adipokine and is difficult to multiplex accurately. 
Leptin was also measured in distal colon homogenates (n = 6 per diet/phenotype) using the 
Mouse/Rat Leptin Quantikine® ELISA (R&D Systems, Minneapolis, MN, USA). Again, 
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due to the expensive cost of this assay, it was not possible to expand leptin measurements 




 The statistical program SigmaPlot v13.0 (Systat Software Inc., San Jose, CA, USA) 
was used to analyze data collected during this trial. In the preliminary trial analysis, 
unpaired t-tests (Student’s t-tests) were carried out to determine differences between DR 
and DIO phenotypes, and the Mann-Whitney U test was utilized when data were not 
normally distributed. For data collected at the end of the trial, two-way ANOVA was used 
to examine differences between DR and DIO phenotypes, overall effects of diet and 
interactions (Phenotype × Diet). ANOVA analysis was followed by Tukey pairwise 
multiple comparison tests. Data was transformed if it did not pass normality (Shapiro-Wilk) 
or equal variance (Brown-Forsythe) tests, using common transformations available in the 
software program. A P value of < 0.05 was considered statistically significant. For some 
measures, there were several values that were below the LoQ. In these instances, the values 
were set to LoQ/√2 (Armbruster et al., 1994) for analysis.  
All results in tables are presented as the mean ± SEM. Figures were created using 
GraphPad Prism v7.01 software (La Jolla, CA, USA). The figures in this chapter are box 
and whisker plots; the ends of the boxes represent the upper and lower quartiles, the line in 
the centre of the box indicates the median value, and the whiskers display the maximum 







Preliminary Trial Analysis 
 
 The preliminary trial was considered to be the first two weeks after the 
acclimatization period, during which time all rats consumed the modified HE AIN-93G 
diet, referred to as the HE control diet. The average weights of the rats at this time point 
were as follows; 290.2 ± 0.7 g for DIO rats, 277.4 ± 0.2 g for MID rats, and 263.0 ± 0.7 g 
for DR rats. The amount of weight gained during the two week HE feeding period is 
displayed in Figure 3-1a, and there was a distinct and significant separation between the 
weights of DR, MID and DIO rats (P < 0.001). Tissues were collected from ten of the 
lightest DR rats and ten of the heaviest DIO rats at the end of this period. The average 
amount of food consumed each day during the preliminary trial is displayed in Figure 3-
1b, and DIO rats (P < 0.001) and MID rats (P = 0.003) consumed more food each day than 
DR rats. The main goals of the preliminary trial were to determine effects of the HE diet 
alone on immunological and physiological measures in DR and DIO groups, and to pre-
test several assays so that optimized procedures were in place for analysis of samples 
collected at the end of the trial.  
The first analyses were performed on blood samples using standard hematology 
measures. Hematological analysis did not reveal any differences in peripheral immune cell 
populations between groups; however, DIO rats had higher percentages of red blood cell 
(rbc) distribution width (P = 0.032), higher platelet counts (P = 0.028) and higher mean 
platelet volumes (P = 0.013) than DR rats (Table 3-6). DR and DIO phenotypes did not 
reveal differences in serum measures, including cytokine/chemokine, CRP, LPS, BUN or 
blood glucose concentrations (Table 3-7). The whole blood TLR stimulation assay 
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performed after the two-week preliminary HE feeding was mainly used to test a panel of 
TLR agonists and stimulatory concentrations in preparation for the end of the trial (Table 
3-8). Sample numbers were small since two concentrations per agonist were tested, making 
it difficult to determine if differences were apparent between phenotypes in responsiveness 
to TLR stimulation. Based on this preliminary testing, the following agonist stimulation 
concentrations were selected: 10 µg/mL for P3C (TLR2), 5 µg/mL for LPS (TLR4) and 
100 ng/mL for Flagellin (TLR5). Responses to TLR9 stimulation with CpG ODN 2006 at 
10 µg/mL were measurable, however this agonist was very costly and it was decided not 
to continue with it for analysis at the end of the trial. Overall, hematology and TLR agonist 
based measures did not reveal many immunological or physiological differences between 
phenotypes in the preliminary trial. 
Examination of gut mucosal tissues was then conducted. Histological scoring was 
used to assess the presence of gut-level inflammation in sections of the small and large 
bowel, and there were no differences in morphology found between the DIO and DR 
groups after the initial two-week HE diet feeding. There were no differences in IEL counts 
in the duodenum, and no IELs were found in the jejunum of DR or DIO rats (Table 3-9). 
In ileal tissue, DR rats displayed a trend toward higher concentrations of total TGF-β1 than 
DIO rats (P = 0.051, Table3-10). The opposite effect was noted in the caecum, where DIO 
rats displayed a trend toward higher total TGF-β1 concentrations than DR rats (P = 0.061, 
Table 3-11). In the proximal colon (Table 3-12), higher concentrations of all measured 
cytokines were highest in DIO rats, however only IL-10 (P = 0.032) and TNF-α (P = 0.016) 
were significantly higher in DIO rats, and IL-17F trended to be higher in DIO rats (P = 
0.070). Cytokine concentrations in distal colon samples were also highest in the DIO 
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phenotype (Table 3-13). Although the differences were not statistically significant in this 
tissue, IL-17F (P = 0.061), IL-22 (P = 0.059), and total TGF-β1 (P = 0.072) all trended to 
be higher in DIO rats. Overall, the pattern in the intestinal tissue was that DIO rats 
displayed higher concentrations of inflammatory cytokines and of total TGF-β1, a 
regulatory cytokine.  
Cytokine profiles were also analyzed in the liver, spleen, MLN, and ileal PP to 
examine impact of diet on immune tissues at systemic and local levels. In liver 
homogenates, CINC-1 was significantly higher in DIO rats (P = 0.017, Table 3-14). Active 
and total TGF-β1 concentrations were nearly matching, indicating that all TGF-β1 in the 
liver was in its active form. In spleen homogenates, very low IL-10 concentrations, just at 
the level of detection, were present in both phenotypes. DIO rats displayed higher splenic 
TNF-α concentrations (P = 0.049) than DR rats (Table 3-15). Examination of the MLN 
revealed that DR rats had higher concentrations of sICAM-1/sCD54 (P = 0.018) than DIO 
rats (Table 3-16). No differences in cytokine or chemokine concentrations or profiles were 
found in the ileal PP (Table 3-17). Overall, there were relatively minor differences found 
in cytokine profiles at either systemic or local immune locations. 
The final group of tissue analyzed was adipose tissue. In mesenteric fat, no 
differences in cytokine or chemokine concentrations were detected, other than a trend 
toward higher CINC-2α/β concentrations in DR rats (P = 0.053, Table 3-18). Although 
every effort was made to ensure that all MLN were dissected out of the mesenteric fat, it 
remains possible that some MLN could have been present during mesenteric fat 
homogenization, and this could have influenced cytokine measurements. Since no major 
differences were found in the mesenteric fat, it was decided not to pursue analysis of this 
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tissue at the end of the trial. In epididymal fat, DIO rats displayed somewhat elevated 
CINC-2αβ, CINC-3, IL-6 and TNF-α concentrations in comparison to DR rats, although 
statistically significant differences were not found (Table 3-19). It was interesting that DIO 
rats had reduced IL-10 concentrations (a regulatory cytokine) in comparison to DR rats. 
Analysis of mesenteric and epididymal fat revealed opposite patterns, with DR rats having 
higher cytokine concentrations in mesenteric fat, and lower concentrations in the 
epididymal fat. 
Leptin was the adipokine chosen for the preliminary trial analysis. Concentrations 
of leptin were measured in serum and adipose tissue (mesenteric and epididymal), as well 
as distal colon for a mucosal measure (Figure 3-2). DIO rats had consistently higher 
concentrations of leptin than DR rats overall, with significantly higher concentrations in 
the distal colon (P < 0.001) and a trend of heightened leptin concentrations in serum (P = 
0.077) and mesenteric fat (P = 0.067). 
After the preliminary two-week HE control diet, DIO and DR phenotypes did 
segregate at a few immunological measures, however biochemical measures seemed to be 
unaffected at this point. Overall, measurements in intestinal gut tissue revealed higher 
concentrations of inflammatory cytokines and regulatory total TGF-β1 in DIO rats, minor 
differences were detected at systemic and local immune tissues, and epididymal fat of DIO 
rats had higher inflammatory cytokine concentrations. A continuous pattern of higher 
leptin concentrations was found in all locations measured in DIO rats, although it was only 
statistically higher in the distal colon. Data collected from assays pre-tested in the 
preliminary trial were used in determining the profiles of cytokines, chemokines and 
adipokines measured in samples collected at the end of the trial. 
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End of Trial Analyses 
 
The feeding trial concluded after consumption of the AIN-93G modified diets for 
11-12 weeks. On the morning of necropsy, the animals’ final weights were recorded, and 
the average weight was 533.0 ± 4.1 g for DIO rats and 479.3 ± 3.6 g for DR rats. The total 
weight gained during the 11-12 weeks on the AIN-93G modified diets is displayed in 
Figure 3-3a/b. An overall phenotype effect was observed in the weight gain values (P < 
0.001), DIO rats had higher weight gain than DR rats on the HE control (P < 0.001), HE 
oat bran (P = 0.008), HE RS (P = 0.002) and HE FOS (P = 0.007) diets. An overall diet 
effect was also observed in the weight gain values (P < 0.001). Rats on the HE oat bran 
diet had higher weight gain that rats on the control (P < 0.001), HE control (P < 0.001), 
HE wheat bran (P = 0.031) and HE RS (P = 0.005) diets. Additionally, rats on HE wheat 
bran (P = 0.007), HE RS (P = 0.041) and HE FOS (P = 0.001) diets had higher final weights 
than those on the control diet. Within the DR phenotype, rats on the HE oat bran diet had 
higher weight gain than those on the HE control (P = 0.005) and control (P < 0.001) diets. 
Within the DIO phenotype, rats on the HE oat bran (P < 0.001), HE FOS (P = 0.012) and 
HE control (P = 0.036) diets had higher weight gain than those on the control diet. 
The average amount of food consumed each day during the trial is displayed in 
Figure 3-4a/b. Rats in each diet group had significantly different daily average food 
intakes from the other diet groups (P = 0.036 or less) with the following exceptions: rats 
on the control diet did not consume more than rats on the HE wheat bran or HE FOS diets, 
rats on the HE control did not consume more than rats on the HE RS or HE FOS diets, and 
rats on HE RS did not consume more than rats on HE FOS. Overall, DIO rats consumed 
significantly more food each day than DR rats (P < 0.001). It is important to note that the 
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recorded daily intakes for the HE oat bran diet may be higher than the amount rats on this 
diet actually consumed, since it was found that this particular kibble diet was brittle, and 
increased the possibility of food spillage. 
 
Analysis of Peripheral and Tissue Immune Cell Populations 
 
Hematological analysis revealed an effect on white blood cell (wbc) counts 
according to phenotype, with DR rats having lower concentrations overall than DIO rats 
(P = 0.008, Table 3-20a/b). On the HE oat bran diet, DR rats had lower wbc counts than 
DIO rats (P = 0.014). An overall diet effect was observed for rbc counts (P = 0.017); rats 
on the HE FOS diet had higher counts than rats on the control diet (P = 0.020), regardless 
of phenotype. Hematocrit levels were lower in DR rats on the HE oat bran diet than in DIO 
rats (P = 0.036). On the control diet, DIO rats had higher neutrophil counts than DR rats 
(P = 0.028). An overall phenotype effect was observed for percentages of circulating 
monocytes, with DIO rats having higher percentages than DR rats (P = 0.022). Within the 
DR phenotype, monocyte percentages for rats on the HE oat bran diet were higher than 
those on the control diet (P = 0.031), and the same pattern was present within the DIO 
phenotype (P = 0.026). Additionally, a diet effect (P < 0.001) was observed on the 
monocyte population. Overall, circulating monocyte percentages for rats on the HE control 
(P = 0.014), HE wheat bran (P = 0.016), HE oat bran (P < 0.001) and HE FOS (P = 0.015) 
diets were higher than those on the control diet. 
 Immune cell populations investigated within the spleen are shown in Table 3-
21a/b. Within the DIO phenotype, rats on the HE RS diet displayed lower CD3+ T 
lymphocyte percentages than those on the control diet (P = 0.043). Within CD3+ T 
127 
 
lymphocyte populations, there was an overall effect due to diet, with rats on the HE FOS 
diet displaying higher CD3+ percentages than those on the control diet (P = 0.019), 
regardless of phenotype. There was an effect on CD3+CD62L+ memory T cells due to diet 
within the DR phenotype; rats on HE RS (P = 0.034) and HE FOS (P = 0.002) diets had 
higher percentages than those on the control diet. Within the DIO phenotype, rats on the 
HE RS diet had higher CD3+CD62L+ percentages than those on the HE control (P = 0.006) 
and control (P = 0.004) diets, and rats on the HE FOS diet had lower CD3+CD62L+ 
percentages than those on the HE control (P = 0.003) and control (P = 0.002) diets. A diet 
effect was observed for CD3+CD62L+ memory T cells (P < 0.001), with combined 
phenotypes on the HE oat bran (P = 0.030), HE RS (P < 0.001) and HE FOS (P < 0.001) 
diets having higher CD3+CD62L+ memory T cell percentages than those on the control 
diet. Combined phenotypes on the HE RS (P = 0.003) and HE FOS (P < 0.001) diets had 
higher CD3+CD62L+ percentages than those on the HE control diet, while rats consuming 
the HE wheat bran displayed higher CD3+CD62L+ percentages than those on the HE FOS 
diet (P = 0.019). In splenic CD3+CD8a+ cytotoxic T cell populations, DIO rats on the HE 
FOS diet had lower percentages than those on the control diet (P = 0.044). With combined 
phenotypes, a diet effect was also observed (P = 0.005), with rats on the HE RS (P = 0.042) 
and HE FOS (P = 0.010) diets having lower CD3+CD8a+ cytotoxic T cell percentages than 
those on the control diet. DIO rats on the HE RS (P = 0.015) and HE FOS (P = 0.005) diets 
had lower percentages of CD3+CD45+ leukocytes than those on the control diet. There was 
also an overall diet effect on CD3+CD45+ leukocyte populations in the spleen (P < 0.001), 
with combined phenotypes on the HE RS diet having higher percentages than rats on the 
control diet (P = 0.010), and rats on the HE FOS diet having lower percentages than rats 
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on the control diet (P < 0.001). An effect due to diet was observed on splenic CD3-
CD45RA+ B cell populations (P = 0.015). All rats on the HE FOS diet had lower B cell 
percentages than those on the control diet (P = 0.042), regardless of phenotype. A mix of 
NK cells and activated monocytes are present in the CD3-CD161a+ populations. Within the 
DIO phenotype, rats on the HE FOS diet had lower percentages of NK cells/activated 
monocytes than rats on the control diet (P = 0.001), and rats on the HE oat bran diet had 
higher percentages than rats on the HE FOS diet (P = 0.029). Within this population of 
splenic CD3-CD161a+ cells, an overall diet effect was observed (P = 0.006), with all DR 
and DIO rats combined on the HE FOS diet having lower percentages than rats on the 
control diet (P = 0.006), and higher percentages than rats on the HE oat bran diet (P = 
0.025). In the CD3-CD4-CD161a+ NK cell population (activated monocytes are excluded) 
an overall effect due to diet was observed (P = 0.045). Within the DIO phenotype, rats on 
the HE FOS diet had lower CD3-CD4-CD161a+ NK cell percentages than rats on the control 
diet (P = 0.022). Within the macrophage population defined by CD3-His36+ cells, DR rats 
on the HE FOS diet had elevated percentages in comparison to DIO rats on the same diet 
(P = 0.016). No differences between diets or phenotypes were observed in percentages of 
CD3+CD4+ TH cells, CD3
+γδTCR+ T cells, CD3+CD4+Foxp3+CD25+ Treg cells or CD3
-
CD103+ DCs.  
In summary, the diets which appeared to impact splenic immune cell population 
percentages most frequently in this study were the HE RS and HE FOS diets. Rats on the 
HE RS diet had decreased percentages of T lymphocytes and cytotoxic T cells, and 
increased memory T cells and leukocytes relative to rats on the control diet. Rats on the 
HE FOS diet displayed lower splenic cell population percentages of cytotoxic T cells, 
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leukocytes, B cells and NK cells, and higher percentages of T lymphocytes and memory T 
cells relative to rats fed the control diet.  
 Immune cell populations investigated within the MLN are shown in Table 3-22a/b. 
On the control diet, DR rats had higher percentages of CD3+CD4+ TH cells than DIO rats 
(P = 0.041). On the HE control diet, DIO rats had higher CD3-CD45RA+ B cell percentages 
than DR rats (P = 0.028). An effect due to diet was observed on MLN B cell populations 
(P = 0.045); combined phenotypes on the HE oat bran diet had higher percentages than rats 
on the HE FOS diet (P = 0.030). A phenotype × diet interaction was observed in the CD3-
CD103+ DC population (P = 0.002). Within the DIO phenotype, rats on the HE wheat bran 
diet displayed higher CD3-CD103+ DC percentages than rats on the HE FOS diet (P = 
0.020). On the HE wheat bran diet, DIO rats had higher CD3-CD103+ DC percentages than 
DR rats (P = 0.002). On the HE FOS diet, DR rats had higher CD3-CD103+ DC percentages 
than DIO rats (P = 0.024). Within the MLN CD3-His36+ macrophage population, DR rats 
on the HE RS diet had elevated percentages in comparison to DIO rats on the same diet (P 
= 0.019). Within the DIO phenotype, rats on the HE RS diet had higher MLN CD3+γδTCR+ 
T cell percentages than rats on the HE control diet (P = 0.041). On the HE control diet, DR 
rats had higher CD3+γδTCR+ percentages than DIO rats (P = 0.017). Upon examining Treg 
cell populations in the MLN, an overall diet effect was observed (P = 0.043). Rats of both 
phenotypes on the HE oat bran diet had lower CD3+CD4+Foxp3+CD25+ Treg cell 
percentages (P = 0.023) than rats on the HE RS diet. In the DR phenotype, rats on the HE 
oat bran diet had lower percentages of CD3+CD4+Foxp3+CD25+ cells (P = 0.031) than rats 
on the HE RS diet. No differences between diets or phenotypes were observed in 
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percentages of CD3+ T lymphocytes, CD3+CD62L+ memory T cells, CD3+CD8a+ 
cytotoxic T cells, CD3+CD45+ leukocytes, CD3-CD161a+ or CD3-CD4-CD161a+ NK cells.  
 To summarize the MLN immune cell population percentages, rats on the HE oat 
bran diet had higher B cell percentages than those on HE FOS and higher Treg cell 
percentages than those on HE RS, and rats of the DIO phenotype on HE wheat bran had 
higher DC percentages than those on HE FOS, and DIO rats on HE RS had higher 
CD3+γδTCR+ T cell percentages than those on the HE control diet. 
 Immune cell populations investigated within the ileal PP are shown in Table 3-
23a/b. On the control diet, DR rats had higher percentages of CD3+ T lymphocyte 
populations than DIO rats (P = 0.016). A similar pattern was observed in CD3+CD4+ TH 
cell populations where DR rats on the control diet had higher percentages than DIO rats (P 
= 0.018). Within the DR phenotype, rats on the HE RS (P = 0.034) and HE FOS (P = 0.031) 
diets had lower CD3+CD8+ cytotoxic T cell percentages than those on the control diet. 
There was an overall diet effect on ileal PP CD3+CD8+ cytotoxic T cell percentages (P = 
0.021), with DIO rats having lower percentages than DR rats on the control diet (P = 0.006). 
An overall diet effect on CD3+CD45+ leukocytes was also present (P = 0.022), and rats 
from both phenotypes on the HE wheat bran diet had higher percentages than those on the 
HE FOS diet (P = 0.046). In populations of CD3-CD45RA+ B cells within the DR 
phenotype, rats on the HE RS diet had lower percentages than rats on the HE oat bran (P 
= 0.039) and control (P = 0.046) diets. Within the DIO phenotype, rats on the HE FOS diet 
had lower CD3-CD45RA+ B cell percentages than rats on the HE wheat bran (P = 0.008), 
HE oat bran (P = 0.034) and HE control (P = 0.006) diets. Also in the DIO phenotype, rats 
on the HE control diet had higher CD3-CD45RA+ percentages than those on the control 
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diet (P = 0.043). An overall diet effect on CD3-CD45RA+ B cells (P = 0.039) was present; 
rats on HE FOS diet had lower percentages than rats on the HE control diet (P = 0.009). In 
populations of CD3-CD161a+ NK cells with activated monocytes, DIO rats had higher 
percentages than DR rats within HE control diet group (P = 0.015). Within the DIO 
phenotype, rats the HE FOS diet had lower CD3-CD161a+ NK cell percentages than those 
on the HE control diet (P = 0.022). A phenotype × diet interaction was observed in the 
CD3-CD4-CD161a+ NK cell population (P = 0.040). Within the DIO phenotype, rats on 
the HE FOS diet had lower CD3-CD4-CD161a+ cell percentages than rats on the HE control 
diet (P = 0.015). Overall, the DIO phenotype had higher CD3-CD4-CD161a+ cell 
percentages than DR rats on the HE RS (P = 0.039) and HE control (P = 0.006) diets. In 
populations of ileal PP CD3-CD103+ DCs, DIO rats had higher percentages than DR rats 
on the HE RS diet (P = 0.043). DR rats displayed higher percentages of CD3-His36+ 
macrophages than DIO rats on the HE RS diet (P = 0.018). No differences between diets 
or phenotypes were observed in percentages of CD3+CD62L+ memory T cells, 
CD3+γδTCR+ T cells, or CD3+CD4+Foxp3+CD25+ Treg cells in the ileal PP.  
In summary of the ileal PP immune cell population percentages, T lymphocytes, 
CD4+ TH cells and cytotoxic T cell percentages were lower in DIO rats than DR rats on 
control. Leukocytes percentages were higher in rats on the HE wheat bran diet than those 
on the HE FOS diet. Effects of diet on B cell population percentages differed between 
phenotypes; DR rats on HE RS had lower percentages than those on HE oat bran or control 
diets, and DIO rats on the HE FOS diet had lower percentages than those on HE wheat 
bran, HE oat bran and HE control diets, while those on HE control diet had higher 
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percentages than those on the control diet. In NK cell populations, DIO rats had lower 
percentages on the HE FOS diet compared to the HE control. 
Due to unfortunate circumstances, the flow cytometry laboratory at Health Canada 
was unavailable during the timing of the preliminary necropsy, preventing pre-testing of 
antibodies. During the flow cytometry acquisition at the end of the trial, the intracellular 
pan macrophage marker CD68+ was not effectively measured, and subsequent macrophage 
markers in the same panel for CD197+ M1 macrophages and CD163+ M2 macrophages 
were subsequently omitted from the analyses of immune cell populations in the spleen, 
MLN and ileal PP tissues.  
 
Ex vivo Analysis of TLR Agonist Induced Responses of Peripheral Blood Cells 
 
 The ex vivo whole blood culture assay involving stimulation of peripheral immune 
cells with TLR agonists was utilised to investigate and compare systemic innate immune 
responses between phenotype and diet groups. At trial completion, the following cytokines 
were measured in supernatants collected from whole blood cultures that had been 
stimulated separately with TLR2 (P3C), TLR4 (LPS) or TLR5 (Flagellin) agonists as well 
as an unstimulated control: CINC-1, IL-1β, IL-6, IL-10 and TNF-α.  
CINC-1 concentrations measured from the whole blood TLR assay are in Table 3-
24a/b. In unstimulated whole blood collected from rats on the HE FOS diet, DIO rat blood 
had higher CINC-1 concentrations than DR rat blood (P = 0.039). In TLR4 stimulated 
whole blood cultures from rats on the HE wheat bran diet, CINC-1 concentrations were 
higher in DR rats than in DIO rats (P = 0.026). A phenotype × diet interaction was found 
in TLR5 stimulated whole blood (P = 0.037). Whole blood cultures from DR rats on the 
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HE wheat bran diet had higher CINC-1 concentrations than DIO rats (P = 0.042), and 
within the HE FOS diet, blood collected from DIO rats had higher CINC-1 concentrations 
than DR rats (P = 0.008). No differences were detected between diets or phenotypes for 
CINC-1 production from whole blood stimulated with TLR2. 
IL-1β concentrations measured from the whole blood TLR assay may be found in 
Table 3-25a/b. Within unstimulated whole blood samples collected from rats on the HE 
oat bran diet, DR rats produced higher IL-1β concentrations than DIO rats (P = 0.015). A 
phenotype × diet interaction was found in TLR2 simulated whole blood cultures (P = 
0.040). In whole blood collected from DR rats and stimulated with TLR2, rats on the HE 
oat bran diet had higher IL-1β concentrations in than rats on the control (P = 0.017), HE 
control (P = 0.034), HE wheat bran (P = 0.028), HE RS (P = 0.010) and HE FOS (P = 
0.010) diets. Additionally, DR rats on the HE oat bran diet had higher IL-1β concentrations 
in blood cultures stimulated with TLR2 than DIO rats on the same diet (P = 0.001). No 
differences were detected between diets or phenotypes for IL-1β production from whole 
blood stimulated with TLR4 or TLR5. 
IL-6 concentrations measured from the whole blood TLR assay are in Table 3-
26a/b.  Within the control diet, TLR2 stimulated whole blood cultures produced higher IL-
6 concentrations from the DR phenotype than the DIO phenotype (P = 0.009). Within the 
HE control diet, TLR4 stimulated samples produced higher IL-6 concentrations in blood 
collected from the DR phenotype than DIO (P = 0.047). No differences were detected 
between diets or phenotypes for IL-6 production from whole blood stimulated with TLR5 
or in the unstimulated control. 
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IL-10 concentrations measured from the whole blood TLR assay may be found in 
Table 3-27a/b. An overall diet effect was observed for TLR4 stimulated samples (P = 
0.019), regardless of phenotype. IL-10 concentrations of blood cultures from all rats on the 
HE RS diet were higher than rats on the control (P = 0.018), HE bran (P = 0.042) and HE 
FOS (P = 0.034) diets. No differences were detected between diets or phenotypes for IL-
10 production from whole blood cultures stimulated with TLR2 or TLR5, or in the control. 
TNF-α concentrations measured from the whole blood TLR assay are in Table 3-
28a/b. Within the DIO phenotype, unstimulated whole blood cultures collected from rats 
on the HE FOS diet had lower TNF-α concentrations than those on the control diet (P = 
0.010), but higher TNF-α concentrations than those on the HE control (P = 0.027) and the 
HE oat bran (P = 0.027) diets. Within the HE FOS diet, unstimulated blood collected from 
DIO rats had higher TNF-α concentrations than blood collected from DR rats (P = 0.002). 
A phenotype × diet interaction was found in TLR4 stimulated whole blood (P = 0.026). 
Within whole blood cultures collected from DIO rats and stimulated with TLR4, rats from 
the HE oat bran diet displayed higher TNF-α concentrations than those on the HE RS diet 
(P = 0.027). In TLR4 stimulated blood cultures from rats on the HE control diet, DIO rats 
had higher TNF-α concentrations than DR rats (P = 0.041). Additionally, DIO rats on the 
HE RS diet had higher TNF-α concentrations than DR rats (P = 0.027) in the TLR4 
stimulated whole blood cultures. No differences were detected between diets or phenotypes 
for TNF-α production from whole blood cultures stimulated with TLR2 or TLR5. 
To encapsulate the main findings of the ex-vivo whole blood TLR agonist assay, 
there were no overall differences due to phenotype. The only overall difference due to diet 
was found in TLR4-stimulated IL-10 production, where blood collected from rats on the 
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HE RS diet produced higher concentrations than those on HE oat bran, HE FOS and control 
diets. A consistent pattern of change across the measured cytokines and TLR agonists could 
not be established for phenotype or for a specific diet.  
 
Assessment of Serum Cytokines, Chemokines, CRP, LPS, BUN and Glucose 
 
Serum measures are displayed in Table 3-29a/b. Within the HE FOS diet, DIO rats 
had significantly higher CINC-1 concentrations than DR rats (P = 0.006). DIO rats on the 
HE RS diet displayed significantly higher CINC-2 concentrations than DR rats on the same 
diet (P = 0.042). A phenotype × diet interaction was found in CINC-3 concentrations (P = 
0.036); DIO rats on the HE oat bran diet had lower CINC-3 concentrations that DR rats on 
the same diet (P = 0.047), and DIO rats on the HE RS diet had significantly higher CINC-
3 concentrations than DR rats on the same diet (P = 0.015). A phenotype × diet interaction 
was also found in examining sICAM-1/sCD54 concentrations (P = 0.044); DIO rats on the 
HE control diet had higher sICAM-1/sCD54 concentrations that DR rats (P < 0.001). 
Within the control diet, DR rats displayed higher concentrations of active TGF-β1 than 
DIO rats (P = 0.045). Within the DR phenotype, rats on the HE control diet had 
significantly higher CRP concentrations than rats on the HE RS diet (P = 0.020). Within 
the DIO phenotype, rats on the control diet had significantly higher CRP concentrations 
than rats on the HE RS diet (P = 0.016). Additionally, an overall diet effect was observed 
with CRP concentrations (P = 0.043), with rats on the control (P = 0.005), HE control (P 
= 0.011) and HE wheat bran (P = 0.027) diets having higher CRP concentrations than rats 
on the HE RS diet. 
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Analysis of serum samples collected at the final necropsy revealed a diet effect (P 
< 0.001) on BUN concentrations, and the highest concentrations were present in the 
animals which consumed the control diet, regardless of phenotype. The HE diet appeared 
to decrease BUN concentrations. Within the DR phenotype, rats on the HE RS diet had 
lower BUN concentrations than rats on the control diet (P = 0.037). Within the DIO 
phenotype, rats on the HE control (P = 0.007), HE oat bran (P = 0.001), HE RS (P = 0.006) 
and HE FOS (P < 0.001) diets had lower BUN concentration than rats on the control diet. 
Combining phenotypes, all rats on HE control (P = 0.020), HE wheat bran (P = 0.003), HE 
oat bran (P < 0.001), HE RS (P < 0.001) and HE FOS (P < 0.001) diets displayed lower 
BUN concentrations than rats on the control diet. There were no differences found between 
phenotypes or diet groups in blood glucose or serum LPS or total TGF-β1 concentrations.  
 
Assessment of Immune Activity in Gut Tissues 
 
Histological scoring was performed to assess the presence of gut-level 
inflammation in sections of the small and large bowel collected from DIO rats at the end 
of the trial to determine if the addition of DFM to a HE diet produced any visible 
morphological change in intestinal tissues. After the examination of duodenum, jejunum, 
ileum, proximal and mid colon sections, pathological assessment did not reveal any 
differences in bowel morphology between the fibre supplemented diets in DIO rats. 
Furthermore, there were no differences in IEL counts in the duodenum or jejunum between 
diets (Table 3-30). 
In the analysis of ileal tissue, concentrations of both proinflammatory and 
regulatory cytokines were measured (Table 3-31a/b). No differences were apparent in IL-
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1β, IL-6, IL-10, IL-17F, active and total TGF-β1 concentrations in the ileum between 
phenotype or any of the diet groups after a multiple comparison test. 
The cytokine/chemokine profile used to examine caecal tissue is in Table 3-32a/b. 
A diet effect on CINC-2αβ concentrations was evident (P = 0.014). In the DR phenotype, 
rats on the HE wheat bran (P = 0.035) and HE RS (P = 0.027) diets had lower CINC-2αβ 
concentrations than those on the control diet, rats on the HE wheat bran (P = 0.017), HE 
RS (P = 0.013) and HE FOS (P = 0.044) diets had lower CINC-2αβ concentrations than 
those on the HE control diet, and rats on the HE oat bran diet had higher CINC-2αβ 
concentrations than those on HE wheat bran (P = 0.038) and HE RS (P = 0.029) diets. 
Within the DR phenotype, rats on the HE RS diet had lower IL-6 concentrations than rats 
on the HE control (P = 0.044), HE wheat bran (P = 0.040) and HE FOS (P = 0.003) diets. 
An overall diet effect was also observed for IL-6 concentrations in caecal tissue (P = 0.003) 
when combining phenotypes; rats on the HE RS diet had lower IL-6 concentrations than 
those on the control (P = 0.010), HE control (P = 0.037) and HE FOS (P = 0.002) diets. A 
phenotype effect was observed for total TGF-β1 concentrations (P = 0.047), with DIO rats 
having higher total TGF-β1 concentrations overall than DR rats. No differences were 
apparent between phenotypes or diets for CINC-1, CINC-3, GM-CSF, IL-10, IL-17F, IL-
22, or active TGF-β1 concentrations in the caecum. During necropsy, the caeca collected 
from rats of both phenotypes on the HE RS and HE FOS diets were visibly different from 
rats on other diets. The caeca from rats on the HE RS diet were wrinkled and shriveled in 
appearance, and the caeca from rats on the HE FOS dies were notably larger and distended. 
The cytokine/chemokine profile used to examine the proximal colon is in Table 3-
33a/b. A phenotype × diet interaction was found in examining IL-6 concentrations (P = 
138 
 
0.016). Within the DIO phenotype, rats on the HE oat bran (P = 0.050) and HE FOS (P = 
0.006) diets had lower IL-6 concentrations than rats on the control diet. A trend was 
observed for a diet effect (P = 0.060), and DIO rats on the control diet had higher IL-6 
concentrations than DR rats on the same diet (P = 0.003). Within the DIO phenotype, rats 
on the HE FOS diet had significantly lower IL-17F concentrations than rats on the control 
diet (P = 0.012). When examining TGF-β1, DIO rats on the HE RS diet had higher 
concentrations of active TGF-β1 (P = 0.040) and total TGF-β1 (P = 0.038) than DR rats 
on the same diet. No differences were apparent between phenotypes or diets for IL-10 or 
TNF-α concentrations in the proximal colon. 
The cytokine/chemokine profile used to examine the distal colon is in Table 3-
34a/b. Within the HE control diet, DR rats had higher IL-10 concentrations than DIO rats 
(P = 0.037). DR rats displayed higher IL-22 concentrations on the HE RS diet than DIO 
rats (P = 0.041). When examining total TGF-β1 concentrations on the control diet, DIO 
rats had higher concentrations than DR rats (P = 0.022). No differences were apparent 
between phenotypes or diets for IL-6, IL-17F, TNF-α or active TGF-β1 concentrations in 
the distal colon.  
After the assessment of immune activity within gut tissues, it was clear that there 
were no lasting impacts of diet on ileal tissue, and no morphological differences were 
apparent between phenotype or diet groups after histological examination of the small and 
large bowel. Rats on HE RS and HE FOS diets had caeca that appeared remarkably 
different from rats on the other diets, however, the caeca collected from rats on the HE RS 
and HE FOS diets had lower pro-inflammatory cytokine and chemokine concentrations 
than rats on the control diets. In the proximal colon, DIO and DR phenotypes differed at 
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active and total TGF-β1 concentrations, and in the distal colon, DIO rats displayed higher 
IL-6 concentrations than DR rats, while DR rats displayed higher IL-10 concentrations than 
DIO rats. 
 
Assessment of Immune Activity in Systemic and Local Tissues 
 
 The cytokine/chemokine profile examined in the liver is shown in Table 3-35a/b. 
Within the DR phenotype, rats on the HE control (P = 0.008), HE oat bran (P = 0.001) and 
HE RS (trend at P = 0.058) diets had higher CINC-2αβ concentrations than those on the 
control diet. On the control diet, DIO rats had higher CINC-2αβ concentrations than DR 
rats (P = 0.035). An overall diet effect was observed for CINC-2αβ concentrations (P = 
0.005); rats combined from DIO and DR phenotypes on the HE control (P = 0.039), HE 
oat bran (P = 0.010) and HE RS (P = 0.032) diets had higher CINC-2αβ concentrations 
than rats on the control diet. Within the DIO phenotype, rats on the HE RS diet had lower 
liver CRP concentrations that rats on the control diet (P = 0.030). On the control diet, DIO 
rats had higher CRP concentrations that DR rats (P = 0.038). An overall diet effect was 
revealed (P = 0.046) in the analysis of liver IL-1β concentrations, and rats on the HE oat 
bran diet had higher concentrations than rats on the control diet (P = 0.025). No differences 
were apparent between phenotypes or diets for CINC-1, CINC-3, IFN-γ, IL-4, IL-6, IL-10, 
TNF-α, active or total TGF-β1 concentrations in the liver. As previously noted in the 
preliminary trial results, concentrations of active and total TGF-β in the liver nearly 
matched, indicating all TGF-β was in its active form.  
 The cytokine/chemokine profile examined in the spleen is in Table 3-36a/b. On 
the HE control diet, DR rats had higher CINC-3 concentrations than DIO rats (P = 0.018). 
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Within the DIO phenotype, rats on the HE wheat bran diet had much lower GM-CSF 
concentrations than rats on the HE oat bran diet (P = 0.015). A diet effect was observed in 
the analysis of splenic GM-CSF concentrations (P = 0.017); overall, rats on the HE wheat 
bran diet had lower concentrations than rats on the HE oat bran diet (P = 0.047). No 
differences were apparent between phenotypes or diets for CINC-1, CINC-2αβ, IFN-γ, IL-
1β, IL-4, IL-6, IL-10, TNF-α, active or total TGF-β1 concentrations in the spleen.  
A profile of eleven cytokines/chemokines was analyzed in MLN homogenates 
(Table 3-37a/b) using Luminex technology. On the control diet, CINC-2αβ concentrations 
were higher in DIO rats than in DR rats (P = 0.017). On the HE control diet, DIO rats had 
lower CINC-3 concentrations than DR rats (P = 0.003). A phenotype effect was also 
observed within CINC-3 concentrations, and DIO rats overall had lower concentrations 
than DR rats (P = 0.005). On the HE FOS diet, DR rats had higher IFN-γ concentrations 
than DIO rats (P = 0.046). Within the DIO phenotype, rats on the HE RS diet had lower 
IL-2 (P = 0.029) and lower IL-1β (P = 0.018) concentrations in the MLN than rats on the 
control diet (P = 0.018). On the HE RS diet, DR rats had higher IL-1β concentrations than 
DIO rats (P = 0.019). Within the DIO phenotype, rats on the HE wheat bran diet had lower 
IL-10 concentrations than rats on the control diet (P = 0.047). On the control diet, DIO rats 
had higher IL-10 concentrations in the MLN than DR rats (P = 0.021). No differences were 
apparent between phenotypes or diets for GM-CSF, sICAM-1/sCD54, IL-4, IL-6, or TNF-
α concentrations in the MLN.  
The same profile of eleven cytokines/chemokines analyzed in the MLN was also 
used examined in the ileal PP homogenates (Table 3-38a/b) with Luminex technology. A 
phenotype effect was present, and DIO rats had significantly higher CINC-2αβ 
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concentrations than DR rats (P = 0.038). Within the DIO phenotype, rats on the HE oat 
bran diet had higher CINC-2αβ concentrations than rats on the HE control diet (P = 0.047). 
An overall diet effect was also present (P = 0.007), with combined phenotypes on the HE 
oat bran diet having higher CINC-2αβ concentrations than rats on the HE control (P = 
0.017) and HE FOS (P = 0.007) diets. After multiple comparison tests, no differences were 
apparent between phenotypes or diets for CINC-3, GM-CSF, sICAM-1/sCD54, IFN-γ, IL-
1β, IL-2, IL-4, IL-6, IL-10 or TNF-α concentrations in the ileal PP.  
In summary, cytokine profile analyses of systemic tissues indicated that HE diets 
increased liver CINC-2αβ concentrations relative to the control diet, the HE RS diet 
lowered liver CRP concentrations in the DIO phenotype, and rats on the HE wheat bran 
diet had lower splenic GM-CSF concentrations than those on the HE oat bran diet. In the 
assessment of cytokine profiles within local tissues, it was found that DIO rats had lower 
MLN CINC-3 concentrations than DR rats, DIO rats on the HE RS diet had lower MLN 
IL-1β and IL-2 concentrations in comparison to the control diet, DIO rats had higher ileal 
PP CINC-2αβ concentrations than DR rats, and rats on the HE oat bran diet had higher 
CINC-2αβ concentrations in the ileal PP than rats on the control diet. Overall, there were 
relatively few patterns in immune activity according to diet and phenotype noted, given 
how many measurements were performed on systemic and local immune tissues. 
 
Assessment of Immune Activity in Adipose Tissue 
 
 The cytokine profile examined in epididymal fat is present in Table 3-39a/b. Rats 
on the HE wheat bran diet displayed lower CINC-2αβ concentrations than those on the 
control diet (P = 0.042), and DR rats on the HE wheat bran diet had higher CINC-2αβ 
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concentrations than DIO rats on the same diet (P = 0.012). Although TNF-α concentrations 
were relatively low in this tissue, DIO rats had higher concentrations than DR rats on the 
control diet (P = 0.030). An overall diet effect was observed on epididymal fat 
concentrations of active TGF-β1 (P = 0.012); rats on the HE wheat bran (P = 0.040), HE 
RS (P = 0.027) and HE FOS (P = 0.012) diets had lower concentrations than rats on the 
HE control diet. DR rats on the HE wheat bran (P = 0.012) and control (P = 0.047) diets 
had lower active TGF-β1 concentrations than those on the HE control diet, and DR rats 
had higher active TGF-β1 concentrations than DIO rats on the HE FOS diet (P = 0.044). 
An overall diet effect was also observed in epididymal fat total TGF-β1 concentrations (P 
= 0.026); rats on the HE wheat bran (P = 0.048) and HE oat bran (P = 0.040) diets had 
lower total TGF-β1 concentrations than rats on the HE control diet. No differences were 
apparent between phenotypes or diets for CINC-1, CINC-3, IL-1β, IL-6, or IL-10 
concentrations in the epididymal fat.  
 
Assessment of Peptide Hormones and Adipokines 
 
Serum concentrations of peptide hormones glucagon and insulin, as well as 
adipokines leptin and adiponectin were measured. There was an overall diet effect on 
glucagon concentrations (P = 0.032, Figure 3-5a/b); rats on the HE FOS diet had higher 
glucagon concentrations than rats on the HE oat bran diet (P = 0.036). A phenotype effect 
was present in insulin concentrations (P = 0.013, Figure 3-6a/b); overall, DIO rats had 
higher serum insulin concentrations than DR rats. On the HE oat bran diet, DIO rats 
displayed higher insulin concentrations than DR rats (P = 0.032). A phenotype effect was 
also present for serum leptin concentrations (P = 0.034, Figure 3-7/b); DIO rats had higher 
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concentrations overall than DR rats. On the control diet, DIO rats had higher leptin 
concentrations than DR rats (P = 0.004). After multiple comparison tests, no differences 
were apparent between phenotypes or diets for adiponectin concentrations in the serum 
(Figure 3-8a/b). 
In epididymal fat tissue, adiponectin concentrations were quantified. (Figure 3-
9a/b). Like the serum concentrations, no differences were apparent between phenotypes or 
diets for adiponectin concentrations in the epididymal fat. In the distal colon, leptin 
concentrations were measured (Figure 3-10a/b). Within the DR phenotype, rats on the HE 
oat bran diet had higher leptin concentrations in the distal colon that rats on the control (P 
= 0.013) and HE RS (P = 0.011) diets. There was an overall diet effect on leptin 
concentrations (P = 0.007); rats from both phenotypes on the HE oat bran diet had higher 
leptin concentrations than those on the control (P = 0.029) and HE RS (P = 0.026) diets. 
 Overall, in examining peptide hormones and adipokines, DIO rats had higher 
concentrations of serum insulin and leptin than DR rats. Additionally, rats on the HE FOS 
diet displayed higher serum glucagon concentrations than rats on the HE oat bran diet, and 
rats on the HE oat bran diet had higher distal colon leptin concentrations that rats on the 












After consumption of a HE diet for only two weeks, Sprague Dawley rats displayed 
two distinct phenotypes, DR or DIO, based on the amount of weight the animals gained. 
There were distinct differences in weight gain between DR, MID and DIO rat groups; the 
average weight of DR rats was 263 g and the average weight of DIO rats was 290 g. The 
trial continued for another 11-12 weeks with 60 DR animals and 60 DIO animals, allowing 
for an investigation of the impact of selected DFM-containing HE diets on immune 
biomarkers, gut inflammation and systemic inflammation. At the end of the trial, the 
distinct DR and DIO phenotypes remained, further indicating the utility of the Sprague 
Dawley rat strain as a model for diet-induced obesity (Abnous et al., 2009; Barbier de la 
Serre et al., 2010). The final average weights were 479 g for DR rats and 533 g for DIO 
rats, and it was not surprising to find that DIO rats consumed significantly more food each 
day than DR rats. Rats on the HE diets displayed higher weight gain overall than those on 
the control diet, although this did not necessarily mirror the pattern in the daily amount of 
food consumed. Rats of both phenotypes had the highest weight gain on the HE oat bran 
diet. The HE oat bran diet had slightly more fat (1.2 – 1.8%) than the other HE diets, 
providing more energy available from fat in the diet. The separation of DR and DIO 
phenotypes according to weight provided non-obese and obese states to study the effects 
of DFM-supplemented HE diets and to compare differences in immune and obesity-
associated biomarkers.  
Hematological analysis was performed to assess whether DFM-supplemented HE 
diets altered standard blood cell measures. After the preliminary trial, there were relatively 
minor hematological differences between DR and DIO rats due to rbc distribution width, 
platelet counts and mean platelet volume. Red blood cell dysfunction may have been 
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suspected if alterations were present in either the rbc count or rbc distribution width. Red 
blood cell dysfunction can lead to increased interaction with macrophages leading to 
enhanced macrophage adhesion to endothelial cells, and has been proposed as a contributor 
to atherosclerosis in a mouse model of diet-induced obesity on high-fat diet (Unruh et al., 
2015). However, the rbc component differences between phenotypes found after the 
preliminary trial dissipated by the end of the trial, and only rats on the HE FOS diet had 
higher rbc counts than rats on the control diet at the trial completion. There were diet and 
phenotype effects observed at the end of the trial on hematocrit levels and neutrophil 
percentages. DR rats had lower hematocrit levels than DIO rats on the HE oat bran diet, 
and DIO rats had higher neutrophil percentages than DR rats on the control diet. While 
these differences, as those observed in the preliminary trial, were relatively minor, other 
hematological differences observed at the end of the trial between circulating monocytes 
and wbc counts may have more significance in the context of this study. Rats of both 
phenotypes had higher circulating monocyte percentages on the HE diets compared to 
those on the control diet. DIO rats displayed higher total wbc counts than DR rats, and this 
population includes lymphocytes, monocytes, neutrophils, basophils and eosinophils. 
Although higher wbc counts would potentially be in keeping with higher circulating 
cytokine and chemokine concentrations, this was not found after serum cytokine analysis. 
Increased numbers of immune cell populations are not necessarily connected to higher 
cytokine or chemokine production levels unless there is involvement of an immune 
stimulus. A study performed by Shabbir et al. (2015) found that increased wbc counts 
coincided with increased serum IL-6 concentrations in obese Sprague Dawley rats on an 
HE diet. However, the serum proinflammatory cytokines measured in the current trial did 
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not increase in a pattern that would reflect heighted monocyte activity in rats on the HE 
diets or wbc activity in DIO rats.  
The diets with the greatest impact on immune cell populations in the spleen were 
HE RS and HE FOS. Rats on the HE RS diet had higher percentages of total leukocytes 
and memory T cells but lower percentages of cytotoxic T cells compared to rats on the 
control diet, and DIO rats on HE RS had lower total T cell percentages than DR rats. Rats 
on the HE FOS diet had the lowest percentages of T lymphocytes, memory T cells, 
cytotoxic T cells, leukocytes, B cells and NK cells relative to those on the control diet, and 
DIO rats on the HE FOS diet had lower percentages of macrophages than DR rats. Rats on 
FOS-supplemented diets have been previously shown to have decreased percentages of 
splenic T cells (Shastri et al., 2015b), which demonstrates that FOS diets influence 
systemic immune cell populations. Since rats consuming the HE FOS diet had lower 
splenic lymphocyte percentages (NK cells, B cells and T cells), it is possible that the rats 
on this diet could have an impaired immune response should infection occur, since few 
lymphocytes would available to migrate from the spleen. However, further testing would 
be required to determine the extent of the outcome of these population changes in the 
context of an immune challenge. 
In the MLN, rats on the HE oat bran diet had higher B cell percentages than rats on 
the HE FOS diet and higher Treg cell percentages than those on the HE RS diet. DIO rats 
on the HE wheat bran had higher DC percentages than those on HE FOS, and DIO rats on 
HE RS had higher γδTCR+ T cell percentages than those on HE FOS. Since rats consuming 
the HE FOS diet had decreased percentages of B cells, Treg cells, DC and γδTCR
+ T cells 
in the MLN compared to other diet groups, it is possible that the HE FOS diet may influence 
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B and T cell migration to the gut, an effect that would have a negative impact in the event 
of an infection. 
Percentages of T lymphocyte populations in the ileal PP were impacted by 
phenotype on the control diet, as DIO rats had lower percentages of total T cells, CD4+ TH 
cells and cytotoxic T cells than DR rats. Rats on the HE wheat bran diet had higher 
leukocyte percentages than rats on the HE FOS diet. B cell percentages in the ileal PP 
fluctuated between diets and phenotypes, and a consistent pattern of change was not 
established other than that rats on the HE FOS diet had the lowest B cell population 
percentage. In examining NK cell populations, DIO rats had higher percentages than DR 
rats on the HE control diet, and rats on the HE FOS diet had lower percentages than those 
on the HE control diet. On the HE RS diet, DIO rats had higher DC percentages than DR 
rats, and this pattern was reversed for macrophage percentages on the same diet, as DR rats 
had higher macrophage percentages than DIO rats. The ileal PP are considered part of the 
gut-associated lymphoid tissue (GALT), and the immune cells contained in these organized 
lymphoid nodules are the first to encounter antigens present in the lower ileum. These 
results suggest that DIO rats may have altered immune responses due to lower percentages 
of T lymphocytes, CD4+ TH cells and CD8
+ cytotoxic T cells compared to DR rats, which 
would ultimately be anticipated to result in decreased cytokine production, T cell help and 
killing of virus-infected cells during infection.  
Literature suggests that the gut microbiota (Furrie et al., 2005) and high-fat diets 
(Jialal et al., 2014; Suganami et al., 2005) influence TLR expression. A change in response 
to TLR agonists is a sensitive indicator of alterations in the innate immune response (Della 
Bella et al., 2008; Ida et al., 2006), and we have previously used this technique to assess 
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effects of DFM on human and rat innate immune activity (Clarke et al., 2016; Shastri, 
2015a). A whole blood TLR-agonist assay was performed to assess parameters of systemic 
immunity and to determine the effects of dietary fibre fermentation by gut microbiota on 
immune responses. This ex vivo whole blood stimulation method allows for determination 
of effects on responses to TLR2, 4 and 5 agonist stimulation, as TLR-expressing immune 
cells in blood samples will respond by releasing cytokines. The cytokine concentrations 
and the profile produced provide a measure of the strength of the TLR-induced response, 
and insight into the responding cell types, as certain cytokines are produced by distinct cell 
types. The cytokines measured in this assay were CINC-1, IL-1β, IL-6, IL-10 and TNF-α. 
Circulating monocytes produce all of these cytokines; macrophages produce CINC-1, IL-
6 and TNF-α, and M2 macrophages produce IL-10; T lymphocytes produce IL-6 and IL-
10 and TH1 cells produce TNF-α; B cells produce IL-10 and TNF-α; and mDC produce IL-
1β.  
CINC-1 concentrations produced in the ex vivo assay mainly differed according to 
phenotype. With TLR4 and TLR5 stimulation, DR rats on the HE wheat bran diet produced 
higher CINC-1 concentrations than DIO rats on the same diet, and DIO rats on HE FOS 
had higher CINC-1 production than DR rats after TLR5 stimulation. IL-1β production after 
TLR2 stimulation was higher in DR rats than in DIO rats on the HE oat bran diet, and DR 
rats on the HE oat bran diet produced the highest IL-1β concentrations compared to DR 
rats on the other diets. IL-6 production was higher in DR rats than DIO rats after TLR2 
stimulation on the control diet and after TLR4 stimulation on the HE control diet. IL-10 
production after TLR4 stimulation was higher in DR rats on the HE RS diet than DIO rats, 
and DIO rats produced higher IL-10 concentrations than the DR rats on the HE FOS diet. 
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After TLR4 stimulation with LPS, rats on the HE RS diet had the highest IL-10 response 
overall. TNF-α production in unstimulated whole blood cultures differed between diets in 
the DIO phenotype; rats on the control diet had the highest TNF-α concentrations in 
comparison to rats on all HE diets. After TLR4 stimulation, DIO rats had higher TNF-α 
concentrations than DR rats on the HE control and HE RS diets. A consistent pattern of 
change in the cytokines produced after TLR activation by various agonists was not 
established for phenotype or diet. The greatest amount of cytokine production was induced 
by TLR4 stimulation, and the cytokine profiles were indicative of monocyte, macrophage, 
M2 macrophage, B cell activity. 
The most robust TLR agonist of this assay was LPS, activating TLR4, since the 
highest levels of cytokine production were detected after LPS stimulation. Cytokine 
profiles induced by TLR5 stimulation with flagellin had fewer differences due to 
phenotype or diet in cytokine production than did TLR2 and TLR4 activation with P3C 
and LPS respectively. This ex vivo assay could be expanded in future experiments to 
include different agonists for TLR2 and TLR4 stimulation, such as a fungal-derived ligand 
in addition to the microbial-derived ligands. The addition of Candida albicans to PBMC 
in vitro has been shown to activate TLR2 and TLR4, the addition of Saccharomyces 
cerevisiae activates TLR2, and both strains enhance cytokine production by monocytes 
(Rizzetto et al., 2016). Another option could be the use of zymosan, a cell wall component 
of S. cerevisiae, as a TLR2 ligand (Underhill et al., 1999). Inclusion of a fungal agonist to 
activate pattern recognition receptors (PPR) in the ex vivo whole blood assay would 
encompass possible stimulus from the mycobiome, a relatively unexplored area in 
examining impacts of DFM and in obesity. It would have also been interesting to further 
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explore the TLR9 activation with unmethylated CpG DNA as an agonist, since TLR9 is 
internal and cells must endocytose antigen for its activation, whereas TLR2, TLR4 and 
TLR 5 are expressed on the outer cell membrane. 
After the preliminary trial, there were no significant differences found in blood 
glucose or BUN between DIO and DR rats, so it is unlikely that the two week HE diet 
altered the physiological parameters to a point where glucose and nitrogen metabolism 
were affected. By the end of the trial, blood glucose concentrations did not differ between 
phenotypes or diet groups, but the BUN concentration was significantly reduced in rats on 
all HE diets compared to the control diet. Rats on HE RS had the lowest BUN 
concentrations in the DR phenotype, and this effect on BUN in association with a RS 
supplemented diet has been observed before in rats (Kalmokoff et al., 2013). Through 
fermentation of dietary or endogenous protein in the gut, ammonia may be derived from 
the breakdown of urea (Smith and MacFarlane, 1998). Rats consuming RS diets have been 
shown to have reduced ammonia content in the caecum (Younes et al., 1995). It has been 
previously proposed that gut bacteria may be utilizing more ammonia derived from 
endogenous urea due to changes in the diet, making less urea available for the host and 
thereby reducing circulating BUN concentrations (Kalmokoff et al., 2013). There have 
been examples of influence on BUN concentrations following consumption of diets with 
varied carbohydrate, fat and protein proportions (Alford et al., 1990) and due to diets 
containing rapidly fermented fibres (Kalmokoff et al., 2013). However, less is known about 
the fluctuation of BUN concentrations in the context of a HE diet, or about the impact of 
this effect on nitrogen utilization on the immune system. 
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Serum LPS concentrations were quantified after the preliminary 2-week HE diet 
and at the end of the trial as an indirect measure of intestinal integrity (Albers et al., 2005). 
No differences in serum LPS concentrations that would have been attributable to diet or 
phenotype were found at either time point. It was surprising there were no differences 
associated with HE feeding in the DIO rats, considering associations of high fat diets and 
elevated LPS concentrations in other studies (Erridge et al., 2007; Ghanim et al., 2009). A 
gut leakiness test was performed by project collaborators at Health Canada; rats were 
gavaged with a sugar probe and temporarily housed into metabolic cages for urine 
collection. Analysis of the gut leakiness test results are pending, and could reveal 
information about the integrity of the IEC barrier that may not have been apparent after 
analysis of circulating LPS concentrations.  
After the preliminary HE feeding trial, no differences were found in serum cytokine 
or CRP concentrations. At the end of the trial, no differences due to diet were found in 
concentrations of circulating chemokines or regulatory cytokines; however, differences 
were apparent between the two phenotypes within specific diets. On the HE FOS diet, DIO 
rats had higher CINC-1 concentrations than DR rats, and had higher CINC-2αβ and CINC-
3 concentrations on the HE RS diet. On the HE oat bran diet however, DR rats had 
significantly higher serum CINC-3 concentrations than DIO rats. On the control diet, active 
TGF-β1 concentrations were higher in DR rats than in DIO rats, but this difference was not 
apparent on any of the test diets. Overall, these differences in CINC-3 and active TGF-β1 




CRP is a marker of inflammatory disorders; the protein interacts with the 
complement system by binding to complement C1q to activate the classical complement 
pathway, and is functionally analogous to IgG, although it is not antigen specific (Pagana 
and Pagana, 2002). Rats on the HE RS diet had lower serum CRP concentrations than rats 
on control, HE control and HE wheat bran diets, however it was not suspected that any of 
the rats were in a state of inflammatory disorder since concentrations of proinflammatory 
cytokines and chemokines did not reflect this. DIO rats had higher concentrations of 
sICAM-1 than DR rats on the HE control diet. The serum represented one means of 
measuring immune activity at the systemic level, however it did not appear that diet or 
phenotype consistently influenced circulating cytokine or chemokine concentrations. 
Spleen and liver tissue may have been more appropriate tissues to measure the impact of 
HE diets on systemic immune activity since blood concentrations only represent the net 
outcome of cytokine production from all tissues in the body (Albers et al., 2005). 
Consequently, these systemic tissues were examined. 
  Histological scoring of tissue collected from section of the small and large bowel 
did not reveal any pathological differences in intestinal mucosa after the 2-week 
preliminary HE feeding or at the end of the trial. This was a surprising finding since RS 
and FOS are rapidly fermented in the lower gut and rapidly decrease the pH of the lumen 
due to increased SCFA production, which could potentially lead to epithelial injury (Ten 
Bruggencate et al., 2003). It was expected that RS and FOS would have different 
histological scorings from control, wheat bran or oat bran diets to due how quickly and 
completely RS and FOS are fermented in the caecum and proximal colon (Cummings et 
al., 1996; Singh and Singh, 2010), and due to the changes in gross morphology evident in 
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the caecum of these rats. However, this was not the case. In a study investigating the effects 
of FOS and lactulose-supplemented diets in Wistar rats, histological analysis of the 
intestinal mucosa did not reveal mucosal inflammation in rats fed FOS diets before they 
were infected orally with Salmonella enteritidis (Bovee-Oudenhoven et al., 2003). After 
infection however, the rats consuming the FOS diet had more severe mucosal inflammation 
compared to rats on a control diet (Bovee-Oudenhoven et al., 2003). This work suggests 
that even though differences were not apparent with the HE FOS diet alone, differences 
might be evident if there was an infectious or pro-inflammatory challenge. IEL counts from 
the duodenum and jejunum of DR and DIO rats did not differ between phenotypes or diets 
after the preliminary trial or at the end of the trial. The IELs represent movement of immune 
cells from the MLN to the lumen for surveillance and are influenced by the microbiota 
(Hooper and Macpherson, 2010). Abnormally high IEL counts, greater than 40 IELs per 
100 epithelial cells, would be indicative of inflammation, and are seen in inflammatory 
bowel disease and coeliac disease (Dickson et al., 2006). However, the rats in this trial 
were healthy and these histopathology measures indicated that severe inflammation was 
not induced with the HE and HE DFM-supplemented diets. 
In the analysis of ileal tissue after the preliminary trial, it was found that DR rats 
tended to have higher total TGF-β concentrations than DIO rats. By the end of the trial, no 
differences were apparent in the ileum for any of the proinflammatory or regulatory 
cytokines measured. This was not a surprising finding since the selected DFMs used in this 
study were not fermented in the small intestine, but further along the GI tract at either the 
caecum, proximal or distal colon. A study which involved mice on high fat diets found that 
the expression of glucose and lipid metabolism-related genes had been altered in the small 
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intestine, providing an adaptation to the metabolic changes induced by the high fat diet 
(Clara et al., 2017). It is possible that the rats in this trial may have metabolically adapted 
to the HE DFM supplemented diets over the 11-12 week period, however sampling after 
DFM supplementation was limited to the trial end point. It would be interesting to 
determine whether there was early evidence of proinflammatory immune activation 
followed by regulation, perhaps 2-3 weeks into the trial. 
In the analysis of caecal cytokines after the preliminary trial, it was found that DIO 
rats tended to have higher total TGF-β concentrations than DR rats. By the end of the trial, 
rats on the HE wheat bran, HE RS and HE FOS diets had lower concentrations of CINC-
2αβ than rats on the HE control diet. Rats on the HE RS starch diet had the lowest caecal 
IL-6 concentrations, which was interesting since RS is quickly fermented in the caecum. 
Since the caeca of rats on the HE RS diet were visibly wrinkled and shriveled, and the 
caeca of rats on the HE FOS diet were notably bloated and distended, it was expected that 
these caeca would have had altered immune activity in comparison to the other diets. 
However, there were no differences in the cytokine profiles that would be in keeping with 
alterations in immune activity in the caeca of HE RS and HE FOS fed rats.  
In the analysis of proximal colon tissue after the preliminary trial, concentrations 
of IL-10 and TNF-α were higher in DIO rats than in DR rats, and IL-17F concentrations 
tended to be higher in the DIO rats. In the distal colon, DIO rats had a tendency toward 
higher IL-17F, IL-22 and total TGF-β concentrations compared to the DR rats. These initial 
findings suggested involvement of mucosal IL-17F/IL-22 activity in the DIO phenotype 
apparent after only 2 weeks of a HE diet. IL-17F is produced by TH17 cells which are 
involved in the clearance of pathogens (Korn et al., 2009), and IL-22 is involved in mucosal 
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epithelial repair mediated through activation of STAT3 in IEC (Mizoguchi, 2012; Neufert 
et al., 2010), although the roles of IL-17 and IL-22 in the context of HE diets and 
metabolism remains to be explored. By the end of the trial, rats on the HE oat bran and HE 
FOS diets had lower IL-6 concentrations than rats on the control diet in the proximal colon. 
DIO rats on the HE FOS diet had lower IL-17F concentrations than rats on the control diet, 
and DIO rats on the HE RS diet had higher active and total TGF-β1 concentrations than 
DR rats in the proximal colon. In the distal colon, IL-10 concentrations were higher in DR 
rats on the HE control diet than DIO rats, and DR rats had higher IL-22 concentrations than 
DIO rats on the HE RS diet. Also, DIO rats had higher total TGF-β concentrations than DR 
rats on the control diet. In the assessment of immune activity within gut tissues, it was 
difficult to associate an overall pattern with diet. The patterns found in the preliminary trial 
due to phenotype dissipated by the end of the trial. It did not appear that HE DFM-
supplemented diets had major or long-term effects on immune activity in the GI tissues 
after 11-12 weeks of consumption. 
After 2 weeks on a HE diet, DIO rats had higher liver CINC-1 concentrations than 
DR rats. By the end of the trial, rats on the HE oat bran, HE RS and HE control had higher 
CINC-2αβ concentrations in the liver than rats on the control diet. Rats of the DIO 
phenotype on the HE RS diet had lower liver CRP concentrations than rats on the control 
diet. Rats on the HE oat bran diet had higher liver IL-1β concentrations than rats on the 
control diet. A rather large panel of cytokines was measured in the liver and no other 
differences were found. In the analysis of splenic tissue after the preliminary trial, DIO rats 
had higher TNF-α concentrations than DR rats. At the end of the trial, DR rats had higher 
CINC-3 concentrations in the spleen than DIO rats. A diet effect was observed for GM-
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CSF, as rats on HE wheat bran had lower splenic GM-CSF concentrations than rats on the 
HE oat bran diet, and DIO rats on the HE wheat bran diet had lower GM-CSF 
concentrations than DR rats. As in the liver analysis, a very large panel of cytokines was 
measured in the spleen, but only a few minor differences were found between phenotypes 
within specific diets. At the systemic level, it does not appear that the HE DFM-supplement 
diets induced major changes in immune activity.  
In the analysis of the MLN after the preliminary trial, it was found that DR rats had 
higher concentrations of sICAM-1 than DIO rats. By the end of the trial, this effect on 
sICAM-1 had dissipated in the MLN, however there were several differences found 
between phenotypes on specific diets. CINC-2αβ concentrations were higher in DIO rats 
than in DR rats on the control diet, and DIO rats had lower concentrations of CINC-3 than 
DR rats on the HE control diet. There was an overall phenotype effect on CINC-3; DIO 
rats had lower concentrations than DR rats. On the HE FOS diet, DR rats had higher IFN-
γ concentrations than DIO rats, and on the HE RS and control diets, DR rats had higher IL-
1β and IL-2 concentrations in the MLN than DIO rats. DIO rats had higher MLN IL-10 
concentrations on the control diet than did DR rats, while DIO rats on the HE wheat bran 
diet had lower IL-10 concentrations than on the control diet. After 2 weeks on the HE diet, 
no differences were apparent in the ileal PP between phenotypes. By the end of the trial, 
differences due to phenotype and to diet were apparent in CINC-2αβ concentrations of the 
ileal PP; DIO rats had higher concentrations than DR rats, and rats on the HE oat bran diet 
had higher concentrations than rats on the HE control or HE FOS diets. These small 
changes in the CINC-2αβ concentrations may represent increased neutrophil activity in the 
DIO rats and those which consumed the HE oat bran diet, as monocytes and macrophages 
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are key sources of this cytokine. At the local immune tissue level, the most pronounced 
differences were that CINC-3 concentrations were lower in the MLN and CINC-2αβ 
concentrations were higher in the ileal PP of DIO rats. Small differences between 
phenotypes within diet groups were apparent, although it did not appear that any specific 
diet produced a long-lasting effect on cytokine or chemokine production in the MLN and 
ileal PP. Lymph fluids from the ileum, caecum and proximal colon drain into the MLN 
(Mowat and Agace, 2014), making it a suitable tissue to examine immune activity from 
these regions. Lymph fluid from the distal colon drains into the caudal lymph node (Mowat 
and Agace, 2014), and this tissue may have been more representative of some immune 
activity influenced by the DFM which are fermented further along the proximal colon and 
in the distal colon.  
No differences were found in the analysis of epididymal fat cytokine production 
after the preliminary trial. At the end of the trial, DIO rats had higher TNF-α concentrations 
than DR rats in the epididymal fat, suggesting potential for higher proinflammatory 
activity. Since no other differences were apparent between phenotype or diet in 
concentrations of IL-1β, IL-6 and IL-10, it was not possible to determine if there were be 
fluctuations in the activity of M1 and M2 macrophages in the adipose tissue. A rise in IL-
10 production on a particular diet or in one phenotype over the other may have indicated 
increased M2 macrophage activity, since heightened IL-10 expression is a marker of M2 
macrophage activity (Mantovani et al., 2002). Although an appropriate ELISA format for 
IL-12 was not available at the time of analysis, increased concentrations of IL-12 in the 
adipose tissue may have indicated increased M1 macrophage activity (Mantovani et al., 
2004). Increased M1 macrophage polarization has been shown in obese models and it 
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exacerbates inflammation to a point where it may influence metabolism and insulin 
resistance (Lumeng et al., 2007).   
Leptin was the only adipokine measured after the preliminary analysis. Higher 
leptin concentrations were found in DIO rats in all tissues measured, with significantly 
higher concentrations than DR rats in the distal colon. Leptin concentrations tended to be 
higher in the serum and mesenteric fat, and no differences were found in epididymal fat. 
At the end of the trial, adiponectin, leptin, glucagon and insulin were measured in serum. 
Rats on the HE FOS diet had higher glucagon concentrations that rats on the HE oat bran 
diet. DIO rats had higher serum insulin and leptin concentrations than DR rats overall, and 
this result was expected due to the difference in body mass between the phenotypes.  In the 
distal colon, rats on the HE oat bran diet had higher leptin concentrations than rats on the 
HE RS and control diets. No differences were found in adiponectin concentrations in serum 
or epididymal fat. Adipokines, specifically leptin, are produced in proportion to body fat 
mass (Matarese and La Cava, 2004) and are involved in immunomodulation by adipocytes. 
Leptin influences TLR expression and responsiveness in pre-adipocytes and mature 
adipocytes (Batra et al., 2007). Elevated concentrations of serum and tissue leptin were 
quantified in the DIO rats compared to the DR, and this finding, combined with the 
observed occasional increases in proinflammatory cytokine concentrations in systemic and 
local immune tissues, suggested that DIO rats would be predicted to have heightened 
sensitivity to TLR stimulation in the whole blood TLR agonist assay. However, the results 
of the ex vivo TLR assay did not suggest that DIO rats were more sensitive than DR rats to 
TLR stimulation through TLR2, TLR4 or TLR5.  
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Resistin is another adipokine which would have been interesting to measure, 
however Luminex or ELISA rat formats were not readily available during the time of this 
study. Increased resistin concentrations are capable of influencing inflammation and the 
expression of adhesion molecules, including ICAM-1 (Verma et al., 2003). Resistin has 
also been shown to upregulate proinflammatory cytokine production by PMBCs in vitro 
(Bokarewa et al., 2005), and correlations have been found between plasma resistin 
concentrations and IL-6, CRP and ICAM-1 concentrations in non-diabetic women (Zhang 
et al., 2010). DIO rats from the current trial had elevated concentrations of sICAM-1 on 
the HE control diet compared to DR rats, however it has not been established if resistin has 
involvement in sICAM-1 concentrations in obesity.  
Composition of the gut bacterial community has been linked to obesity in the 
literature (Ley, 2010; Yoshimoto et al., 2013). Most research investigating this topic has 
been in mice (Ley et al., 2005; Vijay-Kumar et al., 2010), however there are 
inconsistencies with human research (Duncan et al., 2008; Finucane et al., 2014; Walters 
et al., 2014). Gut community analysis of the faecal and caecal microbial communities by 
research collaborators at Health Canada and AAFC will provide further insight into the 
role of the gut microbiota and effects of DFM in the context of HE diets and their impact 
on obesity and metabolism-associated immune parameters in DIO and DR rats. 
This study has examined how HE DFM-supplemented diets influence mucosal, 
systemic and obesity-associated biomarkers under homeostatic immune conditions. 
Although two distinct phenotypes of DR and DIO were investigated, the obese rats were 
disease-free and represented a resting condition. Much of the focus for this study was on 
baseline and innate measures of immune activity. The rats were not immunized since there 
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was interest in determining how DFM impact the immune system in the absence of an 
adaptive immune challenge. Since several differences were observed between diets in 
lymphocyte populations at the systemic and local immune tissue levels, it could be useful 
to investigate the response to immunization. A strong T cell dependent antigen such as 
KLH (Harris and Markl, 1999) should be used in determining if DFM influence 
responsiveness to immunization during HE diet exposure. 
The observed impact of a HE diet on the immune system at the systemic as well as 
the mucosal level after only two weeks indicates the extent to which a HE diet can rapidly 
influence immune parameters, even in the absence of additional immune challenges such 
as infection or defined sources of inflammation. DIO rats had elevated leptin 
concentrations in serum and tissue, and elevated concentrations of regulatory and 
proinflammatory cytokine activity in the distal and proximal colon, liver and spleen in 
comparison to the DR rats. Addition of DFM with distinct physical and chemical 
characteristics and wide range of fermentability to the HE diet had varied impacts on 
cytokine and adipokine profiles associated with diet-induced obesity. Many of the observed 
effects of the HE diet between phenotypes dissipated after DFM supplementation. The 
phenotypic differences by the end of the trial were that DIO rats had higher concentrations 
of CINC-3 in the MLN, higher concentrations of CINC-2αβ in the ileal PP, and higher 
serum insulin and leptin concentrations than DR rats. The most frequently observed 
influences on immune activity according to diet involved the HE oat bran and HE FOS 
diets. Although rats on the HE oat bran diet consumed more food and weighed more than 
rats on other diets in the trial, this group of rats displayed lower IL-6 concentrations in the 
proximal colon and had higher concentrations of CINC-2αβ and IL-1β in the liver, higher 
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CINC-2αβ concentrations in the ileal PP and higher leptin concentrations in the distal colon 
relative to rats on the control diet. HE FOS-fed rats displayed decreased splenic 
lymphocyte population percentages in comparison to rats on the control diet and decreased 
lymphocyte and DC population percentages in the MLN in comparison to rats on other HE 
DFM diets. The effects of DFM-supplemented HE diets on gut microbial communities and 
the network of interactions with the immune system and host metabolism remain to be 
explored, as do the ramifications for the immune changes observed in the context of a 


















Table 3-1. Structural and fermentation properties of DFM added to HE diets used in the 
obese rat trial.  
 





Wheat Bran Insoluble Arabinoxylan; 
branched chain 






fermented in the 
distal colon 






Oat Bran Soluble β-glucan; β1-4 
linked glucose 
units separated by 
β1-3 linked 
glucose every 2-3 
units 
Slowly fermented 







Starch Type II 
Soluble Amylose; polymer 












Soluble Composed of 
short-length chains 
of 2-8 fructose 
units with a 
terminal glucose, 





























Table 3-2. Cytokines and chemokines measured to determine the impact of DFM-








and epithelial cells 





and epithelial cells 
Neutrophil activation, 
first chemokine produced 











most potent of CINCs but 
produced in smaller 
quantities  
(Shibata et al., 
1995; Shibata 
et al., 2000) 
GM-CSF Monocytes, T-
lymphocytes, fibroblasts 
and endothelial cells 
Stimulates development 
of neutrophils, dendritic 




(Caux et al., 
1992) 
IFN-γ Activated NK cells, CD4+ 
and CD8+ T lymphocytes 
Impact on macrophage 
activation, MHC class I 
and II expression, antigen 
processing and 








cytokine, promotes IL-2 




IL-2 T lymphocytes Promotes signaling 
required for T-cell 
proliferation 
(Popmihajlov 
et al., 2012) 
IL-4 Mast cells, T 
lymphocytes and bone 
marrow stromal cells 
Regulates the 
differentiation of naïve 
CD4+ T cells into helper 
TH2 cells; TH2 signature 
cytokine 
(Paul, 1991) 





cytokine and also 
considered an adipokine, 
regulates immune 
responses and stimulates 
antibody production 
(Mauer et al., 
2015) 
This table is continued on the next page. 
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macrophages (M2), T 
lymphocytes, B cells 
and keratinocytes 
Regulatory, inhibits 
TH1 cell activity, 
prevents macrophage 
cytokine release; Treg 
signature cytokine. 
(Borish, 1998) 
IL-17F TH17 cells Stimulates 
proliferation and 
activation of T cells, 
stimulates epithelial 
cells to secrete 
chemokines 
(Korn et al., 2009) 
IL-22 T lymphocytes Regulatory mucosal 
cytokine, inhibits IL-
4 production by TH2 
cells, protective in 
preserving the 
epithelial barrier 




smooth muscle cells; 
ICAM-1 is membrane 
bound (provides 
adhesion between 
endothelial cells and 
leukocytes after 








TGF-β1 Produced by almost 





involved in class 
switching to IgA 
(Annes et al., 
2003) 
TNF-α TH1 cells, adipocytes, 














Table 3-3. AIN-93G modified diets* with high fat and wheat bran, oat bran, RS or FOS. 
 
Product # D14062202 D14062203 D14062204 D14062205 D14062206 D14062207 




HE Wheat Bran HE Oat Bran HE Resistant 
Starch 
HE FOS 
Ingredient g g g g g g 
Casein 200 190 169.2 152.7 190 190 
L-Cystine 3 3 3 3 3 3 
Corn Starch 387.5 173.3 158.4 110.3 155.3 172.6 
Maltodextrin 10 122 68.3 53.4 5.3 50.3 67.6 
Sucrose 100 283.3 268.4 220.3 265.3 282.6 
Cellulose, BW200 70 70 3.3 40 40 40 
Corn Starch, High Amylose 0 0 0 0 83.9 0 
Wheat Bran 0 0 133.3 0 0 0 
Oat Bran 0 0 0 260.9 0 0 
Oligofructose 0 0 0 0 0 32.2 
Soybean Oil 70 120.3 120.3 120.3 120.3 120.3 
Milk Fat, Anhydrous 0 44.2 44.2 44.2 44.2 44.2 
tBHQ 0.014 0.014 0.014 0.014 0.014 0.014 
Mineral Mix S10022G 35 35 35 35 35 35 
Potassium Phosphate, Monobasic 0 0 0 0 0 0 
Vitamin Mix V10037 10 10 10 10 10 10 
Choline Bitartrate 2.5 2.5 2.5 2.5 2.5 2.5 
FD&C Red Dye #5 0 0 0 0 0.05 0.025 
FD&C Yellow Dye #40 0 0.05 0 0.025 0 0 
FD&C Blue Dye #1 0 0 0.05 0.025 0 0.025 
Total 1000.014 999.964 1001.0644 1004.564 999.864 1000.064 
 Diet 1 Diet 2 Diet 3 Diet 4 Diet 5 Diet 6 
g       
Protein 179.0 170.2 172.7 174.7 170.2 170.2 
Carbohydrate (digestible) 609.5 524.9 508.8 495.0 520.6 522.8 
Fat 70.0 164.5 170.1 183.0 164.5 164.5 
Fiber 70.0 70.0 70.0 70.0 70.0 72.2 
Resistant Starch 0.0 0.0 0.0 0.0 30.0 0.0 
Potassium 3.6 3.6 3.6 3.6 3.6 3.6 
Phosphorus 3.0 2.9 2.7 2.6 2.9 2.9 
g%       
Protein 17.9 17.0 17.3 17.4 17.0 17.0 
Carbohydrate (digestible) 60.9 52.5 50.8 49.3 52.1 52.3 
Fat 7.0 16.5 17.0 18.2 16.5 16.4 
Fiber 7.0 7.0 7.0 7.0 7.0 7.2 
Resistant Starch 7.0 7.0 7.0 7.0 7.0 7.2 
kcal       
Protein 716 681 691 699 681 681 
Carbohydrate 2438 2100 2035 1980 2082 2091 
Fat 630 1481 1531 1647 1481 1481 
Total 3784 4261 4257 4326 4244 4253 
kcal%       
Protein 19 16 16 16 16 16 
Carbohydrate 64 49 48 46 49 49 
Fat 17 35 36 38 35 35 
* These formulations were created by Dr. Stephen PJ Brooks (Bureau of Nutritional Sciences, Health Canada) 





Table 3-4. Anti-rat antibodies used in flow cytometry for analysis of cell populations in 
spleen, MLN and ileal PP. 
 
Marker Description Clone Conjugate* Manufacturer 
Control Isotype – IgG1 F8-11-13 AF700 AbD Serotec 
CD3 T lymphocytes IF4 APC BD Biosciences 
CD3** T lymphocytes G4.18 PerCP-eFluor eBioscience 
CD4 T helper cells OX-35 PE-Cy7 BD Biosciences 
CD4*** T helper cells OX-35 V450 BD Biosciences 
CD8a Cytotoxic T cells OX-8 V450 BD Biosciences 
CD25 T cell IL-2R α chain OX-39 FITC BD Biosciences 
CD45 Leukocytes OX-1 APC-Cy7 BD Biosciences 
CD45RA B cells OX-33 PE-Cy5 BD Biosciences 
CD62L T cell subsets, 
effector/memory 
11RL1 PE BD Biosciences 
CD68 Pan macrophage ED1 AF700 AbD Serotec 
CD103 Dendritic cells OX-62 AF647 BioLegend 
CD161a NK cells 10/78 FITC BD Biosciences 
CD163 M2 macrophage ED2 AF647 AbD Serotec 
CD197 M1 macrophage Y59 PE-Cy7 abcam 
Foxp3 Treg FJK-16s PE eBioscience 
HIS36 Pan macrophage HIS36 PE BD Biosciences 
γδ-TCR γδ-T cells V65 FITC eBioscience 
Viability 
dye 
Labels dead cells ----- eFluor 506 eBioscience 
* Conjugates: AF647: Alexa Fluor 647, APC: allophycocyanin, FITC: fluorescein isothiocyanate, MHC II: 
Major histocompatibility complex class molecule II, PE: phycoerythrin, PerCP: peridinin–chlorophyll–
protein complex.  
** Alternate fluorochrome-conjugated anti-CD3 antibody used to differentiate populations in panel 2. 
*** Alternate fluorochrome-conjugated anti-CD4 antibody used to differentiate populations in panel 3. 
Manufacturers: BD Biosciences (San Jose, CA, USA); BioLegend (San Diego, CA, USA); AbD Serotec 




















Table 3.5. Preliminary trial TLR stimulating concentrations used in ex vivo whole blood 
assay. 
 
Receptor Agonist Concentrations Tested 
TLR2 P3C 10 µg/mL and 20 µg/mL 
TLR4 LPS 5 µg/mL and 10 µg/mL 
TLR5 Flagellin 100 ng/mL and 200 ng/mL 
TLR9 E. coli ssDNA 2.5 µg/mL and 5 µg/mL 
TLR9 CpG ODN 2006 5 µg/mL and 10 µg/mL 







































Table 3-6. Hematological measures from the preliminary trial.  
 
Measure* Phenotype Value 2-tailed P value 
WBC 
109/L 
DR 7.1 ± 0.7 0.748 
DIO 7.4 ± 0.7 
RBC 
109/L 
DR 6.50 ± 0.10 0.124 
DIO 6.31 ± 0.06 
Hgb 
g/L 
DR 134 ± 1.07 0.683 
DIO 133 ± 1.89 
Hct 
L/L 
DR 0.386 ± 0.004 0.674 
DIO 0.383 ± 0.006 
MCV 
fL 
DR 59 ± 0.67 0.192 
DIO 61 ± 0.79 
MCH 
pg 
DR 20.6 ± 0.25 0.171 
DIO 21.1 ± 0.23 
MCHC 
g/L 
DR 347 ± 0.88 0.863 
DIO 347 ± 0.73 
RDW 
% 
DR 12.1 ± 0.14 0.032 
DIO 12.5 ± 0.14 
PLT 
109/L 
DR 822 ± 24.68 0.028 
DIO 899 ± 20.94 
MPV 
fL 
DR 6.2 ± 0.13 0.013 
DIO 6.7 ± 0.10 
NE 
% 
DR 9.0 ± 0.92 0.203 
DIO 10.6 ± 0.76 
LY 
% 
DR 87.2 ± 1.02 0.134 
DIO 84.8 ± 1.13 
MO 
% 
DR 2.4 ± 0.23 0.147 
DIO 3.2 ± 0.46 
EO 
% 
DR 1.0 ± 0.14 0.760 
DIO 1.1 ± 0.36 
BA 
% 
DR 0.3 ± 0.06 0.899 
DIO 0.3 ± 0.05 
* WBC, White blood cell count; RBC, Red blood cell count; Hgb, Hemoglobin; Hct, Hematocrit; MCV, 
Mean corpuscular volume, MCH, Mean corpuscular hemoglobin; MCHC, Mean corpuscular hemoglobin 
concentration, RDW, Red cell distribution width; PLT, platelet count; MPV, mean platelet volume; NE, 
neutrophil count, LY, lymphocyte count; MO, monocyte count; EO, eosinophil count; BA, basophil count. 
Concentrations or percentages are presented as mean ± SEM, n = 10. Statistical analyses were performed 









Table 3-7. Serum cytokine/chemokine and biochemistry measures from the preliminary 
trial.  
 
Measure Phenotype Concentration* 2-tailed P value 
CINC-1 
pg/mL 
DR 132.4 ± 14.3 0.376 
DIO 115.8 ± 11.4 
CINC-2αβ 
pg/mL 
DR 30.7 ± 3.1 0.668 
DIO 29.0 ± 2.2 
CINC-3  
pg/mL 
DR 14.0 ± 0.6 0.811 
DIO 13.8 ± 0.5 
Active TGF-β 
pg/mL 
DR 419.3 ± 22.3 0.141 
DIO 380.0 ± 11.8 
Total TGF-β 
ng/mL 
DR 14.6 ± 1.1 0.777 
DIO 15.0 ± 1.2 
sICAM-1/sCD54 
pg/mL 
DR 6412.0 ± 475.0 0.355 
DIO 5893.5 ± 270.1 
CRP 
pg/mL 
DR 277.6 ± 18.6 0.516 
DIO 296.3 ± 21.4 
LPS 
(EU/mL) 
DR 0.443 ± 0.063 0.456 
DIO 0.548 ± 0.122 
BUN 
mmol/L 
DR 4.41 ± 0.32 0.640 
DIO 4.64 ± 0.36 
Glucose 
mmol/L 
DR 7.70 ± 0.34 0.460 
DIO 8.09 ± 0.39 























Table 3-8. Cytokine/chemokine concentrations measured from whole blood cultures after 
TLR stimulation in the preliminary trial.  
 
  Measure* (pg/mL) 
Agonist Phenotype CINC-1 IFN-γ IL-1β IL-6 IL-10 TNF-α 
P3C 
10 µg/mL 


















































































































9.4 ± 9.4 










88.5 ± 9.2 
LPS 
10 µg/mL 

































































50.1 ± 1.8 








17.1 ± 8.8 






















27.1 ± 7.2 






























0.0 ± 0.0 
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Table 3-8 continued.  
 
  Measure* (pg/mL) 














19.4 ± 6.8 












DIO unstim1 0.0 0.0 0.0 0.0 0.0 29.4 




DR unstim ----- ----- ----- ----- ----- ----- 
DR stim ----- ----- ----- ----- ----- ----- 










DIO stim2 5.1 ± 5.1 0.0 ± 
0.0 









DR unstim1 0.0 0.0 78.0 247.0 85.1 0.0 
DR stim1 0.0 0.0 72.5 268.8 97.7 65.7 
DIO unstim1 0.0 0.0 89.1 202.9 97.7 0.0 













34.3 ± 0.5 










DIO unstim1 0.0 0.0 105.9 173.0 31.0 26.2 
DIO stim1 0.0 0.0 128.6 276.0 80.9 44.8 
* Concentrations are presented as mean ± SEM. CINC-2αβ concentrations was also measured; however, 
this chemokine was below the level of quantification in every sample. 
1 n = 1 
2 n = 2 






















Table 3-9. Histological analysis of IEL counts in small bowel sections collected from the 
preliminary trial.  
 
Small Bowel Section Phenotype IEL count* 2-tailed P value 
Duodenum DR 2.53 ± 1.56 0.449 
DIO 4.49 ± 1.90 
Jejunum** DR 0.00 n/a 
DIO 0.00 
* IELs were enumerated per 100 villous enterocytes for 5 villi per section in the small bowel. Counts are 
presented as mean ± SEM, n = 5. Statistical analyses were performed using unpaired t-tests. 







































Table 3-10. Ileal cytokine concentrations measured in rats from the preliminary trial. 
 
Measure Phenotype Concentration* 2-tailed P value 
IL-1β 
ng/mL 
DR 11.7 ± 1.9 0.327 
DIO 14.8 ± 2.4 
IL-6 
pg/mL 
DR1 1199.7 ± 396.0 0.093 
DIO2 498.1 ± 97.4 
IL-22 
pg/mL 
DR3 88.5 ± 29.7 0.582 
DIO3 134.2 ± 70.3 
TNF-α 
pg/mL 
DR 17.9 ± 2.0 0.429 
DIO 26.6 ± 10.6 
Active TGF-β1 
pg/mL 
DR2 635.9 ± 65.7 0.942 
DIO4 647.6 ± 134.2 
Total TGF-β1 
pg/mL 
DR4 6324.9 ± 735.4 0.051 
DIO4 4339.9 ± 543.2 
* Concentrations are presented as mean ± SEM, n = 10 (unless otherwise specified). Statistical analyses 
were performed using unpaired t-tests. 
1 n = 5 for IL-6 in DR rats. 
2 n = 6 for IL-6 in DIO rats and active TGF-β in DR rats. 
3 n = 3 for IL-22 in DR and DIO rats. 




























Table 3-11. Caecal cytokine/chemokine concentrations measured in rats from the 
preliminary trial.  
 
Measure Phenotype Concentration* 2-tailed P value 
CINC-1 
pg/mL 
DR 292.3 ± 12.8 0.308 
DIO 264.8 ± 13.3 
CINC-2αβ 
pg/mL 
DR 426.1 ± 56.6 0.261 
DIO 335.6 ± 53.7 
IL-6 
pg/mL 
DR 2182.6 ± 84.4 0.192 
DIO 1972.0 ± 130.4 
IL-10 
pg/mL 
DR 1048.2 ± 73.2 0.679 
DIO 1097.0 ± 90.0 
IL-22 
pg/mL 
DR1 126.0 ± 29.7 0.482 
DIO1 160.2 ± 32.6 
TNF-α 
pg/mL 
DR 63.8 ± 7.7 0.500 
DIO 92.8 ± 41.4 
Active TGF-β1 
pg/mL 
DR 1092.2 ± 21.4 0.183 
DIO 1176.9 ± 57.2 
Total TGF-β1 
pg/mL 
DR 2986.3 ± 148.5 0.061 
DIO 3445.3 ± 175.4 
* Concentrations are presented as mean ± SEM, n = 10 (unless otherwise specified). Statistical analyses 
were performed using unpaired t-tests. 


























Table 3-12. Proximal colon cytokine concentrations measured in rats from the 
preliminary trial.  
 
Measure Phenotype Concentration* 2-tailed P value 
IL-6 
pg/mL 
DR 4736.4 ± 299.8 0.230 
DIO 5350.6 ± 393.2 
IL-10 
pg/mL 
DR 4155.1 ± 136.6 0.032 
DIO 4644.6 ± 160.2 
IL-17F 
pg/mL 
DR 505.8 ± 38.6 0.070 
DIO 609.0 ± 37.0 
TNF-α 
pg/mL 
DR 1481.0 ± 85.3 0.016 
DIO 1827.2 ± 97.7 
Active TGF-β1 
pg/mL 
DR 527.7 ± 59.8 0.280 
DIO 597.1 ± 17.3 
Total TGF-β1 
pg/mL 
DR 1494.9 ± 137.7 0.096 
DIO 1799.0 ± 104.8 































Table 3-13. Distal colon cytokine concentrations measured in rats from the preliminary 
trial.  
 
Measure Phenotype Concentration* 2-tailed P value 
IL-6 
pg/mL 
DR 3920.9 ± 358.4 0.152 
DIO 4503.5 ± 152.1 
IL-10 
pg/mL 
DR 2638.9 ± 142.1 0.368 
DIO 2817.9 ± 131.5 
IL-17F 
pg/mL 
DR 395.1 ± 34.3 0.061 
DIO 501.3 ± 40.4 
IL-22 
pg/mL 
DR1 67.4 ± 13.9 0.059 
DIO1 132.9 ± 20.8 
TNF-α 
pg/mL 
DR 1026.1 ± 56.1 0.110 
DIO 1148.2 ± 46.3 
Active TGF-β1 
pg/mL 
DR 591.4 ± 34.4 0.107 
DIO 675.2 ± 35.5 
Total TGF-β1 
pg/mL 
DR 1522.0 ± 129.8 0.072 
DIO 1914.7 ± 158.7 
* Concentrations are presented as mean ± SEM, n = 10 (unless otherwise specified). Statistical analyses 
were performed using unpaired t-tests. 




























Table 3-14. Liver cytokine/chemokine concentrations measured in rats from the 
preliminary trial.   
 
Measure Phenotype Concentration* 2-tailed P value 
CINC-1 
pg/mL 
DR 2679.4 ± 164.8 0.017 
DIO 3387.9 ± 211.3 
CINC-2αβ 
ng/mL 
DR 12.9 ± 1.3 0.815 
DIO 13.3 ± 0.8 
CINC-3 
pg/mL 
DR 3845.7 ± 491.9 0.149 
DIO 4809.8 ± 409.3 
IL-1β 
ng/mL 
DR 64.8 ± 6.2 0.098 
DIO 82.7 ± 8.1 
IL-4 
pg/mL 
DR 7283.7 ± 626.8 0.339 
DIO 8070.9 ± 500.0 
IL-6 
ng/mL 
DR 61.8 ± 4.8 0.109 
DIO 74.6 ± 5.9 
IL-10 
ng/mL 
DR 30.4 ± 2.4 0.185 
DIO 35.3 ± 2.6 
TNF-α 
ng/mL 
DR 23.2 ± 2.1 0.163 
DIO 27.7 ± 2.3 
Active TGF-β1 
pg/mL 
DR 4811.0 ± 298.7 0.902 
DIO 4864.4 ± 311.1 
Total TGF-β1 
pg/mL 
DR 4663.0 ± 321.5 0.696 
DIO 4830.1 ± 272.0 
























Table 3-15. Spleen cytokine/chemokine concentrations measured in rats from the 
preliminary trial.  
 
Measure Phenotype Concentration* 2-tailed P value 
CINC-1 
pg/mL 
DR 1572.2 ± 57.2 0.972 
DIO 1575.6 ± 77.8 
CINC-2αβ 
pg/mL 
DR 1722.2 ± 83.8 0.769 
DIO 1755.0 ± 71.5 
CINC-3 
pg/mL 
DR 239.7 ± 25.8 0.391 
DIO 263.9 ± 9.3 
IL-1β 
ng/mL 
DR 81.6 ± 6.0 0.295 
DIO 90.9 ± 6.1 
IL-6 
pg/mL 
DR 170.4 ± 53.8 0.244 
DIO 273.6 ± 66.5 
IL-10 
pg/mL 
DR 53.3 ± 0.0 0.331 
DIO 55.6 ± 2.2 
TNF-α 
pg/mL 
DR 141.5 ± 28.6 0.049 
DIO 215.0 ± 19.8 






























Table 3-16. MLN cytokine concentrations measured in rats from the preliminary trial. 
 
Measure Phenotype Concentration* 2-tailed P value 
IL-1β 
ng/mL 
DR 51.8 ± 15.9 0.705 
DIO 44.9 ± 8.4 
IL-6 
pg/mL 
DR 1662.0 ± 480.2 0.260 
DIO 1089.7 ± 105.1 
IL-10 
pg/mL 
DR 505.7 ± 155.8 0.738 
DIO 568.6 ± 99.5 
IL-22 
pg/mL 
DR1 168.7 ± 86.3 0.835 
DIO1 143.9 ± 70.3 
sICAM-1/sCD54 
ng/mL 
DR 73.1 ± 14.8 0.018 
DIO 32.5 ± 5.1 
* Concentrations are presented as mean ± SEM, n = 10 (unless otherwise specified). Statistical analyses 
were performed using unpaired t-tests. 

































Table 3-17. Ileal PP cytokine/chemokine concentrations measured in rats from the 
preliminary trial.  
 
Measure Phenotype Concentration* 2-tailed P value 
CINC-3** 
pg/mL 




DR 224.0 ± 58.5 0.601 
DIO 187.2 ± 37.0 
IL-4 
pg/mL 
DR 226.4 ± 27.1 0.940 
DIO 223.2 ± 31.2 
IL-6 
pg/mL 
DR 674.8 ± 206.8 0.957 
DIO 704.0 ± 488.2 
IL-10 
pg/mL 
DR 721.7 ± 77.4 0.480 
DIO 814.1 ± 101.9 
IL-17F 
pg/mL 
DR 501.5 ± 41.0 0.952 
DIO 504.4 ± 23.8 
TNF-α 
pg/mL 
DR 364.8 ± 63.4 0.205 
DIO 514.5 ± 94.4 
* Concentrations are presented as mean ± SEM, n = 10. Statistical analyses were performed using unpaired 
t-tests. 




























Table 3-18. Mesenteric fat cytokine/chemokine concentrations measured in rats from the 
preliminary trial.  
 
Measure Phenotype Concentration* 2-tailed P value 
CINC-1 
pg/mL 
DR 418.6 ± 70.3 0.169 
DIO 309.2 ± 30.0 
CINC-2αβ 
pg/mL 
DR 699.6 ± 106.9 0.053 
DIO 459.6 ± 45.1 
IL-6 
pg/mL 
DR 5869.2 ± 1131.5 0.111 
DIO 3497.4 ± 849.0 
IL-10 
pg/mL 
DR 5542.4 ± 1157.4 0.154 
DIO 3491.5 ± 748.1 
TNF-α 
pg/mL 
DR 1615.1 ± 369.9 0.092 
DIO 896.0 ± 161.6 


































Table 3-19. Epididymal fat cytokine/chemokine concentrations measured in rats from the 
preliminary trial.  
 
Measures Phenotype Concentrations* 2-tailed P value 
CINC-1 
pg/mL 
DR 1280.7 ± 121.2 0.944 
DIO 1296.3 ± 184.6 
CINC-2αβ 
pg/mL 
DR 3861.4 ± 352.1 0.690 
DIO 4089.7 ± 439.8 
CINC-3 
pg/mL 
DR 586.9 ± 139.3 0.712 
DIO 665.8 ± 157.4 
IL-6 
ng/mL 
DR 13.1 ± 1.4 0.712 
DIO 13.8 ± 1.3 
IL-10 
ng/mL 
DR 13.3 ± 1.8 0.566 
DIO 11.9 ± 1.6 
TNF-α 
pg/mL 
DR 4591.2 ± 533.4 0.562 
DIO 5095.9 ± 651.4 































Table 3-20a. Hematological measures of DR and DIO rats after consuming AIN-93G modified diets for 11-12 weeks. 
 
 Control High Energy Diets Statistics - P value 
Measure*  AIN-93G AIN-93G Wheat Bran Oat Bran Resistant 
Starch II 




DR 4.4 ± 0.6 4.0 ± 0.2 4.8 ± 0.4 4.5 ± 0.3α 4.4 ± 0.4 5.1 ± 0.6 0.008 0.233 0.368 
DIO 4.4 ± 0.3 4.9 ± 0.3 4.9 ± 0.3 5.9 ± 0.4β 5.6 ± 0.6 4.9 ± 0.4 
RBC 
109/L 
DR 8.23 ± 
0.10α 
8.25 ± 0.12 8.41 ± 0.09 8.26 ± 0.09 8.30 ± 0.11 8.58 ± 
0.13β 
0.316 0.017 0.737 
DIO 8.05 ± 
0.13α 




DR 146 ± 1.85 146 ± 1.94 149 ± 2.62 146 ± 1.47 148 ± 2.22 150 ± 1.83 0.708 0.638 0.586 
DIO 146 ± 2.50 148 ± 2.04 149 ± 1.67 151 ± 2.65 147 ± 2.21 147 ± 1.44 
Hct 
L/L 




0.456 ± 0.008 0.439 ± 
0.011α 
0.451 ± 0.007 0.457 ± 
0.006 
0.605 0.739 0.400 




0.456 ± 0.005 0.459 ± 
0.008β 




DR 54 ± 0.83 54 ± 1.08 54 ± 0.79 54 ± 0.53 54 ± 0.54 53 ± 0.64 0.168 0.358 0.938 
DIO 56 ± 0.31 55 ± 0.86 54 ± 0.72 55 ± 1.16 56 ± 0.75 53 ± 1.10 
MCH 
pg 
DR 17.8 ± 0.28 17.8 ± 0.34 17.7 ± 0.25 17.7 ± 0.19 17.8 ± 0.22 17.4 ± 
0.22 
0.142 0.275 0.982 








326.9 ± 0.75 326.4 ± 1.01 328.2 ± 1.59 327.1 ± 
1.25 
0.784 0.491 0.844 




327.2 ± 1.33 328.1 ± 1.48 328.4 ± 1.82 326.1 ± 
1.35 







Table 3-20a continued. 
 
 Control High Energy Diets Statistics - P value 
Measure*  AIN-93G AIN-93G Wheat Bran Oat Bran Resistant 
Starch II 




DR 11.4 ± 0.24 11.4 ± 0.24 11.6 ± 0.32 11.8 ± 0.22 11.3 ± 0.11 11.7 ± 
0.19 
0.091 0.456 0.652 








668 ± 20.08 691 ± 26.71 603 ± 50.74 644 ± 
31.20 
0.758 0.138 0.681 








DR 6.2 ± 0.10 6.6 ± 0.21 6.2 ± 0.09 6.1 ± 0.08 6.3 ± 0.08 6.4 ± 0.07 0.924 0.127 0.469 
DIO 6.4 ± 0.09 6.3 ± 0.14 6.2 ± 0.09 6.3 ± 0.11 6.1 ± 0.10 6.4 ± 0.15 
NE 
% 
DR 5.3 ± 0.58α 6.7 ± 0.52 5.8 ± 0.55 7.1 ± 0.58 7.2 ± 0.91 6.2 ± 0.14 0.327 0.413 0.306 
DIO 7.1 ± 0.69β 7.1 ± 0.80 6.5 ± 0.72 6.9 ± 0.30 5.8 ± 0.40 7.1 ± 0.93 
LY 
% 
DR 91.0 ± 0.86 88.5 ± 0.56 89.7 ± 0.71 87.3 ± 0.99 88.5 ± 1.23 89.0 ± 
0.29 
0.067 0.195 0.423 




DR 3.0 ± 0.29aα 3.9 ± 
0.34abβ 
3.8 ± 0.25abβ 4.3 ± 0.20bβ 3.6 ± 0.30ab 4.0 ± 
0.18abβ 
0.022 <0.001 0.995 
DIO 3.5 ± 0.50aα 4.7 ± 
0.51abβ 
4.7 ± 0.54abβ 5.0 ± 0.44bβ 4.1 ± 0.31ab 4.4 ± 
0.37abβ 









Table 3-20a continued. 
 
 Control High Energy Diets Statistics - P value 
Measure*  AIN-93G AIN-93G Wheat Bran Oat Bran Resistant 
Starch II 




DR 0.4 ± 0.06 0.5 ± 0.08 0.3 ± 0.05 1.0 ± 0.55 0.4 ± 0.10 0.4 ± 0.05 0.981 0.831 0.331 
DIO 0.7 ± 0.21 0.4 ± 0.09 0.7 ± 0.43 0.4 ± 0.04 0.4 ± 0.09 0.5 ± 0.13 
BA 
% 
DR 0.3 ± 0.05 0.3 ± 0.04 0.3 ± 0.03 0.3 ± 0.05 0.3 ± 0.03 0.4 ± 0.01 0.644 0.185 0.429 
DIO 0.4 ± 0.05 0.3 ± 0.05 0.4 ± 0.05 0.4 ± 0.03 0.4 ± 0.04 0.4 ± 0.03 
* WBC, White blood cell count; RBC, Red blood cell count; Hgb, Hemoglobin; Hct, Hematocrit; MCV, Mean corpuscular volume, MCH, Mean corpuscular 
hemoglobin; MCHC, Mean corpuscular hemoglobin concentration, RDW, Red cell distribution width; PLT, platelet count; MPV, mean platelet volume; NE, 
neutrophil count, LY, lymphocyte count; MO, monocyte count; EO, eosinophil count; BA, basophil count. Concentrations or percentages are presented as mean 
± SEM, n = 10. Significance (P < 0.05) for phenotype, diet, and interaction between phenotype × diet was determined by two-way ANOVA. Superscripted letters 
denote significance differences between diets within a phenotype, and symbols denote significant differences between overall diet or overall phenotype as 




Table 3-20b. Hematological measures of DR and DIO rats after consuming AIN-93G 
modified diets for 11-12 weeks, separated by phenotype. 
  
Measure Phenotype Value* 
WBC 
109/L 
DR 4.5 ± 0.2 
DIO 5.1 ± 0.2 
RBC 
109/L 
DR 8.34 ± 0.05 
DIO 8.26 ± 0.06 
Hgb 
g/L 
DR 147 ± 0.81 
DIO 148 ± 0.86 
Hct 
L/L 
DR 0.449 ± 0.003 
DIO 0.452 ± 0.003 
MCV 
fL 
DR 54 ± 0.30 
DIO 55 ± 0.35 
MCH 
pg 
DR 17.7 ± 0.10 
DIO 17.9 ± 0.12 
MCHC 
g/L 
DR 327.1 ± 0.45 
DIO 327.3 ± 0.62 
RDW 
% 
DR 11.5 ± 0.09 
DIO 11.2 ± 0.15 
PLT 
109/L 
DR 666 ± 15.73 
DIO 674 ± 14.47 
MPV 
fL 
DR 6.3 ± 0.05 
DIO 6.3 ± 0.05 
NE 
% 
DR 6.4 ± 0.25 
DIO 6.7 ± 0.27 
LY 
% 
DR 89.0 ± 0.36 
DIO 88.0 ± 0.41 
MO 
% 
DR 3.8 ± 0.12 
DIO 4.4 ± 0.19 
EO 
% 
DR 0.5 ± 0.10 
DIO 0.5 ± 0.08 
BA 
% 
DR 0.3 ± 0.02 
DIO 0.4 ± 0.02 















Table 3-21a. Total immune cell population percentages within the spleen of DR and DIO rats after consuming AIN-93G modified 
diets for 11-12 weeks. 
 
 Control High Energy Diets Statistics - P value 
Cell 
Marker* 
 AIN-93G AIN-93G Wheat 
Bran 
Oat Bran Resistant 
Starch II 
FOS Phenotype Diet Phenotype 
× Diet 








6.23 ± 1.29αβ 7.18 ± 
1.00β 
0.435 0.019 0.488 




















1.69 ± 0.70bβδ 1.37 ± 
0.61bβ 
0.632 <0.001 0.729 












DR1 2.76 ± 0.47 3.14 ± 0.82 3.23 ± 0.31 3.23 ± 0.21 3.77 ± 0.78 4.27 ± 
0.58 
0.339 0.063 0.444 












2.18 ± 0.55β 2.50 ± 
0.41β 
0.779 0.005 0.656 




















13.08 ± 2.49β 15.88 ± 
1.79β 
0.371 <0.001 0.437 








13.00 ± 2.15bβ 9.97 ± 
3.22bβ 








Table 3-21a continued. 
 
 Control High Energy Diets Statistics - P value 
Cell 
Marker* 
 AIN-93G AIN-93G Wheat 
Bran 
Oat Bran Resistant 
Starch II 












2.98 ± 0.41αβ 3.39 ± 
0.32β 
0.851 0.015 0.645 




















0.80 ± 0.12αβγ 1.12 ± 
0.16β 
0.350 0.006 0.218 














DR1 0.66 ± 0.04 0.69 ± 0.12 0.48 ± 0.06 0.57 ± 0.07 0.65 ± 0.09 0.94 ± 
0.15 
0.254 0.045 0.163 




0.59 ± 0.06ab 0.46 ± 
0.12ab 




DR 0.14 ± 0.02 0.10 ± 0.02 0.11 ± 0.02 0.10 ± 0.01 0.17 ± 0.04 0.12 ± 
0.03 
0.159 0.548 0.583 




DR 0.35 ± 0.09 0.35 ± 0.11 0.34 ± 0.06 0.27 ± 0.03 0.49 ± 0.10 0.52 ± 
0.09α 
0.973 0.687 0.089 




DR 0.24 ± 0.04 0.17 ± 0.05 0.19 ± 0.03 0.17 ± 0.02 0.28 ± 0.06 0.20 ± 
0.04 
0.911 0.083 0.300 
DIO 0.20 ± 0.04 0.21 ± 0.04 0.27 ± 0.04 0.18 ± 0.03 0.25 ± 0.03 0.13 ± 
0.03 






Table 3-21a continued. 
 
 Control High Energy Diets Statistics - P value 
Cell 
Marker* 
 AIN-93G AIN-93G Wheat 
Bran 
Oat Bran Resistant 
Starch II 






DR 1.89 ± 0.31 1.97 ± 0.22 2.02 ± 0.21 1.88 ± 0.14 2.31 ± 0.33 2.02 ± 
0.16 
0.796 0.367 0.863 
DIO 1.72 ± 0.28 1.71 ± 0.24 2.21 ± 0.36 1.82 ± 0.18 2.12 ± 0.26 2.28 ± 
0.19 
* Data are shown as the mean percentage of viable cells ± SEM, n = 5 (unless otherwise specified). Significance (P < 0.05) for phenotype, diet, and interaction 
between phenotype × diet was determined by two-way ANOVA. Superscripted letters denote significant differences between diets within a phenotype, and 
symbols denote significant differences between overall diet or overall phenotype as determined by Tukey’s multiple comparison test. 
** Foxp3+ ISO control has been removed from total CD4+Foxp3+CD25+ Treg cell percentage. 




















Table 3-21b. Total immune cell population percentages within the spleen of DR and DIO 
rats after consuming AIN-93G modified diets for 11-12 weeks, separated by phenotype.  
 
Cell Marker* Phenotype Cell Percentage 
CD3+ DR1 6.04 ± 0.40 
DIO1 5.63 ± 0.49 
CD3+ 
CD62L+ 
DR1 1.38 ± 0.24 
DIO1 1.36 ± 0.29 
CD3+ 
CD4+ 
DR1 3.45 ± 0.24 
DIO1 3.15 ± 0.27 
CD3+ 
CD8a+ 
DR1 2.25 ± 0.18 
DIO1 2.19 ± 0.22 
CD3+ 
CD45+ 
DR1 13.12 ± 0.80 
DIO1 12.22 ± 0.99 
CD3- 
CD45RA+ 
DR1 3.07 ± 0.18 
DIO1 3.14 ± 0.27 
CD3- 
CD161a+ 
DR1 0.80 ± 0.05 
DIO1 0.74 ± 0.07 
CD3-CD4- 
CD161a+ 
DR1 0.68 ± 0.05 
DIO1 0.61 ± 0.06 
CD3- 
CD103+ 
DR 0.12 ± 0.01 
DIO 0.11 ± 0.01 
CD3- 
His36+ 
DR 0.39 ± 0.04 
DIO 0.43 ± 0.07 
CD3+ 
γδTCR+ 
DR 0.21 ± 0.02 
DIO 0.21 ± 0.01 
CD3+CD4+Foxp3+ 
CD25+ 
DR 2.01 ± 0.09 
DIO 1.98 ± 0.11 
* Percentages are presented as mean ± SEM, n = 30 (unless otherwise specified) 


















Table 3-22a. Total immune cell population percentages within the MLN of DR and DIO rats after consuming AIN-93G modified 
diets for 11-12 weeks. 
 
 Control High Energy Diets Statistics - P value 
Cell 
Marker* 
 AIN-93G AIN-93G Wheat Bran Oat Bran Resistant 
Starch II 
FOS Phenotype Diet Phenotype × 
Diet 




69.25 ± 2.10 67.48 ± 4.32 64.30 ± 4.11 64.84 ± 
3.38 
0.196 0.650 0.320 








DR1 3.23 ± 2.86 10.94 ± 
6.39 
17.59 ± 6.48 18.87 ± 6.81 13.70 ± 5.65 11.77 ± 
4.62 
0.973 0.555 0.950 
DIO1 9.41 ± 5.40 10.82 ± 
6.17 








42.20 ± 2.18 36.60 ± 4.45 39.58 ± 5.13  40.62 ± 
2.08 
0.135 0.327 0.445 












25.30 ± 2.80 29.18 ± 1.41 22.90 ± 2.48 22.46 ± 
1.81 
0.982 0.811 0.526 












86.65 ± 1.57 88.70 ± 2.43 81.50 ± 3.22 81.66 ± 
2.49 
0.206 0.345 0.475 




85.18 ± 2.34 81.90 ± 3.51 85.54 ± 4.62 80.66 ± 
3.49 








Table 3-22a continued. 
 
 Control High Energy Diets Statistics - P value 
Cell 
Marker* 
 AIN-93G AIN-93G Wheat Bran Oat Bran Resistant 
Starch II 
















0.727 0.045 0.254 














DR1 0.58 ± 0.31 0.34 ± 0.08 0.40 ± 0.13 0.54 ± 0.05 0.60 ± 0.17 0.89 ± 
0.29 
0.893 0.851 0.320 




DR1 0.24 ± 0.07 0.17 ± 0.02 0.21 ± 0.07 0.27 ± 0.07 0.20 ± 0.02 0.32 ± 
0.13 
0.845 0.895 0.759 




DR 0.22 ± 0.02 0.20 ± 0.02 0.15 ± 0.01α 0.25 ± 0.03 0.31 ± 0.06 0.28 ± 
0.05γ 
0.708 0.580 0.002 








DR 0.08 ± 0.01 0.05 ± 0.01 0.06 ± 0.01 0.08 ± 0.01 0.12 ± 0.03α 0.09 ± 
0.03 
0.178 0.514 0.137 




DR 0.64 ± 0.14 0.70 ± 
0.08α 
0.56 ± 0.07 0.71 ± 0.09 0.67 ± 0.10 0.48 ± 
0.02 
0.360 0.243 0.127 




0.66 ± 0.10ab 0.56 ± 0.06ab 0.76 ± 0.09b 0.56 ± 
0.06ab 






Table 3-22a continued. 
 
 Control High Energy Diets Statistics - P value 
Cell 
Marker* 
 AIN-93G AIN-93G Wheat Bran Oat Bran Resistant 
Starch II 


















0.133 0.043 0.700 




2.45 ± 0.21αβ 2.15 ± 0.08α 2.67 ± 0.24β 2.51 ± 
0.12αβ 
* Data are shown as the mean percentage of viable cells ± SEM, n = 5 (unless otherwise specified). Significance (P < 0.05) for phenotype, diet, and interaction 
between phenotype × diet was determined by two-way ANOVA. Superscripted letters denote significant differences between diets within a phenotype, and 
symbols denote significant differences between overall diet or overall phenotype as determined by Tukey’s multiple comparison test. 
** Foxp3+ ISO control has been removed from total CD4+Foxp3+CD25+ Treg cell percentage. 



















Table 3-22b. Total immune cell population percentages within the MLN of DR and DIO 
rats after consuming AIN-93G modified diets for 11-12 weeks, separated by phenotype. 
 
Cell Marker* Phenotype Cell Percentage 
CD3+ DR1 67.44 ± 1.34 
DIO1 64.96 ± 1.72 
CD3+ 
CD62L+ 
DR1 12.69 ± 2.27 
DIO1 12.74 ± 2.34 
CD3+ 
CD4+ 
DR1 40.58 ± 1.32 
DIO1 37.71 ± 1.59 
CD3+ 
CD8a+ 
DR1 25.13 ± 0.88 
DIO1 25.35 ± 1.04 
CD3+ 
CD45+ 
DR1 84.51 ± 1.10 
DIO1 82.54 ± 1.43 
CD3- 
CD45RA+ 
DR1 13.50 ± 0.81 
DIO1 13.81 ± 0.70 
CD3- 
CD161a+ 
DR1 0.57 ± 0.08 
DIO1 0.57 ± 0.09 
CD3-CD4-  
CD161a+ 
DR1 0.24 ± 0.03 
DIO1 0.23 ± 0.03 
CD3- 
CD103+ 
DR 0.24 ± 0.02 
DIO 0.25 ± 0.02 
CD3- 
His36+ 
DR 0.08 ± 0.01 
DIO 0.07 ± 0.01 
CD3+ 
γδTCR+ 
DR 0.63 ± 0.04 
DIO 0.58 ± 0.03 
CD3+CD4+Foxp3+ 
CD25+ 
DR 2.60 ± 0.13 
DIO 2.39 ± 0.08 
* Percentages are presented as mean ± SEM, n = 30 (unless otherwise specified). 


















Table 3-23a. Total immune cell population percentages within the ileal PP of DR and DIO rats after consuming AIN-93G modified 
diets for 11-12 weeks. 
 
 Control High Energy Diets Statistics - P value 
Cell 
Marker* 
 AIN-93G AIN-93G Wheat 
Bran 
Oat Bran Resistant 
Starch II 
FOS Phenotype Diet Phenotype × 
Diet 
CD3+ DR1 7.95 ± 
2.75α 
4.09 ± 2.26 8.17 ± 5.11 4.27 ± 1.87 1.82 ± 0.36 2.36 ± 1.10 0.587 0.074 0.117 
DIO1 1.75 ± 
0.61β 
5.83 ± 1.09 4.04 ± 0.33 4.28 ± 1.29 4.32 ± 1.42 1.65 ± 0.46 
CD3+ 
CD62L+ 
DR1 0.50 ± 0.31 0.40 ± 0.20 1.67 ± 1.22 0.71 ± 0.54 0.29 ± 0.14 0.53 ± 0.23 0.760 0.624 0.784 
DIO1 0.36 ± 0.22 0.46 ± 0.28 0.68 ± 0.29 0.72 ± 0.36 0.69 ± 0.28 0.25 ± 0.14 
CD3+ 
CD4+ 
DR1 5.19 ± 
2.22α 
2.70 ± 1.66 4.84 ± 2.96 2.63 ± 1.24 1.14 ± 0.19 1.53 ± 0.75 0.601 0.118 0.154 
DIO1 1.01 ± 
0.39β 
3.76 ± 0.90 2.68 ± 0.26 2.42 ± 0.75 2.68 ± 0.88 1.09 ± 0.34 
CD3+ 
CD8a+ 
DR1 2.17 ± 
0.60aα 




0.651 0.021 0.069 
DIO1 0.51 ± 
0.16β 
1.51 ± 0.28 0.94 ± 0.13 1.27 ± 0.36 0.85 ± 0.25 0.42 ± 0.10 
CD3+ 
CD45+ 












0.675 0.022 0.196 






















Table 3-23a continued. 
 
 Control High Energy Diets Statistics - P value 
Cell 
Marker* 
 AIN-93G AIN-93G Wheat 
Bran 
Oat Bran Resistant 
Starch II 
















0.408 0.039 0.203 














DR1 0.12 ± 0.07 0.08 ± 0.05α 0.09 ± 0.05 0.10 ± 0.04 0.10 ± 0.04 0.11 ± 0.06 0.381 0.249 0.104 










DR1 0.09 ± 0.04 0.04 ± 0.02α 0.09 ± 0.05 0.06 ± 0.01 0.06 ± 
0.02α 
0.06 ± 0.03 0.246 0.185 0.040 










DR2 0.11 ± 0.04 0.07 ± 0.03 0.17 ± 0.11 0.14 ± 0.05 0.04 ± 
0.04α 
0.08 ± 0.05 0.340 0.381 0.272 
DIO2 0.18 ± 0.11 0.19 ± 0.07 0.11 ± 0.02 0.09 ± 0.02 0.18 ± 
0.07β 
0.03 ± 0.01 
CD3-
His36+ 
DR2 0.05 ± 0.02 0.04 ± 0.01 0.08 ± 0.05 0.11 ± 0.07 0.28 ± 
0.18α 
0.06 ± 0.02 0.806 0.810 0.207 
DIO2 0.08 ± 0.05 0.17 ± 0.15 0.15 ± 0.08 0.07 ± 0.06 0.03 ± 
0.01β 
0.06 ± 0.03 
CD3+ 
γδTCR+ 
DR2 0.06 ± 0.01 0.04 ± 0.02 0.04 ± 0.01 0.05 ± 0.01 0.03 ± 0.02 0.03 ± 0.01 0.501 0.482 0.714 
DIO2 0.06 ± 0.02 0.05 ± 0.02 0.05 ± 0.02 0.04 ± 0.02 0.07 ± 0.03 0.02 ± 0.02 








Table 3-23a continued. 
 
 Control High Energy Diets Statistics - P value 
Cell 
Marker* 
 AIN-93G AIN-93G Wheat 
Bran 
Oat Bran Resistant 
Starch II 






DR3 0.62 ± 0.16 0.77 ± 0.13 0.84 ± 0.20 0.53 ± 0.16 0.96 ± 0.32 0.72 ± 0.23 0.435 0.419 0.737 
DIO3 0.63 ± 0.15 0.52 ± 0.18 0.79 ± 0.19 0.61 ± 0.08 1.62 ± 0.73 0.87 ± 0.25 
* Data are shown as the mean percentage of viable cells ± SEM, n = 5 (unless otherwise specified). Significance (P < 0.05) for phenotype, diet, and interaction 
between phenotype × diet was determined by two-way ANOVA. Superscripted letters denote significant differences between diets within a phenotype and 
symbols denote significant differences between overall diet or overall phenotype as determined by Tukey’s multiple comparison test. 
** Foxp3+ ISO control has been removed from total CD4+Foxp3+CD25+ Treg cell percentage. 
1 For antibody panel 1, n = 4 for DR rats on control, HE control, HE wheat bran and HE oat bran diets, and n = 4 for DIO rats on control and HE control diets. 
2 For antibody panel 2, n = 4 for DR rats on control, HE control and HE FOS diets, and n = 3 for DIO rats on the HE control diet. 


















Table 3-23b. Total immune cell population percentages within the ileal PP of DR and 
DIO rats after consuming AIN-93G modified diets for 11-12 weeks, separated by 
phenotype.  
 
Cell Marker* Phenotype Cell Percentage 
CD3+ DR1 4.57 ± 1.03 
DIO1 3.64 ± 0.46 
CD3+ 
CD62L+ 
DR1 0.66 ± 0.21 
DIO1 0.54 ± 0.11 
CD3+ 
CD4+ 
DR1 2.87 ± 0.67 
DIO1 2.26 ± 0.30 
CD3+ 
CD8a+ 
DR1 1.32 ± 0.36 
DIO1 0.91 ± 0.11 
CD3+ 
CD45+ 
DR1 13.88 ± 2.47 
DIO1 14.75 ± 1.91 
CD3- 
CD45RA+ 
DR1 8.31 ± 1.68 
DIO1 9.95 ± 1.41 
CD3- 
CD161a+ 
DR1 0.10 ± 0.02 
DIO1 0.13 ± 0.03 
CD3-CD4-  
CD161a+ 
DR1 0.06 ± 0.01 
DIO1 0.09 ± 0.02 
CD3- 
CD103+ 
DR2 0.10 ± 0.02 
DIO2 0.13 ± 0.03 
CD3- 
His36+ 
DR2 0.11 ± 0.04 
DIO2 0.09 ± 0.02 
CD3+ 
γδTCR+ 
DR2 0.04 ± 0.01 
DIO2 0.05 ± 0.01 
CD3+CD4+Foxp3+ 
CD25+ 
DR3 0.74 ± 0.08 
DIO3 0.85 ± 0.15 
* Percentages are presented as mean ± SEM.  
1 n = 26 for DR rats and n = 28 for DIO rats in antibody panel 1. 
2 n = 27 for DR rats and n = 28 for DIO rats in antibody panel 2. 
















Table 3-24a. CINC-1 concentrations measured from TLR agonist-stimulated whole blood cultures of DR and DIO rats after 
consuming AIN-93G modified diets for 11-12 weeks. 
 
 CINC-1 pg/mL*  
Control High Energy Diets Statistics - P value 
TLR 
Agonist** 
 AIN-93G AIN-93G Wheat Bran Oat Bran Resistant 
Starch II 
FOS Phenotype Diet Phenotype × 
Diet 
Control DR 59.3 ± 22.2 74.3 ± 41.2 65.5 ± 35.0 22.1 ± 7.8 27.5 ± 14.5 14.8 ± 
6.5α 
0.852 0.873 0.061 
DIO 30.5 ± 12.6 33.1 ± 13.7 8.5 ± 4.1 87.6 ± 63.9 25.5 ± 7.2 96.2 ± 
28.8β 
TLR2 P3C DR 43.2 ± 23.9 103.4 ± 53.2 32.0 ± 11.7 13.0 ± 5.0 17.1 ± 7.7 10.3 ± 5.9 0.516 0.619 0.123 
DIO 25.6 ± 13.5 30.7 ± 15.5 7.6 ± 4.6 104.1 ± 93.6 20.3 ± 9.8 114.1 ± 
50.3 
TLR4 LPS DR 70.2 ± 29.8 92.3 ± 49.4 105.8 ± 62.0α 38.0 ± 17.6 43.5 ± 28.5 33.7 ± 
13.9 
0.201 0.866 0.145 




DR 49.1 ± 20.6 43.6 ± 31.6 70.9 ± 49.1α 30.0 ± 6.3 30.6 ± 18.1 10.4 ± 8.9γ 0.664 0.485 0.037 
DIO 47.7 ± 25.0 36.6 ± 15.6 7.8 ± 4.6β 133.8 ± 
107.5 
24.1 ± 8.8 78.2 ± 
31.5δ 
* CINC-1 concentrations (pg/mL) are presented as mean ± SEM. Significance (P < 0.05) for phenotype, diet, and interaction between phenotype × diet was 
determined by two-way ANOVA. Superscripted letters denote significant differences between diets within a phenotype, and symbols denote significant 
differences between overall diet or overall phenotype as determined by Tukey’s multiple comparison test. 






Table 3-24b. CINC-1 concentrations measured from TLR agonist-stimulated whole 
blood cultures of DR and DIO rats after consuming AIN-93G modified diets for 11-12 
weeks, separated by phenotype.  
 
TLR Agonist* Phenotype CINC-1 (pg/mL) 
Control  
(Unstimulated) 
DR 43.9 ± 10.2 
DIO 47.2 ± 12.6 
TLR2  
P3C 
DR 36.5 ± 11.3 
DIO 49.9 ± 18.5 
TLR4  
LPS 
DR 65.2 ± 14.9 
DIO 42.3 ± 8.9 
TLR5  
Flagellin 
DR 38.3 ± 10.5 
DIO 52.9 ± 17.7 
* In the DR phenotype, n = 60 for control, n = 39 for TLR2, n = 39 for TLR4 and n = 41 for TLR5 
stimulated blood cultures. In the DIO phenotype, n = 59 for control and n = 40 for TLR2, TLR4 and TLR5 

































Table 3-25a. IL-1β concentrations measured from TLR agonist-stimulated whole blood cultures of DR and DIO rats after consuming 
AIN-93G modified diets for 11-12 weeks. 
 
 IL-1β pg/mL*  
Control High Energy Diets Statistics - P value 
TLR 
Agonist** 
 AIN-93G AIN-93G Wheat Bran Oat Bran Resistant 
Starch II 
FOS Phenotype Diet Phenotype × 
Diet 
Control DR 8.0 ± 6.3 11.4 ± 9.8 7.2 ± 5.6 28.0 ± 15.5α 5.0 ± 2.4 1.7 ± 0.0 0.285 0.628 0.149 
DIO 2.7 ± 1.0 1.7 ± 0.0 1.7 ± 0.0 3.1 ± 1.4β 15.5 ± 12.2 10.2 ± 6.2 
TLR2 P3C DR 4.5 ± 2.9a 9.2 ± 7.5a 12.0 ± 5.7a 42.5 ± 
24.0bα 
2.3 ± 0.6a 1.7 ± 0.0a 0.439 0.156 0.040 
DIO 14.5 ± 12.1 2.2 ± 0.5 15.8 ± 8.5 7.0 ± 3.5β 49.9 ± 48.3 11.9 ± 10.2 
TLR4 LPS DR 77.4 ± 31.5 93.7 ± 33.1 111.5 ± 41.6 131.4 ± 33.3 91.5 ± 23.3 89.5 ± 30.6 0.929 0.729 0.559 
DIO 79.1 ± 34.8 72.5 ± 35.3 49.6 ± 17.0 162.3 ± 51.2 55.2 ± 29.4 87.7 ± 32.4 
TLR5 
Flagellin 
DR 22.8 ± 14.4 13.3 ± 4.7 67.3 ± 62.4 17.7 ± 10.5 6.2 ± 4.1 2.5 ± 0.8 0.634 0.818 0.463 
DIO 15.0 ± 13.4 3.5 ± 1.2 7.1 ± 5.5 22.3 ± 12.3 25.4 ± 23.6 20.4 ± 9.5 
* IL-1β concentrations (pg/mL) are presented as mean ± SEM. Significance (P < 0.05) for phenotype, diet, and interaction between phenotype × diet was 
determined by two-way ANOVA. Superscripted letters denote significant differences between diets within a phenotype, and symbols denote significant 
differences between overall diet or overall phenotype as determined by Tukey’s multiple comparison test. 







Table 3-25b. IL-1β concentrations measured from TLR agonist-stimulated whole blood 
cultures of DR and DIO rats after consuming AIN-93G modified diets for 11-12 weeks, 
separated by phenotype. 
 
TLR Agonist* Phenotype IL-1β (pg/mL) 
Control  
(Unstimulated) 
DR 10.2 ± 3.4 
DIO 5.8 ± 2.3 
TLR2  
P3C 
DR 11.5 ± 4.3 
DIO 17.0 ± 8.8 
TLR4  
LPS 
DR 98.5 ± 12.8 
DIO 85.4 ± 14.7 
TLR5  
Flagellin 
DR 21.8 ± 11.1 
DIO 15.5 ± 5.1 
* In the DR phenotype, n = 60 for control, n = 39 for TLR2, n = 39 for TLR4 and n = 41 for TLR5 
stimulated blood cultures. In the DIO phenotype, n = 59 for control and n = 40 for TLR2, TLR4 and TLR5 

































Table 3-26a. IL-6 concentrations measured from TLR agonist-stimulated whole blood cultures of DR and DIO rats after consuming 
AIN-93G modified diets for 11-12 weeks.  
 
 IL-6 pg/mL*  
Control High Energy Diets Statistics - P value 
TLR 
Agonist** 
 AIN-93G AIN-93G Wheat Bran Oat Bran Resistant 
Starch II 
FOS Phenotype Diet Phenotype × 
Diet 
Control DR 17.3 ± 13.0 22.2 ± 10.1 2.6 ± 0.0 18.4 ± 9.9 31.2 ± 14.1 22.6 ± 
13.3 
0.921 0.377 0.768 
DIO 13.0 ± 8.5 11.5 ± 6.3 21.4 ± 10.7 7.0 ± 3.1 36.8 ± 16.6 20.7 ± 
16.1 
TLR2 P3C DR 25.9 ± 
15.4α 
12.1 ± 6.1 2.6 ± 0.0 24.8 ± 12.0 14.1 ± 5.3 33.1 ± 
27.4 
0.256 0.331 0.320 
DIO 10.8 ± 6.0β 15.0 ± 8.1 22.1 ± 12.9 2.6 ± 0.0 57.7 ± 28.8 2.6 ± 0.0 
TLR4 LPS DR 9.8 ± 6.1 35.0 ± 17.1α 5.3 ± 2.7 13.5 ± 10.9 25.3 ± 22.6 2.6 ± 0.0 0.888 0.404 0.134 
DIO 5.0 ± 2.4 2.6 ± 0.0β 37.2 ± 17.3 4.0 ± 1.4 26.2 ± 13.2 10.9 ± 8.3 
TLR5 
Flagellin 
DR 22.5 ± 14.6 15.5 ± 12.9 26.9 ± 24.3 27.5 ± 14.5 15.7 ± 9.6 8.8 ± 5.5 0.491 0.244 0.312 
DIO 2.6 ± 0.0 14.1 ± 8.4 17.5 ± 14.5 2.8 ± 0.2 39.4 ± 21.5 4.9 ± 2.3 
* IL-6 concentrations (pg/mL) are presented as mean ± SEM. Significance (P < 0.05) for phenotype, diet, and interaction between phenotype × diet was 
determined by two-way ANOVA. Superscripted letters denote significant differences between diets within a phenotype, and symbols denote significant 
differences between overall diet or overall phenotype as determined by Tukey’s multiple comparison test. 







Table 3-26b. IL-6 concentrations measured from TLR agonist-stimulated whole blood 
cultures of DR and DIO rats after consuming AIN-93G modified diets for 11-12 weeks, 
separated by phenotype.  
 
TLR Agonist* Phenotype IL-6 (pg/mL) 
Control  
(Unstimulated) 
DR 19.1 ± 4.5 
DIO 18.5 ± 4.6 
TLR2  
P3C 
DR 18.9 ± 6.0 
DIO 18.8 ± 7.1 
TLR4  
LPS 
DR 15.6 ± 5.2 
DIO 14.3 ± 4.2 
TLR5  
Flagellin 
DR 19.6 ± 5.7 
DIO 14.1 ± 4.9 
* In the DR phenotype, n = 60 for control, n = 39 for TLR2, n = 39 for TLR4 and n = 41 for TLR5 
stimulated blood cultures. In the DIO phenotype, n = 59 for control and n = 40 for TLR2, TLR4 and TLR5 
































Table 3-27a. IL-10 concentrations measured from TLR agonist-stimulated whole blood cultures of DR and DIO rats after consuming 
AIN-93G modified diets for 11-12 weeks, separated by phenotype.  
 
 IL-10 pg/mL*  
Control High Energy Diets Statistics - P value 
TLR 
Agonist** 
 AIN-93G AIN-93G Wheat Bran Oat Bran Resistant 
Starch II 
FOS Phenotype Diet Phenotype × 
Diet 
Control DR 1.4 ± 0.0 3.4 ± 1.9 1.4 ± 0.0 1.4 ± 0.0 1.4 ± 0.0 1.4 ± 0.0 0.800 0.588 0.233 
DIO 1.4 ± 0.0 1.4 ± 0.0 1.4 ± 0.0 2.5 ± 1.1 1.4 ± 0.0 3.0 ± 1.0 
TLR2 P3C DR 1.4 ± 0.0 6.9 ± 4.0 1.4 ± 0.0 8.4 ± 4.4 2.0 ± 0.6 1.4 ± 0.0 0.159 0.864 0.644 
DIO 1.4 ± 0.0 4.7 ± 3.3 10.9 ± 8.8 7.2 ± 5.8 18.4 ± 17.0 12.2 ± 8.7 
TLR4 LPS DR 8.1 ± 4.9α 13.9 ± 8.4αβ 3.1 ± 1.0αβ 15.3 ± 9.3α 46.0 ± 23.5β 1.4 ± 0.0α 0.987 0.019 0.841 
DIO 1.4 ± 0.0α 19.1 ± 
17.2αβ 
11.7 ± 6.6α 10.9 ± 7.0αβ 32.4 ± 17.0β 11.5 ± 5.4α 
TLR5 
Flagellin 
DR 3.9 ± 2.5 1.4 ± 0.0 1.4 ± 0.0 3.7 ± 2.2 1.43± 0.0 5.0 ± 3.5 0.183 0.363 0.780 
DIO 1.4 ± 0.0 5.8 ± 3.6 1.4 ± 0.0 8.6 ± 7.2 4.1 ± 2.7 13.0 ± 8.9 
* IL-10 concentrations (pg/mL) are presented as mean ± SEM. Significance (P < 0.05) for phenotype, diet, and interaction between phenotype × diet was 
determined by two-way ANOVA. Superscripted letters denote significant differences between diets within a phenotype, and symbols denote significant 
differences between overall diet or overall phenotype as determined by Tukey’s multiple comparison test. 












Table 3-27b. IL-10 concentrations measured from TLR agonist-stimulated whole blood 
cultures of DR and DIO rats after consuming AIN-93G modified diets for 11-12 weeks, 
separated by phenotype.  
 
TLR Agonist* Phenotype IL-10 (pg/mL) 
Control  
(Unstimulated) 
DR 1.8 ± 0.3 
DIO 1.9 ± 0.3 
TLR2  
P3C 
DR 3.6 ± 1.0 
DIO 9.0 ± 3.6 
TLR4  
LPS 
DR 14.5 ± 4.7 
DIO 14.0 ± 4.1 
TLR5  
Flagellin 
DR 2.8 ± 0.8 
DIO 5.8 ± 2.0 
* In the DR phenotype, n = 60 for control, n = 39 for TLR2, n = 39 for TLR4 and n = 41 for TLR5 
stimulated blood cultures. In the DIO phenotype, n = 59 for control and n = 40 for TLR2, TLR4 and TLR5 

































Table 3-28a. TNF-α concentrations measured from TLR agonist-stimulated whole blood cultures of DR and DIO rats after consuming 
AIN-93G modified diets for 11-12 weeks.  
 
 TNF-α pg/mL*  
Control High Energy Diets Statistics - P value 
TLR 
Agonist** 
 AIN-93G AIN-93G Wheat Bran Oat Bran Resistant 
Starch II 
FOS Phenotype Diet Phenotype × 
Diet 
Control DR 1.2 ± 0.4 0.8 ± 0.0 1.6 ± 0.8 0.8 ± 0.0 1.1 ± 0.3 0.8 ± 0.0α 0.205 0.172 0.143 
DIO 18.2 ± 
16.6ac 
1.5 ± 0.7ac 0.8 ± 0.0abc 2.5 ± 1.7ac 2.8 ± 2.0abc 12.3 ± 7.2bβ 
TLR2 P3C DR 2.1 ± 1.3 0.8 ± 0.0 0.8 ± 0.0 0.8 ± 0.0 5.6 ± 4.7 0.8 ± 0.0 0.235 0.535 0.955 
DIO 0.8 ± 0.0 2.1 ± 1.3 5.6 ± 4.8 4.7 ± 3.9 8.1 ± 7.3 2.9 ± 1.4 
TLR4 LPS DR 28.9 ± 10.2 2.6 ± 1.8α 8.4 ± 4.8 16.8 ± 12.7 4.5 ± 2.6α 13.0 ± 6.8 0.467 0.240 0.026 
DIO 10.9 ± 6.0ab 29.6 ± 
13.7abβ 
44.5 ± 39.5a 5.8 ± 3.5ab 39.6 ± 
17.8bβ 
20.6 ± 7.8b 
TLR5 
Flagellin 
DR 1.2 ± 0.4 0.8 ± 0.0 2.73 ± 1.9 0.8 ± 0.0 1.6 ± 0.8 0.8 ± 0.0 0.149 0.729 0.498 
DIO 0.8 ± 0.0 0.8 ± 0.0 0.8 ± 0.0 6.8 ± 6.0 5.1 ± 2.9 6.9 ± 6.1 
* TNF-α concentrations (pg/mL) are presented as mean ± SEM. Significance (P < 0.05) for phenotype, diet, and interaction between phenotype × diet was 
determined by two-way ANOVA. Superscripted letters denote significant differences between diets within a phenotype, and symbols denote significant 
differences between overall diet or overall phenotype as determined by Tukey’s multiple comparison test. 











Table 3-28b. TNF-α concentrations measured from TLR agonist-stimulated whole blood 
cultures of DR and DIO rats after consuming AIN-93G modified diets for 11-12 weeks, 
separated by phenotype.  
 
TLR Agonist* Phenotype TNF-α (pg/mL) 
Control  
(Unstimulated) 
DR 1.1 ± 0.2 
DIO 6.2 ± 2.8 
TLR2  
P3C 
DR 1.8 ± 0.8 
DIO 4.0 ± 1.6 
TLR4  
LPS 
DR 12.6 ± 3.4 
DIO 24.7 ± 7.7 
TLR5  
Flagellin 
DR 1.3 ± 0.4 
DIO 3.5 ± 1.5 
* In the DR phenotype, n = 60 for control, n = 39 for TLR2, n = 39 for TLR4 and n = 41 for TLR5 
stimulated blood cultures. In the DIO phenotype, n = 59 for control and n = 40 for TLR2, TLR4 and TLR5 

































Table 3-29a. Serum cytokines/chemokines, CRP, LPS, BUN and glucose concentrations of DR and DIO rats after consuming AIN-
93G modified diets for 11-12 weeks. 
 
 Control High Energy Diets Statistics - P value 
Measure*  AIN-93G AIN-93G Wheat 
Bran 
Oat Bran Resistant 
Starch II 








213.3 ± 29.8 159.5 ± 22.2 156.0 ± 25.7 154.3 ± 
23.8α 
0.123 0.132 0.121 








DR 20.6 ± 0.6 21.1 ± 1.0 19.9 ± 0.9 20.6 ± 0.6 19.8 ± 1.0α 19.9 ± 0.7 0.668 0.937 0.148 
DIO 19.7 ± 0.7 19.5 ± 0.5 20.3 ± 0.9 20.1 ± 0.5 22.2 ± 1.4β 21.4 ± 0.8 
CINC-3 
pg/mL 
DR 13.9 ± 0.5 14.6 ± 1.1 13.3 ± 0.6 16.2 ± 1.6α 12.9 ± 0.4α 13.5 ± 0.7 0.646 0.676 0.036 




DR 9.9 ± 0.6 8.7 ± 0.57α 10.4 ± 0.6 10.3 ± 0.8 10.6 ± 0.6 11.0 ± 0.9 0.068 0.311 0.044 








652.9 ± 46.2 641.5 ± 34.6 566.4 ± 61.6 612.1 ± 
42.4 
0.318 0.801 0.523 









DR 20.3 ± 1.5 20.7 ± 2.7 19.1 ± 1.5 20.2 ± 1.5 17.1 ± 1.9 20.5 ± 1.6 0.480 0.695 0.900 
DIO 21.2 ± 1.9 19.3 ± 2.0 20.9 ± 2.4 21.1 ± 1.7 19.7 ± 1.5 19.8 ± 1.6 










Table 3-29a continued. 
 
 Control High Energy Diets Statistics - P value 
Measure*  AIN-93G AIN-93G Wheat 
Bran 
Oat Bran Resistant 
Starch II 
FOS Phenotype Diet Phenotype 
× Diet 












0.731 0.043 0.737 






















0.766 0.299 0.670 












DR 7.4 ± 0.1aα 7.1 ± 0.4abβ 6.6 ± 0.2abβ 6.6 ± 0.2abβ 6.5 ± 0.1bβ 8.4 ± 0.2abβ 0.887 <0.001 0.389 
DIO 7.8 ± 0.2aα 6.6 ± 0.3bβ 6.9 ± 0.2abβ 6.5 ± 0.1bβ 6.6 ± 0.2bβ 6.4 ± 0.2bβ 
Glucose 
mmol/L 
DR 8.9 ± 0.3 8.7 ± 0.3 8.8 ± 0.3 8.6 ± 0.3 8.7 ± 0.3 6.7 ± 0.4 0.821 0.262 0.637 
DIO 8.8 ± 0.2 8.9 ± 0.5 9.1 ± 0.2 9.1 ± 0.3 8.2 ± 0.2 8.4 ± 0.3 
* Concentrations are presented as mean ± SEM, n = 10. Significance (P < 0.05) for phenotype, diet, and interaction between phenotype × diet was determined by 
two-way ANOVA. Superscripted letters denote significant differences between diets within a phenotype, and symbols denote significant differences between 
overall diet or overall phenotype as determined by Tukey’s multiple comparison test. 







Table 3-29b. Serum cytokine/chemokine, CRP, LPS, BUN and glucose concentrations of 
DR and DIO rats after consuming AIN-93G modified diets for 11-12 weeks, separated by 
phenotype.  
 
Measure* Phenotype Concentration 
CINC-1 
pg/mL 
DR 184.9 ± 11.7 
DIO 201.3 ± 10.6 
CINC-2αβ 
pg/mL 
DR 20.3 ± 0.3 
DIO 20.5 ± 0.4 
CINC-3 
pg/mL 
DR 14.1 ± 0.4 
DIO 14.3 ± 0.4 
sICAM-1/sCD54 
ng/mL 
DR 10.1 ± 0.3 
DIO 10.8 ± 0.3 
Active TGF-β1 
pg/mL 
DR 632.6 ± 20.5 
DIO 604.8 ± 18.0 
Total TGF-β1 
ng/mL 
DR 19.7 ± 0.7 
DIO 20.3 ± 0.7 
CRP 
µg/mL 
DR 405.8 ± 22.4 
DIO 406.8 ± 18.0 
LPS  
EU/mL 
DR 0.500 ± 0.019 
DIO 0.513 ± 0.023 
BUN 
mmol/L 
DR 6.8 ± 0.1 
DIO 6.8 ± 0.1 
Glucose 
mmol/L 
DR 8.7 ± 0.1 
DIO 8.7 ± 0.1 






















Table 3-30. Histological analysis of IEL counts in small bowel sections collected from DIO rats after consuming AIN-93G modified 
diets for 11-12 weeks. 
 
 Control High Energy Diets 1-way ANOVA 
Section* AIN-93G AIN-93G Wheat Bran Oat Bran Resistant Starch II FOS P value 
Duodenum 8.93 ± 1.19 7.33 ± 0.07 7.87 ± 1.57 7.20 ± 1.20 7.00 ± 1.42 8.73 ± 0.59 0.753 
Jejunum 6.93 ± 3.73 4.93 ± 2.53 12.13 ± 0.79 2.67 ± 2.67 3.47 ± 3.47 13.83 ± 3.28 0.086 
* IELs were enumerated per 100 villous enterocytes for 5 villi per section in the small bowel. Counts are presented as mean ± SEM, n = 5. Statistical analyses 
























Table 3-31a. Ileal tissue cytokine concentrations of DR and DIO rats after consuming AIN-93G modified diets for 11-12 weeks. 
 
 Control High Energy Diets Statistics - P value 
Measure*  AIN-93G AIN-93G Wheat 
Bran 
Oat Bran Resistant 
Starch II 
FOS Phenotype Diet Phenotype 
× Diet 
IL-1β ng/g DR 10.6 ± 2.5 9.7 ± 2.5 9.1 ± 2.3 11.1 ± 2.8 7.4 ± 1.5 8.3 ± 2.2 0.624 0.577 0.822 
DIO 9.1 ± 3.2 5.2 ± 2.2 8.4 ± 2.3 11.4 ± 2.5 7.6 ± 2.1 10.4 ± 2.0 
IL-6  
pg/g 












0.323 0.235 0.788 


















526.9 ± 67.3 243.3 ± 
49.7 
451.3 ± 85.2 0.232 0.219 0.509 
DIO 465.5 ± 
85.0 
295.0 ± 57.7 372.0 ± 
55.3 
406.2 ± 83.5 354.4 ± 
64.6 
338.8 ± 66.7 
IL-17F 
pg/g 






452.0 ± 85.1 449.4 ± 
57.6 
470.2 ± 103.0 0.421 0.833 0.689 
DIO 455.5 ± 
65.9 
333.8 ± 67.0 351.5 ± 
60.6 
554.6 ± 92.0 432.5 ± 
81.2 




DR 1.8 ± 0.7 1.9 ± 0.6 1.3 ± 0.2 1.3 ± 0.2 2.8 ± 0.5 1.8 ± 0.3 0.204 0.163 0.721 




DR 9.0 ± 0.5 8.5 ± 1.2 8.4 ± 0.8 9.8 ± 0.6 10.3 ± 0.9 9.3 ± 1.1 0.087 0.420 0.913 
DIO 10.0 ± 1.1 8.8 ± 1.4 9.8 ± 0.7 9.9 ± 0.7 10.7 ± 1.0 10.7 ± 0.9 
* Concentrations are presented as mean ± SEM, n = 10. Significance (P < 0.05) for phenotype, diet, and interaction between phenotype × diet was determined by 






Table 3-31b. Ileal tissue cytokine concentrations of DR and DIO rats after consuming 
AIN-93G modified diets for 11-12 weeks, separated by phenotype. 
 
Measure* Phenotype Concentration 
Il-1β 
ng/g 
DR 9.4 ± 0.9 
DIO 8.7 ± 1.0 
IL-6 
pg/g 
DR 1391.7 ± 105.4 
DIO 1244.1 ± 104.3 
IL-10 
pg/g 
DR 424.8 ± 34.1 
DIO 372.0 ± 28.1 
IL-17F 
pg/g 
DR 470.2 ± 36.1 
DIO 431.6 ± 29.6 
Active TGF-β1 
ng/mL 
DR 1.8 ± 0.2 
DIO 2.2 ± 0.2 
Total TGF-β1 
ng/mL 
DR 9.2 ± 0.4 
DIO 10.1 ± 0.4 
Protein Quantification 
by Bradford Assay 
mg/g 
DR 49.8 ± 1.8 
DIO 49.5 ± 1.8 




























Table 3-32a. Caecal tissue cytokine/chemokine concentrations of DR and DIO rats after consuming AIN-93G modified diets for 11-
12 weeks. 
 
 Control High Energy Diets Statistics - P value 
Measure*  AIN-93G AIN-93G Wheat Bran Oat Bran Resistant 
Starch II 








222.6 ± 32.5 205.4 ± 30.3 164.5 ± 21.3 191.9 ± 
30.2 
0.880 0.604 0.834 


















0.597 0.014 0.638 








DR 7.4 ± 1.7 26.6 ± 12.3 29.9 ± 15.1 37.3 ± 13.0 6.2 ± 1.3 5.1 ± 0.2 0.296 0.111 0.372 
DIO 13.8 ± 5.6 18.9 ± 9.9 12.4 ± 7.5 15.4 ± 10.5 6.0 ± 1.1 15.3 ± 6.9 
GM-CSF 
pg/g 
DR 95.5 ± 32.0 102.6 ± 
35.2 
64.3 ± 25.1 73.2 ± 23.4 67.2 ± 28.3 102.6 ± 
30.3 
0.775 0.617 0.357 















0.291 0.003 0.523 


















251.2 ± 67.7 277.8 ± 61.8 141.7 ± 35.4 299.6 ± 
73.8 
0.467 0.813 0.704 




290.4 ± 74.3 194.7 ± 50.6 222.4 ± 59.7 244.9 ± 
60.3 







Table 3-32a continued. 
 
 Control High Energy Diets Statistics - P value 
Measure*  AIN-93G AIN-93G Wheat Bran Oat Bran Resistant 
Starch II 








215.0 ± 84.5 203.0 ± 82.2 125.9± 48.4 201.2 ± 
72.2 
0.752 0.436 0.680 












174.7 ± 52.2 149.4 ± 38.5 209.0 ± 58.0 221.6 ± 
87.6 
0.431 0.359 0.459 













767.6 ± 79.0 917.2 ± 
113.4 
873.7 ± 84.7 992.5 ± 
53.3 
0.713 0.212 0.799 





















0.047 0.379 0.813 












* Concentrations are presented as mean ± SEM, n = 10. Significance (P < 0.05) for phenotype, diet, and interaction between phenotype × diet was determined by 
two-way ANOVA. Superscripted letters denote significant differences between diets within a phenotype, and symbols denote significant differences between 










Table 3-32b. Caecal tissue cytokine/chemokine concentrations of DR and DIO rats after 
consuming AIN-93G modified diets for 11-12 weeks, separated by phenotype.  
 
Measure* Phenotype Concentration 
CINC-1 
pg/g 
DR 205.5 ± 12.4 
DIO 202.8 ± 12.7 
CINC-2αβ 
pg/g 
DR 278.7 ± 24.8 
DIO 235.9 ± 17.7 
CINC-3 
pg/g 
DR 18.8 ± 4.1 
DIO 13.5 ± 3.0 
GM-CSF 
pg/g 
DR 84.2 ± 11.6 
DIO 79.4 ± 12.4 
IL-6 
pg/g 
DR 723.1 ± 89.1 
DIO 548.7 ± 54.8 
IL-10 
pg/g 
DR 269.1 ± 31.7 
DIO 239.7 ± 25.0 
IL-17F 
pg/g 
DR 185.4 ± 29.7 
DIO 199.3 ± 32.1 
IL-22 
pg/g 
DR 165.2 ± 21.5 
DIO 170.5 ± 16.20 
Active TGF-β1 
pg/mL 
DR 879.4 ± 35.2 
DIO 898.9 ± 39.5 
Total TGF-β1 
pg/mL 
DR 5878.3 ± 155.4 
DIO 6349.8 ± 173.0 
Protein Quantification by 
Bradford Assay 
mg/g 
DR 37.0 ± 1.2 
DIO 38.2 ± 1.0 




















Table 3-33a. Proximal colon cytokine concentrations of DR and DIO rats after consuming AIN-93G modified diets for 11-12 weeks. 
 
 Control High Energy Diets Statistics - P value 
Measure*  AIN-93G AIN-93G Wheat 
Bran 
Oat Bran Resistant 
Starch II 
















0.612 0.060  0.016 


























0.879 0.793 0.182 










927.4 ± 145.0 
IL-17F 
pg/g 




336.0 ± 48.1 413.0 ± 49.6 275.1 ± 48.9 343.0 ± 57.9 0.737 0.110 0.255 










197.3 ± 45.5b 
TNF-α 
pg/g 




192.2 ± 43.4 180.5 ± 27.4 149.4 ± 41.3 156.6 ± 36.6 0.764 0.458 0.422 












868.9 ± 76.9 972.0 ± 57.9 787.6 ± 
89.7α 
1001.1 ± 57.9 0.694 0.883 0.312 




956.0 ± 78.8 911.5 ± 61.9 993.2 ± 
70.2β 
937.4 ± 91.1 









Table 3-33a continued. 
 
 Control High Energy Diets Statistics - P value 
Measure*  AIN-93G AIN-93G Wheat 
Bran 
Oat Bran Resistant 
Starch II 

















0.433 0.823 0.357 












* Concentrations are presented as mean ± SEM, n = 10. Significance (P < 0.05) for phenotype, diet, and interaction between phenotype × diet was determined by 
two-way ANOVA. Superscripted letters denote significant differences between diets within a phenotype, and symbols denote significant differences between 






















Table 3-33b. Proximal colon cytokine concentrations of DR and DIO rats after 
consuming AIN-93G modified diets for 11-12 weeks, separated by phenotype.  
 
Measure Phenotype Concentration 
IL-6 
pg/g 
DR 1432.3 ± 67.5 
DIO 1484.7 ± 86.2 
IL-10 
pg/g 
DR 1228.4 ± 69.3 
DIO 1213.1 ± 72.7 
IL-17F 
pg/g 
DR 348.8 ± 22.0 
DIO 338.2 ± 23.6 
TNF-α 
pg/g 
DR 168.0 ± 16.5 
DIO 175.3 ± 17.6 
Active TGF-β1 
pg/mL 
DR 922.9 ± 28.1 
DIO 938.9 ± 28.5 
Total TGF-β1 
pg/mL 
DR 4317.7 ± 142.1 
DIO 4551.9 ± 173.2 
Protein Quantification 
by Bradford Assay 
mg/g 
DR 50.1 ± 1.6 
DIO 49.0 ± 1.2 




























Table 3-34a. Distal colon tissue cytokine concentrations of DR and DIO rats after consuming AIN-93G modified diets for 11-12 
weeks. 
 
 Control High Energy Diets Statistics - P value 
Measure  AIN-93G AIN-93G Wheat Bran Oat Bran Resistant 
Starch II 
















0.778 0.963 0.445 
























0.954 0.972 0.108 
















476.8 ± 86.2 506.1 ± 
80.3 
354.9 ± 58.6 439.3 ± 79.2 0.552 0.305 0.227 




602.0 ± 70.1 331.6 ± 
62.7 
385.7 ± 62.2 475.5 ± 74.4 
IL-22 
pg/g 








194.0 ± 36.6 0.924 0.155 0.192 








239.8 ± 64.7 
TNF-α 
pg/g 




281.9 ± 42.2 212.8 ± 
19.9 
159.1 ± 40.9 220.4 ± 71.8 0.903 0.444 0.341 




206.7 ± 24.7 216.2 ± 
73.9 
196.3 ± 53.3 197.8 ± 39.8 








Table 3-34a continued. 
 
 Control High Energy Diets Statistics - P value 
Measure  AIN-93G AIN-93G Wheat Bran Oat Bran Resistant 
Starch II 















0.361 0.435 0.173 

























0.753 0.096 0.089 












* Concentrations are presented as mean ± SEM, n = 10. Significance (P < 0.05) for phenotype, diet, and interaction between phenotype × diet was determined by 
two-way ANOVA. Superscripted letters denote significant differences between diets within a phenotype, and symbols denote significant differences between 


















Table 3-34b. Distal colon tissue cytokine concentrations of DR and DIO rats after 
consuming AIN-93G modified diets for 11-12 weeks, separated by phenotype.  
 
Measure Phenotype Concentration 
IL-6 
pg/g 
DR 2012.2 ± 129.3 
DIO 2071.3 ± 159.4 
IL-10 
pg/g 
DR 703.5 ± 79.2 
DIO 697.2 ± 75.0 
IL-17F 
pg/g 
DR 443.8 ± 31.6 
DIO 469.8 ± 30.8 
IL-22 
pg/g 
DR 165.3 ± 11.9 
DIO 169.9 ± 14.3 
TNF-α 
pg/g 
DR 215.7 ± 19.3 
DIO 208.5 ± 19.9 
Active TGF-β1 
pg/mL 
DR 1496.4 ± 27.7 
DIO 1457.1 ± 33.2 
Total TGF-β1 
pg/mL 
DR 3601.2 ± 112.4 
DIO 3652.7 ± 126.7 
Protein Quantification 
by Bradford Assay 
mg/g 
DR 40.0 ± 1.0 
DIO 41.0 ± 1.0 



























Table 3-35a. Liver cytokine/chemokine and CRP concentrations of DR and DIO rats after consuming AIN-93G modified diets for 11-
12 weeks. 
 
 Control High Energy Diets Statistics - P value 
Measure  AIN-93G AIN-93G Wheat Bran Oat Bran Resistant 
Starch II 




DR 5.8 ± 0.5 10.0 ± 1.4 7.4 ± 0.8 9.8 ± 1.3 8.3 ± 0.9 7.2 ± 0.4 0.423 0.081 0.835 
DIO 7.6 ± 0.7 8.8 ± 1.3 8.2 ± 1.1 9.7 ± 2.2 9.3 ± 1.4 8.2 ± 0.5 
CINC-2αβ 
ng/g 
DR 18.7 ± 
1.2aαγ 
25.8 ± 2.6bβ 21.6 ± 1.3abαβ 26.7 ± 2.1bβ 23.7 ± 1.9bβ 21.6 ± 
1.3abαβ 
0.569 0.005 0.221 
DIO 21.8 ± 1.2αδ 22.8 ± 0.8β 22.4 ± 1.3αβ 25.4 ± 3.8β 25.8 ± 2.5β 21.1 ± 0.9αβ 
CINC-3 
ng/g 
DR 7.9 ± 1.4 9.8 ± 1.9 7.0 ± 1.4 9.6 ± 2.0 8.1 ± 1.6 10.8 ± 0.8 0.563 0.415 0.440 
DIO 6.5 ± 1.5 9.5 ± 1.7 9.5 ± 1.3 10.5 ± 2.3 11.7 ± 1.3 8.6 ± 1.4 
CRP  
µg/g 
DR 65.8 ± 5.1α 70.2 ± 7.7 64.8 ± 5.6 63.0 ± 6.7 57.2 ± 4.4 66.9 ± 2.8 0.409 0.140 0.488 
DIO 84.9 ± 
13.6aβ 
65.2 ± 4.4ab 69.6 ± 4.7ab 65.4 ± 3.2ab 56.8 ± 5.6b 64.4 ± 6.2ab 
IFN-γ ng/g DR 31.8 ± 4.5 44.2 ± 5.8 36.1 ± 5.2 39.9 ± 6.8 39.3 ± 4.2 48.1 ± 8.0 0.502 0.250 0.635 
DIO 33.2 ± 8.1 34.7 ± 5.0 38.1 ± 5.6 42.5 ± 4.5 42.7 ± 3.4 33.8 ± 4.1 
IL-1β  
ng/g 












0.502 0.046 0.724 












DR 52.1 ± 7.3 66.9 ± 7.7 59.6 ± 8.9 68.8 ± 11.2 62.2 ± 5.8 69.8 ± 13.6 0.605 0.375 0.861 
DIO 55.40 ± 
11.0 
56.1 ± 7.8 62.9 ± 9.6 69.2 ± 6.4 66.6 ± 7.8 51.4 ± 7.4 









Table 3-35a continued. 
 
 Control High Energy Diets Statistics - P value 
Measure  AIN-93G AIN-93G Wheat Bran Oat Bran Resistant 
Starch II 








188.4 ± 29.9 20.0 ± 34.0 180.3 ± 19.6 194.5 ± 
40.7 
0.681 0.334 0.918 




193.6 ± 34.3 196.4 ± 
18.1 




DR 34.1 ± 3.3 39.5 ± 2.8 41.6 ± 2.9 41.5 ± 4.0 41.7 ± 2.9 41.1 ± 4.1 0.328 0.172 0.975 
DIO 34.6 ± 4.4 36.4 ± 2.7 41.2 ± 3.4 42.3 ± 4.5 39.3 ± 3.8 35.9 ± 2.9 
TNF-α 
pg/g 












0.911 0.250 0.498 



























0.215 0.443 0.845 



























0.383 0.562 0.848 












* Concentrations are presented as mean ± SEM, n = 10. Significance (P < 0.05) for phenotype, diet, and interaction between phenotype × diet was determined by 
two-way ANOVA. Superscripted letters denote significant differences between diets within a phenotype, and symbols denote significant differences between 







Table 3-35b. Liver cytokine/chemokine and CRP concentrations of DR and DIO rats 
after consuming AIN-93G modified diets for 11-12 weeks, separated by phenotype.  
 
Measure Phenotype Concentration 
CINC-1 
ng/g 
DR 8.1 ± 0.4 
DIO 8.6 ± 0.5 
CINC-2αβ 
ng/g 
DR 23.0 ± 0.8 
DIO 23.2 ± 0.8 
CINC-3 
ng/g 
DR 8.9 ± 0.6 
DIO 9.4 ± 0.7 
CRP 
µg/g 
DR 64.6 ± 2.2 
DIO 67.7 ± 3.0 
IFN-γ 
ng/g 
DR 39.9 ± 2.4 
DIO 37.5 ± 2.1 
IL-1β 
ng/g 
DR 142.9 ± 6.1 
DIO 136.3 ± 5.4 
IL-4 
ng/g 
DR 63.2 ± 3.8 
DIO 60.3 ± 3.4 
IL-6 
pg/g 
DR 184.8 ± 11.5 
DIO 177.7 ± 10.7 
IL-10 
pg/g 
DR 39.9 ± 1.4 
DIO 38.3 ± 1.5 
TNF-α 
pg/g 
DR 7117.9 ± 236.7 
DIO 7155.2 ± 234.9 
Active TGF-β1 
ng/mL 
DR 2805.8 ± 85.7 
DIO 2664.7 ± 80.7 
Total TGF-β1 
ng/mL 
DR 3262.0 ± 79.8 
DIO 3148.0 ± 99.8 
Protein Quantification by 
Bradford Assay 
mg/g 
DR 113.9 ± 2.7 
DIO 108.7 ± 2.8 

















Table 3-36a. Spleen cytokine/chemokine concentrations of DR and DIO rats after consuming AIN-93G modified diets for 11-12 
weeks. 
  
 Control High Energy Diets Statistics - P value 
Measure  AIN-93G AIN-93G Wheat 
Bran 
Oat Bran Resistant 
Starch II 
















0.645 0.499 0.564 


























0.833 0.953 0.381 




















368.9 ± 46.2 265.2 ± 31.8 255.4 ± 24.7 0.181 0.458 0.311 






292.2 ± 27.9 289.5 ± 45.5 280.7 ± 33.3 
GM-CSF 
pg/g 












0.479 0.017 0.371 




















406.2 ± 97.2 661.1 ± 
124.2 
0.643 0.688 0.552 












DR 60.1 ± 3.3 57.9 ± 4.2 66.0 ± 5.8 62.7 ± 5.2 66.8 ± 3.9 61.8 ± 5.6 0.504 0.705 0.598 
DIO 69.9 ± 6.8 68.8 ± 8.7 66.9 ± 7.7 64.4 ± 6.9 65.4 ± 5.4 53.6 ± 5.0 






Table 3-36a continued.  
 
 Control High Energy Diets Statistics - P value 
Measure  AIN-93G AIN-93G Wheat 
Bran 
Oat Bran Resistant 
Starch II 








185.1 ± 59.6 197.7 ± 56.9 117.1 ± 55.8 0.516 0.669 0.729 
DIO 152.6 ± 
59.5 
74.9 ± 37.9 115.8 ± 
35.7 
141.6 ± 60.5 192.9 ± 65.6 126.0 ± 55.8 
IL-6  
pg/g 












0.381 0.125 0.260 




















650.1 ± 88.5 574.4 ± 90.0 549.7 ± 80.9 0.447 0.798 0.838 






593.4 ± 78.6 563.2 ± 81.4 568.9 ± 65.9 
TNF-α 
pg/g 






289.1 ± 74.1 300.4 ± 45.6 212.0 ± 51.0 0.254 0.868 0.209 










DR 8.4 ± 1.4 6.9 ± 0.8 6.4 ± 0.8 7.5 ± 0.9 7.0 ± 1.0 7.4 ± 0.8 0.971 0.721 0.973 




DR 86.3 ± 10.6 78.4 ± 10.4 91.0 ± 9.6 92.4 ± 10.6 78.4 ± 8.9 81.0 ± 11.6 0.351 0.269 0.456 
DIO 96.0 ± 8.4 94.8 ± 10.9 111.5 ± 9.7 74.4 ± 7.3 76.48 ± 10.0 87.3 ± 12.5 
* Concentrations are presented as mean ± SEM, n = 10. Significance (P < 0.05) for phenotype, diet, and interaction between phenotype × diet was determined by 
two-way ANOVA. Superscripted letters denote significant differences between diets within a phenotype, and symbols denote significant differences between 
overall diet or overall phenotype as determined by Tukey’s multiple comparison test. 
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Table 3-36b. Spleen cytokine/chemokine concentrations of DR and DIO rats after 
consuming AIN-93G modified diets for 11-12 weeks, separated by phenotype.  
 
Measure Phenotype Concentration 
CINC-1 
pg/g 
DR 1444.2 ± 57.3 
DIO 1393.4 ± 43.2 
CINC-2αβ 
pg/g 
DR 1439.7 ± 55.8 
DIO 1456.6 ± 55.8 
CINC-3 
pg/g 
DR 306.3 ± 15.7 
DIO 280.3 ± 15.5 
GM-CSF 
pg/g 
DR 118.4 ± 11.5 
DIO 108.4 ± 12.3 
IFN-γ 
ng/g 
DR 531.4 ± 47.2 
DIO 563.1 ± 48.0 
IL-1β 
ng/g 
DR 62.6 ± 1.9 
DIO 64.8 ± 2.8 
IL-4 
ng/g 
DR 154.2 ± 21.6 
DIO 134.0 ± 21.5 
IL-6 
pg/g 
DR 1153.1 ± 149.2 
DIO 1387.2 ± 227.6 
IL-10 
pg/g 
DR 597.2 ± 33.4 
DIO 562.4 ± 29.4 
TNF-α 
pg/g 
DR 285.3 ± 25.3 
DIO 246.4 ± 22.3 
Active TGF-β1 
ng/mL 
DR 7.3 ± 0.4 
DIO 7.2 ± 0.4 
Total TGF-β1 
ng/mL 
DR 84.6 ± 4.1 
DIO 90.1 ± 4.2 
Protein Quantification by 
Bradford Assay 
mg/g 
DR 52.6 ± 1.5 
DIO 56.2 ± 1.6 

















Table 3-37a. MLN cytokine/chemokine concentrations of DR and DIO rats after consuming AIN-93G modified diets for 11-12 
weeks. 
 
 Control High Energy Diets Statistics - P value 
Measure  AIN-93G AIN-93G Wheat 
Bran 
Oat Bran Resistant 
Starch II 




DR 26.9 ± 7.4α 33.1 ± 5.7 24.6 ± 4.8 37.2 ± 6.8 40.9 ± 5.3 35.8 ± 4.4 0.233 0.760 0.064 
DIO 46.2 ± 7.6β 38.2 ± 6.0 36.6 ± 3.0 29.4 ± 5.2 29.4 ± 4.1 41.6 ± 3.2 
CINC-3 
pg/g 
DR 62.7 ± 10.3 74.9 ± 11.2α 141.9 ± 86.8 43.7 ± 13.2 51.0 ± 11.5 45.0 ± 8.7 0.005 0.597 0.257 
DIO 50.3 ± 17.9 31.1 ± 1.4β 45.1 ± 8.7 43.0 ± 11.9 42.8 ± 7.7 32.7 ± 2.3 
GM-CSF 
pg/g 
DR 28.0 ± 6.0 27.3 ± 5.1 26.3 ± 3.6 29.0 ± 4.9 23.8 ± 3.9 29.3 ± 5.6 0.401 0.685 0.887 




DR 32.5 ± 4.9 23.6 ± 4.0 32.1 ± 7.0 26.0 ± 6.2 14.3 ± 3.4 21.2 ± 5.4 0.621 0.099 0.582 
DIO 23.9 ± 4.3 27.2 ± 6.9 27.3 ± 4.8 25.8 ± 4.7 21.8 ± 3.2 15.2 ± 3.2 












0.112 0.215 0.218 


























0.318 0.602 0.072 














DR 173.6 ± 44.6 151.4 ± 21.4 149.0 ± 24.2 155.7 ± 11.8 180.5 ± 31.5 208.0 ± 
36.7 
0.601 0.193 0.285 



















Table 3-37a continued. 
 
 Control High Energy Diets Statistics - P value 
Measure  AIN-93G AIN-93G Wheat 
Bran 
Oat Bran Resistant 
Starch II 




DR 31.7 ± 8.8 47.7 ± 10.5 31.8 ± 9.1 33.3 ± 10.0 48.1 ± 3.4 33.0 ± 10.1 0.487 0.771 0.273 
DIO 48.5 ± 9.7 28.6 ± 11.0 27.6 ± 7.8 38.7 ± 8.2 29.5 ± 6.2 30.8 ± 9.6 
IL-6  
pg/g 












0.664 0.398 0.224 














DR 26.3 ± 4.0α 34.2 ± 8.2 20.6 ± 1.7 32.0 ± 6.9 27.7 ± 3.0 23.5 ± 2.8 0.518 0.144 0.231 
DIO 50.7 ± 
10.8aβ 
27.9 ± 6.6ab 22.3 ± 2.8b 28.6 ± 2.4ab 22.5 ± 3.0ab 28.6 ± 5.3ab 
TNF-α 
pg/g 
DR 137.7 ± 41.2 165.9 ± 41.7 199.8 ± 40.2 160.4 ± 41.1 103.9 ± 34.2 143.9 ± 
53.4 
0.092 0.508 0.529 
DIO 172.1 ± 71.8 140.7 ± 50.8 184.3 ± 45.2 90.5 ± 35.5 125.1 ± 43.1 111.8 ± 
39.3 
* Concentrations are presented as mean ± SEM, n = 5. Significance (P < 0.05) for phenotype, diet, and interaction between phenotype × diet was determined by 
two-way ANOVA. Superscripted letters denote significant differences between diets within a phenotype, and symbols denote significant differences between 











Table 3-37b. MLN cytokine/chemokine concentrations of DR and DIO rats after 
consuming AIN-93G modified diets for 11-12 weeks, separated by phenotype.  
 
Measure* Phenotype Concentration 
CINC-2αβ 
pg/g 
DR 33.1 ± 2.4 
DIO 36.9 ± 2.2 
CINC-3 
pg/g 
DR 69.9 ± 15.1 
DIO 40.8 ± 3.9 
GM-CSF 
pg/g 
DR 27.3 ± 1.9 
DIO 24.9 ± 2.0 
sICAM-1/sCD54 
withng/g 
DR 24.9 ± 2.3 
DIO 23.5 ± 1.9 
IFN-γ 
ng/g 
DR 1359.9 ± 137.2 
DIO 1127.1 ± 187.0 
IL-1β 
ng/g 
DR 1745.6 ± 119.6 
DIO 1590.3 ± 106.0 
IL-2 
pg/g 
DR 169.7 ± 11.9 
DIO 178.4± 12.3 
IL-4 
ng/g 
DR 37.6 ± 3.6 
DIO 33.9 ± 3.6 
IL-6 
pg/g 
DR 2461.9 ± 450.5 
DIO 1726.2 ± 127.3 
IL-10 
pg/g 
DR 27.4 ± 2.1 
DIO 30.1 ± 2.8 
TNF-α 
pg/g 
DR 151.9 ± 16.7 
DIO 137.4 ± 19.2 





* n = 30 for DR and DIO rats. 

















Table 3-38a. Ileal PP cytokine/chemokine concentrations of DR and DIO rats after consuming AIN-93G modified diets for 11-12 
weeks. 
 
 Control High Energy Diets Statistics - P value 
Measure  AIN-93G AIN-93G Wheat Bran Oat Bran Resistant 
Starch II 




DR 23.0 ± 3.1αβ 16.0 ± 2.5α 15.8 ± 1.8αβ 29.8 ± 11.0β 21.8 ± 4.0αβ 15.2 ± 4.0α 0.038 0.007 0.672 
DIO 22.2 ± 
5.6abαβ 






DR 68.0 ± 47.0 32.3 ± 7.9 24.9 ± 2.3 32.9 ± 7.0 25.1 ± 1.3 24.0 ± 1.7 0.601 0.214 0.172 
DIO 19.8 ± 4.9 23.0 ± 3.3 22.9 ± 0.9 148.4 ± 94.3 26.5 ± 1.3 22.4 ± 2.5 
GM-CSF 
pg/g 
DR 20.4 ± 3.9 16.9 ± 4.6 16.0 ± 1.6 19.3 ± 4.4 19.7 ± 4.9 22.9 ± 9.8 0.492 0.921 0.956 




DR 29.3 ± 7.2 24.4 ± 5.4 24.0 ± 5.0 28.7 ± 3.7 20.2 ± 2.4 18.6 ± 2.5 0.976 0.889 0.681 
DIO 29.0 ± 8.4 21.0 ± 4.2 21.8 ± 5.6 26.5 ± 5.0 23.9 ± 3.4 32.4 ± 8.5 










0.459 0.088 0.988 






















0.929 0.545 0.417 


















Table 3-38a continued. 
 
 Control High Energy Diets Statistics - P value 
Measure  AIN-93G AIN-93G Wheat Bran Oat Bran Resistant 
Starch II 




DR 84.3 ± 23.5 72.7 ± 32.2 69.8 ± 27.8 66.2 ± 18.2 74.7 ± 28.4 65.7 ± 28.7 0.390 0.928 0.886 
DIO 87.6 ± 24.2 92.9 ± 32.0 70.5 ± 32.3 124.0 ± 39.0 67.9 ± 24.0 75.2 ± 20.8 
IL-4  
pg/g 
DR 13.4 ± 1.6 12.4 ± 2.0 13.1 ± 2.5 15.9 ± 2.4 13.9 ± 2.6 13.8 ± 2.1 0.400 0.565 0.753 
DIO 25.9 ± 15.6 11.3 ± 2.8 12.8 ± 2.0 24.1 ± 10.7 12.0 ± 1.3 13.5 ± 2.6 
IL-6  
pg/g 










0.676 0.105 0.105 












DR 12.4 ± 1.8 13.4 ± 1.1 12.5 ± 1.7 16.6 ± 1.8 18.8 ± 4.1 17.2 ± 2.9 0.151 0.496 0.446 
DIO 12.8 ± 2.1 10.7 ± 2.1 15.7 ± 1.9 13.4 ± 3.0 12.9 ± 2.8 13.7 ± 0.8 
TNF-α 
pg/g 




0.307 0.110 0.579 
DIO 148.6 ± 
26.5 




* Concentrations are presented as mean ± SEM, n = 5. Significance (P < 0.05) for phenotype, diet, and interaction between phenotype × diet was determined by 
two-way ANOVA. Superscripted letters denote significant differences between diets within a phenotype, and symbols denote significant differences between 
overall diet or overall phenotype as determined by Tukey’s multiple comparison test. 








Table 3-38b. Ileal PP cytokine/chemokine concentrations of DR and DIO rats after 
consuming AIN-93G modified diets for 11-12 weeks, separated by phenotype. 
 
Measure* Phenotype Concentration 
CINC-2αβ 
pg/g 
DR 20.3 ± 2.2 
DIO 25.4 ± 2.4 
CINC-3 
pg/g 
DR 34.5 ± 7.9 
DIO 43.9 ± 16.8 
GM-CSF 
pg/g 
DR 19.2 ± 2.1 
DIO 21.4 ± 2.1 
sICAM-1/sCD54 
ng/g 
DR 24.2 ± 1.9 
DIO 25.8 ± 2.4 
IFN-γ 
ng/g 
DR 777.7 ± 459.0 
DIO 896.9 ± 379.4 
IL-1β 
ng/g 
DR 708.8 ± 103.6 
DIO 637.7 ± 89.6 
IL-2 
pg/g 
DR 72.2 ± 10.0 
DIO 86.3 ± 11.5 
IL-4 
ng/g 
DR 13.8 ± 0.9 
DIO 16. ± 3.2 
IL-6 
pg/g 
DR 553.8 ± 70.9 
DIO 529.8 ± 66.7 
IL-10 
pg/g 
DR 15.2 ± 1.0 
DIO 13.2 ± 0.9 
TNF-α 
pg/g 
DR 126.4 ± 10.3 
DIO 143.4 ± 11.7 





* n = 30 for DR and DIO rats. 

















Table 3-39a. Epididymal fat cytokine/chemokine concentrations of DR and DIO rats after consuming AIN-93G modified diets for 11-
12 weeks. 
 
 Control High Energy Diets Statistics - P value 
Measure  AIN-93G AIN-93G Wheat 
Bran 
Oat Bran Resistant 
Starch II 








201.5 ± 52.4 221.3 ± 52.1 215.1 ± 45.8 105.6 ± 
31.9 
0.113 0.403 0.202 




















0.260 0.449 0.194 
















287.9 ± 77.8 289.4 ± 80.5 366.8 ± 87.5 227.9 ± 
75.3 
0.274 0.554 0.434 
















733. ± 96.2 582.8 ± 
126.2 
0.461 0.476 0.578 


























0.434 0.888 0.150 




















0.385 0.612 0.399 














Table 3-39a continued. 
 
 Control High Energy Diets Statistics - P value 
Measure  AIN-93G AIN-93G Wheat 
Bran 
Oat Bran Resistant 
Starch II 




DR 19.5 ± 
0.0α 
19.5 ± 0.0 19.5 ± 0.0 19.5 ± 0.0 19.5 ± 0.0 29.8 ± 10.4 0.141 0.418 0.363 
DIO 40.2 ± 
14.5β 
19.5 ± 0.0 34.9 ± 13.2 19.5 ± 0.0 21.5 ± 2.1 25.8 ± 6.4 
Active TGF-
β1 pg/g 












0.292 0.012 0.133 


























0.262 0.026 0.830 












* Concentrations are presented as mean ± SEM, n = 10. Significance (P < 0.05) for phenotype, diet, and interaction between phenotype × diet was determined by 
two-way ANOVA. Superscripted letters denote significant differences between diets within a phenotype, and symbols denote significant differences between 









Table 3-39b. Epididymal fat cytokine/chemokine concentrations of DR and DIO rats 
after consuming AIN-93G modified diets for 11-12 weeks, separated by phenotype.  
 
Measure* Phenotype Concentration 
CINC-1 
pg/g 
DR 178.7 ± 17.0 
DIO 148.6 ± 18.0 
CINC-2 
pg/g 
DR 727.6 ± 55.6 
DIO 633.5 ± 62.9 
CINC-3 
pg/g 
DR 284.2 ± 29.3 
DIO 227.9 ± 28.2 
IL-1β 
pg/g 
DR 665.0 ± 46.0 
DIO 720.1 ± 57.8 
IL-6 
pg/g 
DR 811.4 ± 73.1 
DIO 732.8 ± 68.1 
IL-10 
pg/g 
DR 731.9 ± 55.5 
DIO 661.6 ± 48.8 
TNF-α 
pg/g 
DR 21.2 ± 1.7 
DIO 26.9 ± 3.5 
Active TGF-β1 
pg/mL 
DR 1365.4 ± 69.2 
DIO 1280.2 ± 58.1 
Total TGF-β1 
pg/mL 
DR 2356.3 ± 115.1 
DIO 2201.7 ± 80.3 
Protein Quantification 
by Bradford Assay 
mg/g 
DR 7.0 ± 0.5 
DIO 7.1 ± 0.5 
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Figure 3-1. Rat weight gain and food consumption during the two-week preliminary trial 
on the HE control diet. Significance (P < 0.05) for phenotype was determined by one-way 
ANOVA. a. Weight gained; rats in the upper 40% weight gain were considered DIO (n = 
70), rats in the lower 40% weight gain were considered DR (n = 70), and rats in the middle 
were labelled as MID (n = 36). Phenotypes were significantly different from each other (P 
< 0.001) and bars with differing letters represent differences between phenotypes. b. 
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Figure 3-2. Serum leptin (pg/mL) and tissue leptin (pg/g) concentrations measured in rats 
from the preliminary trial. Statistical analyses were performed using unpaired t-tests (n = 
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Figure 3-3. Weight gained after rats consumed AIN-93G modified diets for 11-12 weeks. 
Significance (P < 0.05) for phenotype, diet, and interaction between phenotype × diet was 
determined by two-way ANOVA. a. Weight gain separated by diet (n = 10), * denotes a 
significant difference between DR and DIO rats on a specific diet, and bars with differing 
letters represent significant differences between diets overall as determined by Tukey’s 
multiple comparison test. b. Weight gain separated by phenotype only (n = 60). DIO rats 
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Figure 3-4. Average daily food consumption of AIN-93G modified diets over 11-12 
weeks. Significance (P < 0.05) for phenotype, diet, and interaction between phenotype × 
diet was determined by two-way ANOVA. a. Food consumption separated by diet group 
(n = 10), * denotes a significant difference between phenotypes on specific diets, and bars 
with differing letters represent significant differences between diets overall as determined 
by Tukey’s multiple comparison test. b. Food consumption separated by phenotype only 
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Figure 3-5. Serum glucagon concentrations measured in rats after consuming AIN-93G 
modified diets for 11-12 weeks. Significance (P < 0.05) for phenotype, diet, and interaction 
between phenotype × diet was determined by two-way ANOVA. a. Serum glucagon 
concentrations separated by diet group (n = 5), Bars with differing letters represent 
significant differences between diets overall as determined by Tukey’s multiple 
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Figure 3-6. Serum insulin concentrations measured in rats after consuming AIN-93G 
modified diets for 11-12 weeks. Significance (P < 0.05) for phenotype, diet, and interaction 
between phenotype × diet was determined by two-way ANOVA. a. Insulin concentrations 
separated by diet group (n = 5), * denotes a significant difference between DR and DIO 
rats on the HE oat bran diet (P = 0.032). b. Insulin concentrations separated by phenotype 
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Figure 3-7. Serum leptin concentrations measured in rats after consuming AIN-93G 
modified diets for 11-12 weeks. Significance (P < 0.05) for phenotype, diet, and interaction 
between phenotype × diet was determined by two-way ANOVA. a. Leptin concentration 
separated by diet group (n = 5), * denotes a significant difference between DR and DIO 
rats on the control diet (P = 0.004). b. Leptin concentrations separated by phenotype (n = 
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Figure 3-8. Serum adiponectin concentrations measured in rats after consuming AIN-93G 
modified diets for 11-12 weeks. Significance (P < 0.05) for phenotype, diet, and interaction 
between phenotype × diet was determined by two-way ANOVA. a. Adiponectin 
concentrations separated by diet group (n = 10). b. Adiponectin concentrations separated 
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Figure 3-9. Epididymal fat adiponectin concentrations measured in rats after consuming 
AIN-93G modified diets for 11-12 weeks. Significance (P < 0.05) for phenotype, diet, and 
interaction between phenotype × diet was determined by two-way ANOVA. a. 
Adiponectin concentrations separated by diet group (n = 10). b. Adiponectin 
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Figure 3-10. Distal colon leptin concentrations measured in rats after consuming AIN-93G 
modified diets for 11-12 weeks. Significance (P < 0.05) for phenotype, diet, and interaction 
between phenotype × diet was determined by two-way ANOVA.  a. Leptin concentrations 
separated by diet group (n = 6). Bars with differing letters represent significant differences 
between diets overall as determined by Tukey’s multiple comparison test. b. Leptin 




In summation of these three distinct studies, the main goal of this research project 
was to understand the impact of diet on immunity in realistic settings. Human subjects, 
bovine and rat models were used to investigate the influence of dietary interventions on the 
immune system. Although these were diverse models, the findings demonstrated that 
dietary components do influence immune activity to an extent.  
In the first study, Holstein dairy cattle were utilized as model to investigate how 
altering the feeding regime with omega-3 fatty acid supplementation and altering the 
environment between separate feed management systems affects the immune system. 
Holstein cattle are an outbred population, they are considered to be genetically diverse, and 
are a breed of cattle that are ranched in Canada using both traditional and industrial farming 
practices. The results of this study have shown that supplementation with omega-3 fatty 
acids in dairy cattle, especially in the form of microalgae, improved responses to 
immunization with KLH. However, the strongest influence on the immune response was 
the feed management system, which suggests cattle respond to immunization more 
efficiently in a pasture grazing environment than when confined in barn tie stalls. It is 
possible that cattle freely grazing pasture may have encountered different PPR ligands such 
as bacterial or fungal components which could have bolstered the immune response, or that 
cattle confined in the barn may have been exposed to stressors which contributed to 
suppressed immunization responses.  
In future bovine studies investigating immunization responses during alterations to 
feed management systems or dietary supplements, it will be important to consider sampling 
time points, the types of samples that will be collected, and the use of a vaccine relevant to 
a cattle population. Small volume blood draws to sample antibody production should be 
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collected more frequently (every one to two days) so that the kinetics in the time to respond 
to immunization may be studied. It is unknown in the current trial if dietary omega-3 
supplements or feed management systems affected the rate of Ig production based on the 
chosen sampling points, and this information would be useful to determine the impact on 
timing of a maximal response. To further investigate mucosal responses to immunization, 
other mucosal secretions besides milk should be collected for Ig analysis, such as nasal or 
salivary secretions or faecal samples. It will also be meaningful to determine if feed 
management systems and omega-3 dietary supplements influence immunization responses 
in cattle to infectious agents. Immunization with the bovine vaccine J-VAC® (Merial 
Canada Inc., Baie d’Urfé, Québec, Canada), which confers protection against E. coli 
mastitis and endotoxemia caused by E. coli and S. typhimurium, could be a relevant strategy 
to study antibody production in this context. 
Human subjects were utilized in the second study to investigate how supplementing 
regular daily diets of healthy adults with β2-1 fructans influences the immune system. In 
this experiment, there were no controls on environmental factors, and the subjects would 
have been genetically diverse. β2-1 fructans have been widely claimed as beneficial to the 
health of those who consume them. Results of this human clinical trial suggested that 
immune activity had been impacted at a systemic level in healthy people, while consuming 
ordinary diets supplemented with β2-1fructans. These findings of increased serum IL-4, 
GM-CSF and LPS concentrations, decreased serum IL-10 concentrations, increased 
circulating percentages of CD282+/TLR2+ mDC and increased ex vivo responsiveness to 
TLR2 ligand stimulation do not necessarily reflect a benefit to the immune system in 
healthy individuals. For example, increases in IL-4 could offer potential enhancement in 
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response to immunization, however decreases in regulatory cytokine IL-10 could be 
detrimental while fighting an infection. Alterations in immune activity are context 
dependent, and although some disease-states may benefit from alterations in circulating 
cytokines and immune cell populations, others may not. Other researchers involved in the 
trial investigated gut community structure and determined that β2-1 fructan 
supplementation increased faecal Bifidobacteria, however this change was not related to 
any of the measured immunological parameters.  
Human diet intervention studies are very useful; however, they do have limitations. 
Participant compliance is extremely important for the validity of the results. In this trial, 
participant compliance rates were high, as the placebo phase compliance was 97.6 % and 
the β2-1 fructan phase compliance was 99.9 %. However, compliance rates were 
determined based on the amount of returned unopened supplement sachets. In a study 
conducted by Lomax et al. (2012), compliance rates were calculated on the total amount 
of returned supplement sachets, including both consumed and unconsumed. This may be a 
more effective way to measure compliance and to deter dishonesty. It may also be useful 
to control for BMI, as the average BMI in the current trial was 24.2 kg/m2, and several 
participants would have been considered to be over-weight. It could be important to ask 
participants about social habits during pre-screenings, as cigarette smoking has been shown 
to influence TLR2 and TLR4 expression on monocytes (Versteeg et al., 2009), and binge 
drinking has been shown to increase serum and bacterial DNA levels in healthy subjects 
(Bala et al., 2014). Future studies could include a routine flu vaccination strategy to 
examine impacts of dietary interventions on response to vaccination, as a previous study 
investigating β2-1 fructan supplementation found alterations in responsiveness (Lomax et 
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al., 2015). Additionally, it may be important to examine male and female subjects 
separately, as this trial demonstrated that healthy subjects did differ between immune cell 
markers and cytokines when separated by sex.  
For the final study, a rat model was used to investigate the impact of supplementing 
a HE diet with DFM on immune activity and obesity-related biomarkers. Sprague Dawley 
rats, an outbred and genetically diverse strain with a history of experimental use in medical 
and metabolic studies, were utilized and selected for obese or non-obese phenotypes based 
on their genetic propensity to put on weight in a controlled environmental setting. After 
the development of an obese state in rats over a two-week period on a HE diet, interventions 
with DFM were not able to ameliorate obesity, and the obese and non-obese phenotypes 
remained distinct in not only their body weight, but also in their relative levels of systemic 
and local inflammation. The DFM-supplemented HE diets were not capable of influencing 
immune activity to counter the deleterious effect of the high fat diet. 
Several results of this obese-rat study were surprising, including the fact that DFM 
did not appear to decrease inflammation in DIO rats and the histological analysis of gut 
tissue did not reveal differences between diets in DIO rats. Other studies in mouse models 
have previously demonstrated that high-fiber diets and SCFA production have decreased 
allergic inflammation in the lung (Trompette et al., 2014), suppressed allergic airway 
disease through enhancing the function of Treg cells (Thorburn et al., 2015), and enhanced 
oral tolerance while contributing to protection from food allergy (Tan et al., 2016). It was 
anticipated that the increase in SCFA production through fermentation of the selected DFM 
used in this current trial would have led to dampening down of inflammatory mediators in 
the obese rats, and that there would be distinct differences in proinflammatory biomarkers, 
253 
 
and the extent to which they were affected by DFM, between obese and non-obese rats. 
The ceca of rats on the highly fermented diets, HE RS and HE FOS, were distinguishable 
from ceca collected from rats on other diets due to their shriveled, stretched or distended 
appearance. However, histological analysis using haemotoxylin and eosin staining of gut 
tissue above and below anatomical location of the caecum did not reveal differences in 
tissue level inflammation between any of the HE diets compared the control. Perhaps in 
future HE DFM supplemented diet studies in rat models, alternate staining with agents such 
as methyl green or methylene blue (Lee’s Stain) could be used to examine differences 
during histological analysis of tissues, or immunohistochemistry approaches specific for 
lymphocyte subsets (Ward et al., 2006) or macrophage M1 and M2 markers could be 
implemented to interrogate effects of diet at the tissue level. 
It was also unexpected that there were not more pronounced differences in obesity-
associated biomarkers between DR and DIO rats. Based on results collected from the 
human β2-1fructan trial, it was predicted that the rats on the HE FOS diet would have had 
higher levels of inflammation in comparison to the control diets. Healthy Sprague Dawley 
rats have been previously shown to adapt to high fat and high fructose diets after a three-
month intervention period (Stark et al., 2000). These rats did not develop the classical signs 
of insulin resistance or impaired glucose tolerance during the dietary intervention period 
(Stark et al., 2000), an effect that was also noted in the current study. To combat this 
resistance to metabolic dysfunction, the Wistar rat breed could be used as model since the 
effects caused by a HE diet appear to be more pronounced and these rats will display 
worsened features of metabolic syndrome (Marques et al., 2016), thought to be associated 
with differences in gut bacterial community structure between the two breeds. However, 
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using Wistar rats would not allow for the direct comparison between obese-resistant and 
obese animals, and Sprague Dawley rats have been repeatedly used as an effective model 
to investigate two distinct phenotypes while on the same diet (Levin et al., 1997, Aziz et 
al., 2009, Barbier de la Serre et al., 2010). 
The most sensitive measures of the influence of HE diet and the DIO phenotype on 
immune activity in this rat model were CINC-2αβ and TGF-β1, as this proinflammatory 
chemokine and regulatory cytokine were most frequently associated with differences 
between diet groups or phenotypes. It was unfortunate that the M1 and M2 macrophage 
immunofluorescent cell markers utilized in this study were not suitable with our flow 
cytometry application. Although efforts were made to examine cytokine profiles of M1 and 
M2 macrophages, distinctive alterations were not found between phenotype or diet groups. 
It would have been very interesting to determine if the DFM supplemented in the HE diet 
influenced the M1/M2 macrophage phenotype in DIO rats. It is possible rat-specific flow 
cytometry antibodies for M1 and M2 macrophages may have increased in availability since 
this rat trial took place, increasing the likelihood for successful flow cytometry 
measurements. An alternate approach would be to use real-time polymerase chain reaction 
(qPCR) to investigate the relative levels of gene expression associated with these 
macrophage phenotypes (Martinez and Gordon, 2014); this would be an interesting avenue 
to explore in future studies.  
To further interrogate a possible mechanism for differences between phenotypes in 
the onset of obesity and links with inflammation, other variables could be measured. 
Animal gene knockout models may be beneficial in determining molecular mechanisms of 
obesity development, as studies in mice have shown that animals lacking TLR4 have 
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protection from obesity-associated inflammation and insulin resistance (Jia et al. 2014). 
The reason DIO rats gained more weight throughout this current trial was due to their 
increased daily food consumption. It is possible that differences in metabolism may have 
been linked to adipokine production, as DIO rats produced higher concentrations of leptin 
than DR rats throughout the trial. The peptide hormone ghrelin is involved in controlling 
hunger and could be influenced by leptin, and it would be interesting to measure potential 
fluctuations of this hormone in DR and DIO rats. In this study, I was unable to determine 
whether inflammation proceeded obesity since there were no measures to assess the level 
of inflammation before the introduction of the HE diet in the preliminary phase of the trial. 
For future studies, it will be important to perform a small volume blood draw following the 
acclimatization period and prior to starting dietary interventions to assess whether 
inflammation precedes obesity, occurs alongside obesity, or if it is an outcome caused by 
obesity in this rat model.  
In conclusion, this research investigated the impact of diet on immunity in realistic 
settings and determined that immune activity is affected by dietary interventions of omega-
3 fatty acids, β2-1 fructans, and HE diets supplemented with various DFM. However, the 
outcomes of the impact of diet on immune activity may differ in intensity due to 
environmental factors, exercise and lifestyle, health status, genetic background or obesity, 
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Figure A1. Diagrams of basic chemical structures of omega-3 fatty acids in the microalgae 
and fish oil supplements of AIF Trial #7. a. Docosahexaenoic Acid (DHA) 22:6(n-3). b. 
Eicosapentaenoic Acid (EPA) 20:5(n-3). These structures were drawn using ChemDraw 

















Table B1. Demographic data of individual participants at study baseline. 
 




(kg/m2) Sys BP1 Dia BP 
001 M 26 1.790 73.4 22.91 135 75 
002 M 28 1.846 90.3 26.50 135 76 
003 F 27 1.496 50.4 22.52 107 70 
004 F 29 1.699 59.4 20.58 115 79 
005 F 25 1.670 69.5 24.92 112 84 
006 M 34 1.830 79.0 23.59 131 83 
007 M 28 1.830 71.7 21.41 123 82 
008 F 27 1.635 52.0 19.45 104 69 
009 F 20 1.603 52.7 20.51 112 68 
010 F 23 1.617 70.2 26.85 115 68 
011 F 25 1.634 57.9 21.69 94 65 
012 M 25 1.770 73.4 23.43 135 79 
013 F 32 1.765 72.0 23.11 132 89 
015 M 27 1.780 78.4 24.74 120 63 
016 M 36 1.718 73.3 24.83 139 87 
018 M 35 1.657 80.0 29.14 130 65 
022 F 26 1.595 57.5 22.60 121 87 
023 F 22 1.622 67.2 25.54 116 82 
024 M 24 1.860 91.3 26.39 152 94 
025 M 25 1.770 75.5 24.10 136 76 
026 F 24 1.695 66.6 23.18 116 68 
027 F 30 1.630 77.0 28.98 111 82 
028 M 29 1.680 82.8 29.34 119 86 
029 F 42 1.515 58.0 25.27 122 93 
030 F 24 1.600 57.8 22.58 110 78 
031 M 38 1.840 96.7 28.56 122 76 
032 F 34 1.655 62.4 22.78 108 81 
033 M 23 1.660 66.2 24.02 127 72 
034 F 25 1.652 81.0 29.68 114 79 
035 F 30 1.665 50.0 18.04 120 80 
Median 27 1.668 71.0 23.8 120 79 
Mean 28.1 1.693 69.8 24.2 121 78 
95% CI 26.3 – 29.9  1.66 – 17.3  65.4 – 74.2 23.2 – 25.3 116.7 – 125.5 74.9 – 80.9 













Appendix B continued 
a) 
























































Figure B1. Peripheral mDC CD282+/TLR2+ and CD284+/TLR4+ percentages on day 28 of 
placebo and β2-1 fructan phases, separated by sex. Significance (P < 0.05) for gender and 
phase were determined by rANOVA (n = 13 for males, n = 17 for females). a. Peripheral 
mDC CD282+/TLR2+ percentages; * denotes a significant difference between phases (P = 
0.016), and bars with differing letters represent significant differences between sex as 
determined by Tukey’s HSD (P = 0.025). b. Peripheral mDC CD284+/TLR4+ percentages; 




Appendix B continued 
 
Table B2. Impact of supplement on serum LPS, LBP and cytokine/chemokine 
concentrations in males and females. 
 



















male1 0.32 ± 0.08 0.43 ± 0.12 0.35 ± 0.07 0.38 ± 0.073 
female2 0.67 ± 0.14 0.61 ± 0.12 0.67 ± 0.11 0.80 ± 0.16 
LBP  
(µg/mL) 
male 11.1 ± 1.2 14.8 ± 2.9 11.7 ± 1.6 10.9 ± 1.1 
female 14.2 ± 2.0 15.4 ± 2.2 15.5 ± 2.3 16.7 ± 2.2 
sCD-40L 
(ng/mL) 
male 14.2 ± 10.8 14.7 ± 11.2 13.6 ± 10.9 12.1 ± 9.1 
female 0.8 ± 0.1 0.6 ± 0.1 0.5 ± 0.0 0.4 ± 0.1 
G-CSF 
(pg/mL) 
male 11.0 ± 6.4 11.6 ± 4.6 3.4 ± 3.1 4.6 ± 3.3 
female 12.4 ± 5.7 16.5 ± 5.4 2.4 ± 1.5 6.0 ± 3.6 
GM-CSF 
(pg/mL) 
male 500.0 ± 392.4 532.6 ± 401.4 495.8 ± 396.8 549.6 ± 403.9 
female 12.1 ± 6.1 13.1 ± 6.0 9.8 ± 4.5 6.6 ± 3.8 
IFN-γ 
(pg/mL) 
male BLQ 0.4 ± 0.4 24.6 ± 16.9 93.1 ± 43.7 
female BLQ 4.4 ± 3.7 7.9 ± 5.5 46.1 ± 23.1 
IL-1β 
(pg/mL) 
male 370.6 ± 234.3 363.5 ± 235.4 366.7 ± 235.8 384.5 ± 256.7 
female 6.7 ± 3.1 8.4 ± 3.0 11.0 ± 5.9 5.2 ± 3.2 
IL-1Ra 
(pg/mL) 
male 166.8 ± 89.2 177.6 ± 113.3 135.5 ± 94.6 1300.3 ± 935.0 
female 15.7 ± 7.3 53.2 ± 25.7 21.6 ± 7.6 17.7 ± 9.6 
IL-4 
(pg/mL) 
male 27.7 ± 14.1 25.3 ± 14.0 22.5 ± 12.2 29.3 ± 16.1 
female 1.7 ± 0.9 1.1 ± 0.6 1.1 ± 0.7 2.3 ± 0.7 
IL-6 
(pg/mL) 
male 209.7 ± 128.8 177.6 ± 108.6 103.1 ± 70.1 186.9 ± 113.9 
female 4.3 ± 1.7 3.0 ± 1.4 3.5 ± 1.5 3.4 ± 1.8 
IL-8 
(pg/mL) 
male 30.5 ± 10.8 41.8 ± 18.3 39.7 ± 16.4 59.7 ± 19.3 
female 9.1 ± 1.0 8.9 ± 1.8 16.8 ± 7.3 7.9 ± 1.4 
IL-10 
(pg/mL) 
male 140.7 ± 80.2 156.8 ± 94.2 98.4 ± 62.9 82.6 ± 66.4 
female 18.6 ± 10.1 20.9 ± 9.7 16.2 ± 7.0 9.5 ± 3.6 
IL-12p70 
(pg/mL) 
male 475.0 ± 303.6 442.6 ± 314.7 341.5 ± 270.2 460.5 ± 369.5 
female 17.4 ± 12.5 14.1 ± 8.4 10.5 ± 6.74 12.6 ± 7.7 
IP-10 
(pg/mL) 
male 818.3 ± 593.8 1031.4 ± 632.9 996.7 ± 589.0 966.3 ± 619.4 
female 56.7 ± 8.5 71.5 ± 10.8 86.5 ± 15.4 61.8 ± 10.1 
TNF-α 
(pg/mL) 
male 114.8 ± 87.4 260.8 ± 194.2 223.8 ± 190.4 270.1 ± 231.4 
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Table B2 continued. 
 
1 n = 13 for male subjects.  
2 n = 17 for female subjects. 

























male 3.8 ± 2.5 5.3 ± 2.51 5.8 ± 2.6 9.7 ± 2.7 




male 4183.6 ± 
462.4 
4177.8 ± 745.7 4078.0 ± 
685.9 
3755.6 ± 498.1 
female 3908.7 ± 
446.5 
3445.7 ± 339.6 3925.9 ± 
436.1 
3700.0 ± 55.8 
286 
 
Appendix B continued 
 
Table B3. Concentrations of serum and faecal Ig in males and females at baseline and endpoint of placebo and β2-1 fructan phases. 
 
Sample Class Sex Placebo β2-1 Fructan rANOVA 
P Value3 d-0 d-28 d-0 d-28 
Serum1 
(ng/mL) 
IgA male 731.3 ± 386.8 1805.7 ± 357.5 1721.8 ± 405.6 928.3 ± 128.9 0.271 
female 673.3 ± 117.7 1249.9 ± 305.0 1136.2 ± 268.0 898.9 ± 227.0 
IgM male 354.1 ± 44.7 852.1 ± 287.4 649.3 ± 160.1 411.8 ± 63.8 0.565 
female 441.9 ± 46.9 797.7 ± 117.2 874.1 ± 183.7 542.3 ± 106.6 
IgG1 male 2675.7 ± 226.3 7114.5 ± 1933.0 5408.8 ± 1335.1 2952.8 ± 346.1 0.975 
female 2801.4 ± 348.7 7258.99  ± 1706.4 4949.6 ± 1003.8 2821.9 ± 279.3 
IgG2 male 1731.6 ± 211.6 29 228.7 ± 12 518.2 12 485.6 ± 4883.7 1631.8 ± 246.5 0.247 
female 1596.5 ±  169.3 14 282.3 ± 3464.0 7497.7 ± 1813.5 15 168.0 ± 265.1 
IgG3 male 9609.98 ± 2122.8 27 806.5 ± 5904.8 25 331.6 ± 348.5 28 999.4 ± 5807.2 0.428 
female 11 096.2 ± 177.0 28 468.7 ± 4740.8 31 182.4 ± 3617.6 31 754.72 ± 4058.1 
IgG4 male 1064.5 ± 177.0 3375.6 ± 738.3 2619.6 ± 549.2 2880.6 ± 568.2 0.027 
female 380.9 ± 132.1 1307.6 ± 496.5 1115.1 ± 436.2 1587.7 ± 623.9 
Faecal2 
(ng/g) 
IgA male 109 093.5 ± 
23 318.2 
108 350.95 ± 
26 502.9 
106 134.8 ± 
33 951.3 
100 341.8 ± 
24 954.4 
0.913 
female 83 687.5 ± 25 248.7 79 830.5 ± 17 378.9 68 284.0 ± 9685.0 77 554.2 ± 10 000.5 
IgG male 9006.8 ± 5520.0 12 898.94 ± 4084.3 25 319.1 ± 7705.6 25 897.9 ± 10 289.7 0.232 
female 3573.854 ± 1329.1 13 782.0 ± 4283.3 20 386.5 ± 12 699.2 5093.3 ± 1516.0 
IgM male 1961.7 ± 806.3 1227.0 ± 535.7 852.9 ± 295.3 4360.1 ± 2173.6 0.259 
female 3307.6 ± 2662.7 682.5 ± 213.0 578.1 ± 140.2 913.3 ± 250.5 
1 n = 13 for males and n = 17 for females. 
2 n = 13 for males, n = 17 for females (except for placebo day 0, n = 16). 






Appendix B continued 
 
Table B4. Ex vivo cytokine production in unstimulated and TLR agonist-stimulated whole blood cultures from males and females at 
the endpoints of placebo and β2-1 fructan phases. 



















male1 BLQ BLQ BLQ BLQ BLQ BLQ 




male BLQ 0.1 ± 0.1 7.8 ± 0.8 8.2 ± 0.8 0.3 ± 0.1 0.4 ± 0.1 




male 0.1 ± 0.1 0.7 ± 0.6 39.4 ± 1.9 39.7 ± 2.3 8.5 ± 1.0 12.2 ± 3.3 




male 6.0 ± 2.6 28.9 ± 17.3 65.1 ± 3.7 72.3 ± 3.9 60.4 ± 4.2 60.8 ± 7.8 
female 4.7 ± 1.2 9.3 ± 5.1 64.6 ± 2.0 73.0 ± 3.0 54.1 ± 3.9 60.5 ± 5.0 
IL-10  
(pg/mL) 
male BLQ 48.8 ± 49.8 2352.3 ± 200.1 2119.4 ± 245.0 33.9 ± 13.0 78.9 ± 34.03 




male BLQ BLQ BLQ BLQ BLQ BLQ 
female BLQ BLQ BLQ BLQ BLQ 6.1 ± 5.4 
TNF-α 
(ng/mL) 
male BLQ 0.3 ± 0.2 3.2 ± 0.3 4.0 ± 0.6 0.3 ± 0.0 0.2 ± 0.1 
female BLQ 0.01 ± 0.01 2.2 ± 0.5 2.3 ± 0.3 0.1 ± 0.0 0.2 ± 0.0 
1 n = 13 for unstimulated and LPS stimulated samples, and n = 11 for P3C stimulated samples in males. 
2 n = 17 for unstimulated and LPS stimulated samples, and n = 13 for P3C stimulated samples in females. 




Table C1. Diet formulation and nutritional profile of the test diet, AIN-93G. 
 
Ingredients % Nutritional Profile 
Corn Starch 39.7 Protein % 18.3 Minerals 
Casein 20.0 Arginine 0.70 Calcium % 0.51 
Maltodextrin 13.2 Histidine 0.52 Phosphorus % 0.32 
Sucrose 10.0 Isoleucine 0.96 Potassium % 0.36 
Soybean Oil 7.0 Leucine 1.73 Magnesium % 0.05 
Powdered Cellulose 5.0 Lysine 1.45 Sodium % 0.13 
AIN-93G Mineral Mix 3.5 Methionine 0.52 Chloride % 0.22 
AIN-93G Vitamin Mix 1.0 Cysteine 0.37 Fluorine ppm 1.0 
L-Lysine 0.3 Phenylalanine 0.96 Iron ppm 40 
Choline bitartrate 0.25 Tyrosine 1.01 Zinc ppm 35 
t-Butylhydroquinone 0.0014 Threonine 0.77 Manganese 
ppm 
11 
  Tryptophan 0.22 Copper ppm 6.0 
Energy (kcal/g) 3.89 Valine 1.14 Cobalt ppm 0.0 
From: Kcal Alanine 0.55 Iodine ppm 0.21 
Protein 0.731 
(18.8 %) 










Glycine 0.39 Selenium ppm 0.24 
  Proline 2.36 Vitamins  
  Serine 1.10 Vitamin A 
IU/g 
4.0 
  Taurine 0.00 Vitamin D3 
IU/g 
1.0 
  Fat % 7.1 Vitamin E 
IU/g 
81.6 
  Cholesterol ppm 0.00 Vitamin K 
ppm 
0.75 




  Linolenic acid % 0.55 Riboflavin 
ppm 
6.7 
  Arachidonic acid, 
% 
0.00 Niacin ppm 30 
  n-3 fatty acids, % 0.55 Pantothenic 
acid ppm 
16 
  Total saturated 
fatty acids, % 
1.05 Folic acid ppm 2.1 
  Total 
monounsaturated 




  Polyunsaturated 
fatty acids, % 
3.78 Biotin ppm 0.2 
    Vitamin B12 
µg/kg 
29 
  Fibre % 5.0 Choline 
chloride ppm 
1250 
  Carbohydrates % 63.2 Ascorbic acid 
ppm 
0.0 
 
